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General Introduction 
In recent years, nanoscience and nanotechnology have attracted a lot of sight in many areas 
such as food safety, medicine, energy, environment science, and information technology1-4. At 
present, governments, organizations and research institutes invest more and more human and 
financial resources for their development and already achieved unprecedented progress. Data 
indicated that the USA have invested $3.7 billion using its NNI in 2012, whereas the European 
Union has invested $1.2 billion, and $750 million for Japan5. More importantly, such 
investment is still developing rapidly that not only contributes to social benefits, but also greatly 
promotes economic growth. This area of science concerned with nanomaterials focuses on the 
following aspects: synthesis (new materials, or methods), manipulation, assembly, and 
application.  
Among the most studied inorganic or organic materials, nanomaterials such as gold 
nanoparticles, silica, magnetic oxides (Fe3O4), carbon materials and semiconductors attract a 
lot of attention 6. These nanoparticles already play an important role in the real life, such as 
colloidal gold for immunological analysis7, carbon nanotubes suitable for electron transistor8, 
and QDs utilized as colourful screen materials9. One of the interests of these nanoparticles is 
the possibility to control the shape, size, composition and even the structures during the 
synthesis process that make them much flexible for the further surface functionalization and 
applications.  
Silica is widely considered as a type of promising materials that can be used in the biomedical 
field. The reason is that there are many advantages of silicon dioxide. For examples, silica is a 
relatively common substance and its source of raw materials is very rich. Moreover, the 
synthesis and functionalization of silica nanoparticles by molecules, polymers, proteins, genes, 
are relatively easy to implement10. In addition, silica also has many excellent biological 
properties: low toxicity, degradation, good biocompatibility etc. Silica is already used in the 
food industry, environmental science, and medical field 11. There are many current or planned 
applications of silica nanoparticles in bioimaging, drug delivery, gene therapy12. However, it 
inevitably raises several important questions, especially for the biological and medical areas. 
To develop the use of silica nanoparticles in the biomedical field, it is particularly important to 
understand their behavior in physiological conditions and intracellularly, including colloidal 
stability, biotoxicity, endocytosis, biodegradation, etc. Moreover, to understand to what extent 
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the control of particle characteristics allows to modify their behavior will optimize the 
nanoparticles adjusted to the intended applications.  
Nanomaterial-based drug delivery system is an emerging drug delivery method. Nanocarriers 
for drug delivery can overcome many shortcomings of the traditional drug administration, such 
as improving drug solubility, controlling drug release, and targeting characteristics, all of which 
confer to this drug delivery method promising application prospects. At present, many organic 
nanocarriers, such as liposomes or polymeric microspheres13, inorganic nanocarriers, such as 
carbon nanomaterials, titanium dioxide, silicon dioxide14, alone or associated to hydrogels, 
were used for the delivery of drugs, genes, polypeptide proteins15, etc. Again, silica has been a 
widely studied nanocarrier. 
The objective of this doctoral work is to study the physicochemical properties and biological 
interactions of different silica nanostructures, and evaluate their potential biomedical 
applications in imaging and drug delivery either in a 2D culture or within 3D collagen hydrogel 
matrices. With this purpose, the study was conducted at different levels. In the following pages, 
we first provide a literature review of the development of nanotechnology and nanomedicine, 
introduce the current drug delivery strategies and the problems they encountered. Then we focus 
on the physicochemical properties and surface functionalization of silica nanomaterials, as well 
as their reported applications in drug delivery. Their biological properties including toxicity, 
uptake, degradation of silica in vitro and in vivo are also summarized (Chapter 1).  
In the second part, we present the first part of our project dedicated to the understanding of the 
intracellular fate of silica nanoparticles. We synthesized three types of fluorescent silica 
nanoparticles with various internal structures (core-shell bio-composite, multi-layered and 
hollow mesoporous). Then, the structures and surface properties of the nanoparticles were 
characterized, after which their biological toxicity and colloidal stability and dissolution were 
studied in a buffer and in a biological medium. Finally, fibroblasts were exposed to these 
particles in order to determine the interactions between the cells and the silica particles and their 
consequences on both the cellular activity and the fate of the colloids (Chapter 2).  
The encouraging outcomes of this study led us to explore further biomedical applications of 
silica nanostructures. Here, we constructed multifunctional silica-based nanocarriers intended 
to be used as nanotheranostics platform. These nanostructures consist of hollow silica 
nanoparticles as the core containing the drugs and a thin layer of MnO2 as a shell, acting both 
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as a gatekeeper and a source of paramagnetic species. In addition, a targeting agent aptamer 
(AS1411) was added on the outer layer. These nanocarriers exhibit excellent targeted and 
stimulated response properties for magnetic resonance imaging and doxorubicin release both in 
2D conditions and in 3D biomimetic environments (Chapter 3).  
One step further we explored 3D composite biomaterials consisting of two types of well-known 
bio-materials: silica and collagen. Collagen is the main structural protein mostly existed in 
fibrous tissues such as tendons, ligaments, and skin which owns excellent biocompatibility. 
Combining these two materials to form a composite gel material offer almost unlimited space 
for imagination. In the work, we prepared a composite collagen hydrogel incorporating silica 
nanorods. Here, silica nanorods can have two functions: regulating mechanical properties and 
acting as a drug carrier. The mechanical and chemical properties of the composite hydrogel 
could be tuned by adjusting the ratio of silica to collagen. The influence of the composite 
hydrogel on fibroblast cells growth and proliferation was studied. Lastly, magnetic hydrogels 
were prepared using magnetite nanoparticles attached to silica rods. It was found that this new 
type of magnetic composite can be structured under the action of an external magnetic field. 
(Chapter 4). 
A conclusion section gathers our main results, enlightening our contribution to the area of silica 
nanoparticles in biomedicine, and provides some perspectives in the different fields relevant to 
this work. 
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Chapter 1 Literature review 
 
“千里之行，始于足下”  
 
《道德经》 
 
Abstract 
Since the beginning of the century, nanoparticles have developed with possible applications in 
many fields such as energy, materials and the medical and pharmaceutical field. Silica, thanks 
to the great ease and adaptability of particle synthesis and it’s biological inertia in the 
macroscopic state, is very widely studied for medical applications. Moreover, silica 
nanoparticles are already present in many products of daily life (cosmetics, food ...). In this 
chapter will first gather some key information about the synthesis and physicochemical 
properties of silica-based nanomaterials. Then, we will present the known elements concerning 
the internalization mechanisms, the toxicity as well as the fate of the silica nanomaterials. 
Finally, some of the biomedical applications of silica nanomaterials in 2D and the 3D matrix 
will be reviewed.  
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Revue de la littérature 
 
 
 
 
 
 
 
Résumé 
Depuis le début du siècle, les nanoparticules se sont développées avec des applications possibles 
dans de nombreux domaines tels que l'énergie, les matériaux et le domaine médical et 
pharmaceutique. La silice, grâce à la grande facilité et adaptabilité de la synthèse des 
nanoparticules et à son inertie biologique à l'état macroscopique, est très largement étudiée pour 
des applications médicales. De nombreuses voies de synthèse, de structuration et de 
nanomatériaux à base de silice sont décrites dans la littérature. Leurs interactions avec les 
cellules (toxicité, internalisation, devenir) ont déjà fait l’objet de nombreuses études. Certaines 
applications biomédicales des nanomatériaux de silice en 2D et en matrice 3D paraissent 
particulièrement prometteuses. 
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1.1 The development of nanotechnology and nanomedicine  
1.1.1 Nanotechnology and its applications 
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular 
scale, widely considered as one of the most important breakthroughs in the last century1. 
Actually, the concept of nanotechnology was first introduced by Richard Feynman in 1959. The 
advent of scanning tunneling microscopy and atomic force microscopy enabled humans to 
observe the structure and surface properties of atoms and molecules that greatly speed up the 
development of nanotechnology. According to the predictions by experts, nanotechnology will 
become the three major supports for economic and social development in this century together 
with biotechnology and information technology. 
 
Figure 1-1 Nanotechnology is a highly interdisciplinary field of science 
Nanomaterials generally defined as materials in which at least one dimension sized from 1 to 
100 nanometers from the three-dimensional space or the substances are made up of basic 
structural units in nanoscale range2. Nanomaterials can be made of metals, ceramics, polymers, 
biomacromolecules, and as hybrids of these. They show a variety of morphology including 
nanospheres, nanoclusters, nanorods, nanotubes, nanofibers, nanowires, nanofilms and core-
shell nanostructures, etc. To date, numerous bottom-up and top-down nanofabrication 
technologies3 (such as sol-gel, electrospinning, self-assembly, phase separation,  thin film 
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deposition, chemical vapor deposition, chemical etching, nano-imprinting, photolithography) 
are available to synthesize nanomaterials with ordered or random nanotopographies. 
Materials with structure at the nanoscale often have unique properties because when the scale 
of macroscopic materials gradually decreases, the density of electron states changes from a 
continuous distribution to an independent distribution similar to the energy level of the atom, 
giving rise to  a series of peculiar effects4, such as small size effects, surface effects, volume 
effects, quantum size effects, and macroscopic tunneling effects, etc. Today, nanotechnology is 
integrated with many disciplines including chemistry, materials, biology, medicine, physics and 
has been successfully used in fields of catalysis, bioanalysis, energy storage, environment, 
human health and microelectronics processing5-8 etc. (Figure 1-1) 
 
Figure 1-2 Various of nanomaterials in biomedical applications9 
Among them, nanotechnology for biological and medical applications is considered as one of 
the most important branches, which has shown great promising as biomarkers for the 
investigation of biological processes that are hard to access with conventional approaches as 
well as for advanced therapeutic/imaging solutions. Nanomaterials have unique advantages for 
biological research because their size is similar to that of most biological molecules and 
structures. Thus various kinds of functional nanomaterials have been well developed which 
offers exciting opportunities in biomedical applications10, 11. A wide variety of nanostructured 
materials have been described in the literature such as gold and silver nanoparticles, quantum 
dots, magnetic nanoparticles, carbon nanotubes, silica-based nanomaterials, titania 
nanoparticles, liposomes, and soft polymer nanoparticles used for imaging, sensing, drug 
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delivery, tissue engineering and medical device etc. A very general scheme summarizing the 
materials, and their applications are reported in Figure 1-2. 
1.1.2 Nanomedicine 
Nanomedicine refers to the medical application of nanotechnology which involved in a wide 
range of biomedical areas. It is currently available to overcome some of the difficulties 
experienced by traditional medical approaches in the field of targeted drug delivery, diagnostic 
imaging as well as the production of hybrid treatments. At present, nanomedicine already has 
been used globally to improve the treatments and lives of patients suffering from a range of 
disorders including malignant tumor12, fungal infections13, elevated cholesterol, multiple 
sclerosis14, chronic pain15, asthma16. These benefits of nanomedicine can be classified as the 
advantages produced by nanotherapeutics, nanodiagnostics, and nanotheranostics (Figure 1-3). 
 
Figure 1-3 Applications of nanomedicine in clinical theranostics 
Most drug molecules have low solubility in water and are very difficult to absorb and utilize at 
the desired lesion17. Nanotechnology has been used to increase absorption capacity via 
produced nano-drugs18, 19. In some cases, the drug is metabolized too quickly and may be 
effective only just after treatment. Therefore, nanomedicine can also increase the cycle time 
that the drug remains active in the body. It is also important to specifically treat damaged cells 
to avoid damage to surrounding healthy cells. With the ability to increase the specificity of drug 
targets, nanotherapeutics can also reduce the amount of drugs used, avoiding serious side 
effects.  
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Nanotechnology has also been applied to diagnostics because of the distinct optical, magnetic 
and structural properties of nanomaterials which make them suitable for diagnostic imaging and 
tumor detection. Nanoparticles have the excellent optical features benefit of quantum effects at 
the nanoscale20. This is especially useful for color coding and labeling of materials used during 
diagnostic tests21. Nanotechnology has been used to enhance current medical imaging methods 
such as US,CT, MR, SPECT and PET22.  
Theranostics is a new field of medicine which combines targeted therapy with specific 
diagnostic tests. Nanotechnology is particularly suitable for the provision of materials with both 
imaging and drug agents that can produce practical theranostic tools. An advantage of this 
technique is that it provides the capacity for personalized and precision medicine.  
1.2 Drug delivery 
1.2.1 Overview 
Drug delivery is a strategy for transferring drug compounds to the body as needed to safely 
achieve their desired therapeutic effect. This process is related to specific targeting, distribution, 
and systemic pharmacokinetics of the drug in the body23.  
 
Figure 1-4 Five types of common routes of drug administration 
Accurate drug delivery and good metabolism in the body can improve the efficacy and reduce 
the side effects of the drug. Drug delivery is usually approached by chemical formulations of 
  
19 
 
drugs, but it may also involve medical devices or drug-device combination products. Drug 
delivery technologies modify drug release profile, absorption, distribution and elimination for 
the benefit of improving product efficacy and safety, as well as patient convenience and 
compliance. Currently, most common routes of administration include the preferred non-
invasive oral route as well as topical, transmucosal, inhalation, and intravenous routes24(Figure 
1-4). However, many drugs such as peptides and proteins, and gene-based drugs, are very 
susceptible to enzymatic degradation or cannot be effectively absorbed into the systemic 
circulation due to molecular size and charge problems. Therefore, many proteins and peptide 
drugs must be delivered by injection or nanoneedle arrays. When the drugs reached the desired 
site, the drug release from the system consists of the following processes: dynamic diffusion, 
progressive degradation, infiltration, and affinity-based mechanisms25.  
An ideal dosage regimen in the drug therapy of any disease is one which immediately attains 
the desired therapeutic concentration of drug in plasma and maintains it constant for the entire 
duration of treatment. This is possible through the administration of conventional dosage forms 
in a particular dose and at a particular frequency. The frequency of administration or dose 
interval of any drugs depends upon its half-life or mean residence time and its therapeutic index 
(i.e. ratio between therapeutic efficiency and toxicity). In most cases, dosing interval is much 
shorter than the half-life of the drug, resulting in a number of limitations associated with such 
a conventional dosage form. For example, some patients have poor compliance and may often 
miss the time of administration. In other situations, the typical peak-valley plasma 
concentration-time profile is obtained which makes attainment of steady state condition 
difficult. Moreover, the unavoidable fluctuation in the concentration may lead to adverse effects 
especially for a drug with a small therapeutic index.  
To overcome above-discussed limitations of conventional dosage forms, two methods are 
possible. On the one hand, it should be developed new, better and safer drugs with a long half-
life and large therapeutic indices. On the other hand, effective and safer use of existing drugs 
may be obtained through concepts and techniques of sustained/controlled and targeted drug 
delivery systems. This approach can be achieved by designing a drug-device, which of course 
requires first ensuring the biosafety of the device material. 
1.2.2 Nanocarriers used in drug delivery system 
A drug carrier is any substance or device used in the process of drug delivery which serves to 
improve the selectivity, safety and efficacy of drug administration. In terms of a successful drug 
 
20 
carrier, it must not only protect the drug from degradation but also control the release of the 
drug into the systemic circulation for therapeutic purposes. As noted above, nanomaterials 
typically exhibit different physicochemical properties, including small size, high surface area, 
and flexible structure, that make them of potential interest as drug carriers. Moreover, their 
intrinsic properties of light, heat, magnetism and electricity are of great significance for the 
preparation of functional and stimuli-responsive carriers26. In addition, some studies have 
shown that larger objects with optimized size and shape are more easily uptaken by cells.  
Nanocarriers are nanomaterials that are used as transport modules for drugs (small molecules, 
peptides, proteins, etc.) into the body. The way the drugs are conjugated to the nanocarrier is 
either by adsorption, covalent linking, or encapsulation. Drug loading strategy affects the 
amount of drug, stability, the release of drugs, and even the surface properties of nanocarriers.  
 
 
Figure 1-5 Different types of nanocarriers. (a) lipid; (b) polymer; (c) inorganic nanoparticles 
Nanocarriers used for medical applications must be biocompatible, nontoxic and functional. 
Undesirable effects of nanoparticles strongly depend on their hydrodynamic size, shape, 
amount, surface chemistry, the route of administration, reaction of the immune system and 
residence time in the bloodstream. Although it is rather difficult to predict the fate of 
nanocarriers in the body, it is generally accepted that too small nanoparticles are subject to 
tissue extravasations and renal clearance whereas large one are quickly opsonized and removed 
from the bloodstream via the macrophages of the reticuloendothelial system27. Therefore, 
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nanoparticles with a hydrodynamic diameter of 10-100 nm are considered to have optimal 
pharmacokinetic properties for in vivo applications. Nowadays, liposomes, solid lipids 
nanoparticles, dendrimers, polymers, silica or carbon materials, and magnetic nanoparticles28 
are the examples of nanocarriers that have been tested as drug delivery systems (Figure 1-5). 
1.2.2.1 Lipid based nanocarriers 
Lipid-based drug delivery systems consist of liposomes, solid lipid nanoparticles (SLN), 
microemulsions, nanosuspensions and lipid nanotubes. Liposomes are vesicles surrounded by 
a lipid bilayer, much like a cell membrane, separating the internal aqueous core from the 
outside, ranging in diameter from about 25-1000 nm. Since first being described by the 
hematologist Alec Bangham in 1964, liposomes have long been defined as good candidates for 
effective drug delivery29. In terms of structure, liposomes can be classified into multilamellar 
vesicles (MLV), small unilamellar vesicles (SUV), large unilamellar vesicles (LUV), and 
cochlear vesicles. There are several methods for liposomes preparation which include injection 
method, film dispersion method, ultrasonic dispersion, and reverse evaporation30. Liposomes 
were used for the first nanoscale anticancer drug (Doxil®) to approved by F.D.A. for clinical 
use in 1995. Today, there are already more than 15 liposomal drug formulations on the market 
for indications such as cancer, fungal infections, macular degeneration, pain management and 
vaccines. 
  
Figure 1-6 The structure of liposome nanocarriers 
As a drug delivery system, liposomes offer several advantages including biocompatibility, the 
ability to protect drugs from degradation, reach targeted sites, and reduce toxic and side effects. 
In addition, the unique feature of liposomes is their ability to entrap both hydrophilic and 
hydrophobic molecules, in the aqueous core and bilayer membrane, respectively. Furthermore, 
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in order to prolong liposome circulation times, surface modification can be achieved through 
the introduction of polymers, such as PEG, PEI, PVP (Figure 1-6). Yuda et al. studied various 
lipid derivatives of polyethyleneglycols and found that terminal PEG groups can effectively 
prolong the circulation time of liposomes31. Moreover, ability of the cholesterol derivative of 
PEG in prolonging the circulation time of liposomes was proportional to the average molecular 
weight.  
It is also very interesting to modify such lipid structures form multifunctional liposomes with 
specific proteins, antigens, or other biological substances, that can be used to design drugs for 
targeted delivery of therapeutics32. Much of the current research involving liposomes is focused 
on improving the delivery of anticancer drugs33, neurotransmitters34, antibiotics35 etc. 
Disadvantages associated with using liposomes as drug carriers include low encapsulation 
efficiency, easy rupture of liposomal membranes, leakage of drugs, poor reproducibility, 
instability in the body, and rapid drug release. Drugs which have high membrane-permeability 
can readily leak from the carrier, while optimization of in vivo stability can cause drug release 
by diffusion to be a slow and inefficient process. Moreover, an increasing number of studies 
have shown that liposomes are not as immunologically inert as initially suggested. 
Solid lipid nanoparticles (SLN) are a new generation of nanodrug delivery systems, which show 
typically spherical structure, and possess a solid lipid core matrix stabilized by surfactants. SLN 
combines the advantages of lipid emulsions and polymer nanoparticle systems while 
overcoming the stability issues that plague conventional and polymeric nanoparticle drug 
delivery methods.36 In addition, they can be mass-produced by high-pressure emulsion 
homogenization. A recent study useed solid lipid nanoparticles as nanocarriers for oral delivery 
of the iron nutrient by incorporating ferrous sulfate (FeSO4) into a lipid matrix composed of 
stearic acid37. Altogether, solid lipid nanoparticles have important development potential in 
future drug delivery systems. 
1.2.2.2 Polymer-based nanocarriers 
Polymer-based nanocarriers have emerged as a promising approach for drug delivery by 
dendrimers, polymer self-assembly micelles, nanoparticles, polymersomes etc. Dendrimers are 
large, complex molecules with a radius ranging from 2.5 to 8 nm. They are spherical, with a 
three-dimensional branched structure, which contains three parts: a core, branching repeat units, 
and outer terminal functional groups (Figure 1-7). The size of the dendrimer is easily controlled 
via polymerization of branches using monomers to form repeat layers, with each layer making 
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up a generation. Dendrimers can be made cationic, anionic, or neutral depending on their 
terminal groups38. Some natural molecules possess dendritic structures such as glycogen, 
amylopectin, and proteoglycans.  
Dendrimers have a high drug-loading capacity and may encapsulate both hydrophilic and 
hydrophobic drugs. The drug may be encapsulated in the internal structure of dendrimers or it 
can be chemically attached or physically adsorbed on dendrimers surface. Clementi et al. 
utilized PEG-dendrimers loaded with both hydrophobic paclitaxel (PTX) and hydrophilic 
alendronate (ALN) and show enhanced activity compared with free drugs39. However, a 
possible disadvantage of dendrimers is that steric crowding of the branching arms occurs at 
higher generation numbers, which limits growth to a larger size and results in decreased drug 
encapsulation.  
 
Figure 1-7 Architecture of dendrimer involves different construction units 
Polymeric nanoparticles are solid colloidal systems. A very wide range of biocompatible and, 
when required, biodegradable polymers, either natural or synthetic, can be used to design such 
nanoparticles. According to different preparation methods, nanospheres or nanocapsules (i.e. 
hollow nanoparticles) can be obtained. Drugs can be physically dispersed, dissolved or 
chemically conjugated to the polymer chain. Main advantage of nanoparticle stems from the 
ability to incorporate large molecules such as proteins as well hydrophobic drugs at 
concentrations above their inherent water solubility40.  
Polymeric micelles are self-assembled core-shell nanostructures generated with amphiphilic 
block copolymers in an aqueous solution at or above critical micelle concentration 41 (Figure 
1-8). Both the intrinsic and modifiable properties of polymeric micelles enable the system to 
incorporate poorly soluble drugs thus improving their bioavailability while protecting them 
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from inactivation in biological media. The typical methods used for encapsulation of poorly 
water-soluble drugs are dialysis, emulsion solvent evaporation, and solid dispersion42.  
The last decade has seen significant progress in the development of various micellar systems 
and proved already to be a relevant approach for the delivery of hydrophobic drugs and 
hydrophilic contrast agents, drugs and biomacromolecules (DNA, SiRNA, protein), with the 
possibility to be functionalized by many different ligands43. However, much improvement is 
still needed for the existing systems with respect to drug-loading capacity and formulation 
stability.  
 
Figure 1-8 Polymeric micelles as supramolecular nanomedicines 
1.2.2.3 Inorganic-based nanocarriers 
In recent years, inorganic nanomaterials, such as QDs, gold/silver nanoparticles, iron oxide 
nanoparticles, carbon-based nanomaterials, and silica nanoparticles, have demonstrated 
distinctive advantages for drug delivery including high specific surface, controllable size and 
shape, tunable internal structures, and easy surface modification44. Compared with organic 
nanocarriers, inorganic nanomaterials have better stability and controllability; moreover, some 
inherent properties of these nanomaterials can contribute to enlarge the versatility of 
nanocarriers. 
Quantum dots (QDs) are nanocrystals ranging from 2 to 10 nm in diameter composed of 
semiconductor materials45. These QDs have excellent fluorescence properties due to quantum 
size effects. QDs have high surface-to-volume ratios and are easily combined with therapeutic 
agents for multifunctional applications. Bagalkot et al. linked A10 RNA aptamer on the surfaces 
of CdSe/ZnS core-shell fluorescent QDs and then loaded doxorubicin(DOX) forming a QD-
aptamer(DOX) conjugate (Figure 1-9) for targeted cancer imaging, therapy, and sensing in 
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vitro based on FRET mechanism46. Although there have been many related studies, the direct 
use of QDs for drug delivery remains questionable due to their potential long-term toxicity47. 
 
Figure 1-9 Schematic illustration of QD-aptamer (DOX) Bi-FRET system 
Carbon-based nanomaterials48 have attracted tremendous attention in drug delivery due to 
various advantages, including their high resistance, large specific surface area, cross cell 
membrane easily, and convenient surface modification. Among all those materials, carbon 
nanotubes (CNTs) are one of the most interesting nanocarriers currently under investigation. 
They possess a cylindrical nanostructure that can be used to encapsulate or bind diagnosis and 
therapy agents.  
 
Figure 1-10 A schematic diagram of preparing DOX-MWCNTs-PEG-TAT for drug delivery 
Dhar et al have trapped a strongly hydrophobic Pt(IV) prodrug in carbon nanotubes and shown 
that chemical reduction causes a dramatic reversal in CNT hydrophobicity leading to the release 
of the active Pt(II) complex49. Surface modification of CNTs by anchoring of polymers, such 
as PEG, hyaluronic acid etc., or covalent linking of targeting ligands, including folic acid (FA), 
peptides and antibodies, may remarkably reduce their cytotoxic effects and side effects50. Hu et 
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al. linked a cell-penetrating peptide (transactivating transcriptional factor TAT) to PEGylated 
multi-walled carbon nanotubes (MWCNTs) to create a highly effective antitumor 
multifunctional drug delivery system 51 (Figure 1-10). Graphene oxide 52 has also attracted 
recent interest in nanomedicine. Pan and co-workers synthesized ultra-small graphene oxide 
(carbon dots) around 10 nm that displayed photoluminescence ranging from the visible to the 
NIR53. Zheng et al integrated the optical properties of carbon dots and the anticancer function 
of oxaliplatin in theranostic nanomedicine (CD‐Oxa) that could be used for simultaneous drug 
delivery and fluorescent tracking54. Recently, hollow carbon nanoparticles also showed promise 
as drug delivery systems. DOX-hollow carbon sphere drug delivery systems exhibited high 
drug-loading capacity, pH-controlled release and rapid uptake by cells 55.  
Iron oxide nanoparticles, mainly as magnetite (Fe3O4) or maghemite (γ-Fe2O3) phase, have 
attracted extensive interest in the biomedical field due to their superparamagnetic properties as 
well as due to the low toxicity of iron. For instance, Shen et al constructed a drug carrier 
DOX@ES-MION3@RGD2@mPEG3  which is based on the exceedingly small 3.6 nm magnetic 
iron oxide nanoparticles (ES-MIONs) with modification by the RGD2 peptide and mPEG3 for 
T1-weighted tumor imaging and chemotherapy56. The results showed this drug delivery system 
is promising for high-resolution T1-weighted MR imaging and precise chemotherapy of 
tumors. Magnetic iron oxide nanoparticles can also be used for controlled drug release at a 
targeted site in order to reduce the cytotoxicity, enhance drug uptake or allow magnetic 
hyperthermia under high-gradient of external magnetic fields. Espinosa and co-workers 
introduced novel multifunctional iron oxide nanoparticles with the dual capacity to act as both 
magnetic and photothermal agents. Todd et al. co-loaded small molecule drugs with iron oxide 
nanoparticles onto diatoms. Using an external magnetic field, diatoms could be attracted to the 
tumor site for systemic administration57.  
Gold nanoparticles are noble metal nanoparticles with special optical properties due to localized 
surface plasmon resonance phenomenon. Gold nanoparticles can be used to optimize the 
biodistribution of drugs to diseased organs, tissues or cells, in order to improve and target drug 
delivery. Hong et al. reported that intracellular glutathione (GSH) can displace the thiol 
monolayer on gold nanospheres, thus releasing the therapeutic cargo covalently bound to the 
monolayer 58. Faroo et al. reported a facile one-step method to synthesize stable AuNPs loaded 
with the combination of two anticancer therapeutics, bleomycin, and doxorubicin. The results 
show that the therapeutic efficacy of hybrid nanomedicine based on gold nanoparticles is 
significantly enhanced by active targeting of HeLa cells59. Gold nanorods (GNRs) possess 
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stronger size-normalized absorption cross-sections than common gold nanospheres. Scattered 
photons can be used for imaging applications, while the absorbed photons can be utilized for 
photothermal effects60. Such NIR-active nanostructures have shown tremendous potential in 
controlled release drug delivery. The generated heat can also be used to increase drug efficacy. 
In particular, the combined effects of heat and chemotherapeutic agents can synergistically 
improve the efficacy of drug delivery. Zhang et al. synthesized a thiolated pH-responsive DNA 
conjugated gold nanorod (GNR) as a multifunctional nanocarrier for targeted, pH-and near 
infrared (NIR) radiation dual-stimuli triggered the drug delivery61. A further surface 
modification was developed by a thiolated poly(ethylene glycol)-biotin to improve its cancer-
targeting ability, reduce side effects and increase blood circulation time (Figure 1-11).  
 
 
Figure 1-11 A dual-stimuli triggered anti-cancer drug delivery system based on GNRs 
As pointed out above, each delivery platform has its advantages and disadvantages. Lipid and 
polymer carriers are highly versatile in terms of chemistry and their cyto/biocompatibility can 
be rationally engineered. However, this often requires extensive synthetic efforts and stability 
issues are still faced in many systems. Inorganic nanocarriers presented so far mainly benefit 
from their intrinsic physical properties and quite easy surface functionalization. However, 
besides cytotoxicity issues and standing questions about their biodegradability, drug loadings 
are often quite low.  Interestingly, as described in the following section, silica nanoparticles 
stand quite in between these two categories. 
1.3 Preparation of silica-based nanomaterials  
Silica (silicon oxide, SiO2) is one of the most complex and abundant families of materials. It is 
already used in many different forms in structural materials, microelectronics, and as 
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components in the food and pharmaceutical industries62, 63, thanks to  its many attractive 
physicochemical properties such as large specific surface area, high mechanical stability, easy 
functionalization, good biocompatibility and low toxicity etc. Therefore,  there is not surprising 
that silica nanomaterials have been widely studied for biomedical applications: detection, 
biosensing, medical imaging, drug delivery, and theranostics64. In particular, the evaluation of 
silica-based nanomaterials as drug carriers has become very popular over the past decades. In 
2011, an investigational new drug application for exploring an ultra-small nonporous silica NP 
for targeted molecular imaging of cancer was approved by the US Food and Drug 
Administration (FDA) for a first-in-human clinical trial, highlighting the great potential and the 
most recent progress of clinical translation of silica NP drug delivery platform.  
1.3.1 The solution chemistry of silica  
Silica has a tetrahedral structure with each silicon covalently bonded to four oxygen atoms. 
Most oxygen atoms will be bonded to two silicon atoms so that two tetrahedra are joined at a 
corner65. This orientation can be random, leading to an amorphous structure. To date, a large 
number of techniques have been available for preparing silica nanoparticles, such as flame spray 
pyrolysis, chemical vapor deposition, ball milling, sol-gel 66-69.  Among these, preparation by 
sol-gel techniques has been the focus of research as the synthesis is straightforward, scalable 
and controllable. 
 
Figure 1-12 The hydrolysis (1) and condensation (2a, 2b) reaction of silicon alkoxide 
precursors 
The sol-gel synthesis typically involves the hydrolysis (1) and condensation (2) of a silicon 
alkoxide precursor (Si(OR)4), where R is typically Et or Me, under basic or acidic catalysis 
(Figure 1-12). The hydrolysis of silanes leads to reactive silanol species (-Si-O-H) which 
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condense with other silane (2b) or silanol (2a) groups to form covalent siloxane bonds (Si-O-
Si) 70.  
If hydrolysis is complete, the alkoxide groups are replaced by hydroxyl groups and orthosilicic 
acid Si(OH)4 is formed. Orthosilicic acid is stable in water at room temperature as long as its 
concentration remains below the solubility limit of the amorphous phase (typically 100 ppm, 
~1 mM) 71. Above this concentration, it will undergo autopolycondensation to lower the 
concentration of orthosilicic acid in solution and generate oligomers. These serve as nuclei for 
the formation of particles. As the levels of orthosilicic acid above the solubility limit decrease, 
smaller, more soluble particles dissolve, releasing silicic acid that redeposits onto the larger 
particles present, a process is known as Ostwald ripening. At circumneutral pH (6.0-8.0), 
particles can continue growing as isolated particles until the levels of soluble silica reach the 
solubility of amorphous silica, as the particles carry a negative charge and repel one another. In 
more acidic conditions and/or if salts or other charged species are present, then the surface 
charge that causes repulsion between individual particles is reduced or canceled, and the 
particles aggregate to form dense 3D networks 72(Figure 1-13). More generally, many reaction 
conditions such as precursors nature, pH, temperature, molar ratios of reactants, solvent 
composition have an important influence on the sol-gel process, in terms of kinetics, particle 
size and condensation state and properties of the final gels73.  
 
Figure 1-13 The process of sol-gel in silica formation with different conditions 
In addition to tetrafunctional silicon alkoxides Si(OR)4, organosilanes bearing one non-
hydrolysable groups can also be used to form organically-modified silica materials. While the 
hydrolysis/condensation reactions remain identical, the nature of these additional organic 
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moieties impact on the solubility and reactivity of the silane and, therefore on the structure and 
properties of the obtained particles or gels. Because only three Si-O-Si bonds can be formed, 
the resulting networks are less stable than pure silica ones but are usually more flexible. They 
also incorporate an additional function that can be useful for further modification of the 
material. 
1.3.2. Preparation of silica nanoparticles 
1.3.2.1 Main synthetic pathways 
In practice, a wide variety of methods and procedures have been introduced and applied for the 
fabrication of different silica particles of various sizes, shapes, structures and physicochemical 
characteristics.  
 
Figure 1-14 Two mainly methods to synthesis of silica nanoparticles. (a) Stöber method; (b) 
Reverse phase microemulsion 
The Stöber method74 is the most popular route to obtain colloidal silica. The synthesis procedure 
involves the controlled hydrolysis and condensation of a silica precursor in ethanol and water 
mixture solution with ammonia as a catalyst (Figure 1-14a). The particle formation process is 
strongly influenced by the surface potential of the silica particles and the ionic strength of the 
reaction medium so that a careful control of process parameters (volume, stirring, mixing rate) 
is required to get access to monodisperse populations, especially in small size domain. To 
improve the size distribution, a seed-growth strategy was explored that starts from well-defined 
small colloids that are further grown in a TEOS/ammonia solution75.  
An aqueous route using water glass solutions (i.e. highly concentrated aqueous solutions of 
sodium silicates) allows to form silica nanoparticles by simple mixing with an aqueous acidic 
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solution76. The size of the particles is controlled by the concentrations of the two reagents as 
well as other processing parameters, such as addition rate, stirring rate, temperature, etc. The 
microemulsion method77 is a widely used technique to prepare materials with novel and unique 
properties at the nanoscale. A microemulsion consists of two types of homogenous systems of 
water-in-oil (W/O) or oil-in-water (O/W) that are thermodynamically stable thanks to surfactant 
molecules (Figure 1-14b). The system is composed of a dispersion of nanodroplets, also known 
as nanoreactors, that act as cages that limiting particle growth and therefore determining the 
final size of nanoparticles. Several other factors can affect the morphology of nanoparticles, 
such as the texture of these nano-droplets, reactant concentration, type of surfactant, 
concentration of capping agent etc78. Finally, silica particles can also be obtained using spray-
drying techniques but this approach has been mainly applied to hybrid and porous 
nanomaterials79, as described below. 
1.3.2.2 Size control 
By the Stöber method, the size of the particles can be tuned by adjusting the reaction condition. 
Monodisperse silica spheres with uniform diameters ranging from 50 nm to 2 µm were 
successfully prepared in this system in one step. The particle size can be very uniform, but the 
particle size distribution broadens as the reaction conditions are changed to form larger particles. 
Boissière et al. developed a two-step process whereby the hydrolysis at low pH (1-4) is 
completed before the condensation reaction is initiated by the addition of sodium fluoride (NaF),  
yielding to spherical particles in the micrometric size range80. Smaller NPs that can be prepared 
by a modified Stöber method without aggregation have diameters as small as 12 nm using an 
heterogeneous reaction with lysine or arginine instead of ammonia as a basic catalyst81. Rida 
et. al. reported that amorphous silica was synthesized using sodium silicate and hydrochloric 
acid by precipitation, the average size of silica nanoparticles can be finely tuned in the range 
148-212 nm by changing the chain length of a cationic surfactant82. 
The diameter of silica NPs that obtained from reverse microemulsion depends on the diameter 
of water nanodroplets in which the hydrolysis reaction is limited as well as the ratio of water to 
surfactant. The particle size decreases and the particle population become more monodisperse 
with increasing water-to-surfactant molar ratio. The particles obtained by this method have 
higher uniformity of particle size ranging from 20 to 100 nm. The other approach for the 
preparation of spherical, ultra-small silica NPs is the oil-in-water microemulsion. This process 
has been mostly used for synthesizing organically modified silica nanoparticles known as 
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ORMOSIL nanoparticles83. The results showed that the properties of the surfactants, such as 
solubility, play a significant role in the obtained size distribution of the resulting nanoparticles. 
Large-scale preparation of silica microspheres via a spray drying process could be achieved and 
the size could be easily controlled from ~50 to 100 μm from the same diameter nozzle via 
changing the initial solute content or changing the drying temperature84. 
1.3.2.3. Shape control 
The shape of nanoparticles dramatically affects their blood circulation and cell penetration 
behavior. It has been reported that nanorods penetrate tumor tissues more rapidly than 
nanospheres likely because of improved transport through tumor vasculature pores85. These 
results suggest the importance of controlling the shape of nanomedicine for favored circulation 
or tissue penetration properties. Although there are many methods for the size-controlled 
preparation of silica nanospheres, only a handful of methods have been reported for the 
preparing of silica nanostructures with different shape: cone86, sphere, matchstick87, rod, wire 
88(Figure 1-15).  
 
Figure 1-15 Silica nanoparticles with various shape: cone, sphere, matchstick, hollow rod 
The methods for shape control of silica nanomaterials are mainly using templates or through 
polymer adsorption. For example, silica nanotubes can be prepared with various templates, 
including metal salts, porous anodic alumina or polycarbonate membranes, cylindrical polymer 
brushes, and nickel-hydrazine complex nanorods89. Recently, Kuijk et al. reported the PVP-
mediated synthesis of monodisperse silica nanorods with a tunable aspect ratio in an emulsion 
system90. Using the similar method, Zhang et al. prepared a series of silica nanowires by 
adjusting the temperature and time of the reaction91.  
1.3.2.4. Structure control 
Silica nanoparticles can be divided into non-porous silica and porous silica nanoparticles. The 
non-porous silica particles, as typically obtained by the Stöber process, have some porosity in 
the micropore range that means these pores are too small to serve as host. Drug incorporation 
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can therefore only be achieved by encapsulation or surface grafting. Thus a wide amount of 
work been devoted to the preparation of particles with pores of dimensions compatible with the 
incorporation of drugs. 
Mesoporous silica nanoparticles (MSNs) The first reported mesoporous silica materials were 
molecular sieves called M41S but MCM-41 and SBA-15 materials with larger pore size and 
better organization rapidly became the most studied, with the pore size ranging from 2-10 nm 
and 2D-hexagonal and 3D-cubic structural characteristics92. Further on, mesoporous silica 
nanoparticles (MSN) could be synthesized using a simple Stöber-like sol-gel method in the 
presence of a template made of micellar rods. The result is a collection of nanosized spheres or 
rods that are filled with a regular arrangement of pores. The template can then be removed by 
washing with a solvent adjusted to the proper conditions (Figure 1-16). 
 
 
Figure 1-16 Soft template synthesis of mesoporous silica nanoparticles 
Mesoporous nanoparticles are obtained after removal of the structure directing agent leading to 
the opening of the porosity. MSNs typically have a high specific surface area (600-1000 m2.g-
1 ) and a large pore volume (0.6-1.0 cm3 .g-1 ) that allow for high levels of drug loadings to be 
achieved. Typical pore dimensions of MSNs are 2-4 nm, but recent advances have made it 
possible to synthesize MSNs with pore dimensions as large as 50 nm, which are generally 
referred as large-pore MSNs93. Several synthetic methods have been proposed to enlarge the 
pore sizes of MSNs including post-enlargement by introducing a swelling agent (1,3,5-
trimethylbenzene)94 into the core part of micelles or using large molecular weight block 
copolymers (F127, P123, and PS-b-PEO) with long organic molecular chains as mesopore 
template95.  
 
Periodic mesoporous organosilicas (PMO) have both organic and inorganic groups as an 
integral part of the porous framework96. The framework of PMOs consists of inorganic 
components (polysilsesquioxanes) uniformly bridged by organic linkers. Most of the bridged 
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polysilsesquioxane can be generically represented by the formula O1.5Si-R-SiO1.5. where R 
represents the organic bridging group. Each individual organic group is covalently bonded to 
two or more silicon atoms in the framework (Figure 1-17). Depending on the synthetic 
conditions used to make mesoporous organosilicas, the mesoscale structure can either be 
amorphous or crystalline. The methods used to make mesoporous organosilicas are 
evaporation-induced self-assembly, surfactant-mediated synthesis, post-synthetic grafting, and 
co-condensation 97,98. 
 
Figure 1-17 Synthesis routes of periodic mesoporous organosilicas 
Hollow/rattle-type particles. With the rapid development of a variety of applications, new 
demands for mesoporous silica nanoparticles with special structure and performance gradually 
increase. Recently, hollow and rattle-type nanomaterials have been actively explored for 
enzyme immobilization, catalysis, DNA delivery99-101. Hollow/rattle-type MSNs with 
interstitial hollow space and mesoporous shell have low density and high specific area, which 
are ideal as new-generation drug delivery systems with extraordinarily high loading capacity 
(Figure 1-18). 
Conventionally, hollow-type mesoporous silica nanoparticles are fabricated using a dual 
template method with a hard template or soft template to generate a hollow interior and a soft 
template as a pore-forming agent to induce mesopores in the shell. After the sol-gel process 
around the pore template to generate silica matrix coating on the core template, the templates 
could be removed by thermal calcination or/and solvent extraction. For rattle-type particles, the 
multi-step coating on the core particles is needed to generate a removable middle layer. The 
fabrication is tedious, high-cost and difficult to fabricate nanoparticles with small size and 
complicated structure. Therefore, new methods should be investigated for developing simple, 
controllable, and scalable fabrication.  
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Dependent on the fabrication method, hollow/rattle-type MSN can be divided into ordered pore 
particles and disordered, non-oriented counterparts. Ordered straight channels are believed to 
be favorable for diffusion of adsorbed molecules, whereas disordered pore in the shell is 
considered to be advantageous for controlled and multi-stage drug release102. Compared with 
conventional ordered MSN, hollow/rattle-type particles present an additional challenge: all of 
the pores connected to the hollow interior must be controlled. In hollow particles with multiple 
pore connectivity to the hollow center, the absence of control would result in the loss of all of 
the contents of the particles. Up to now, development of hollow/rattle-type MSN is still in its 
very early stage in terms of both synthesis and applications.  
 
Figure 1-18 The structures of the hollow and rattle-type mesoporous silica nanoparticles 
1.3.3 Surface functionalization of silica nanoparticles 
The surface functionalization of silica nanoparticles can not only increase the colloids stability 
but also produce unprecedented properties. Most importantly, the surface properties of 
nanoparticles influence their interaction with the biological system, which includes cellular 
internalization, cellular trafficking, biodistribution103. Therefore, surface modification of 
nanoparticles is essential in order to enhance the disease targeting and therapeutic effects. There 
are currently three main surface modification methods that can be summarized as co-
condensation, post-synthetic grafting silanization, surface polymerization.  
1.3.3.1 Co-condensation 
In the co-condensation technique, it is possible to directly functionalize the surface of silica 
nanoparticles during the synthesis process104. This approach incorporates the organic groups 
into the silica framework during the one-pot synthesis process via sol-gel method by 
introducing the corresponding organosilane (APTES, CTES, etc.) in the reaction solution 
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containing the tetrafunctional silane. Co-condensation revealed to be superior for the 
functionalization of the internal surface of the mesoporous silica nanoparticles.  
1.3.3.2 Post-synthetic grafting strategy 
Post-synthesis grafting is usually implemented for functionalizing the external surface of silica 
nanoparticles105. The coupling of surface silanols and organosilanes occurs by hydrolysis of the 
latter and its condensation so that care must be taken to avoid its self-condensation. Thus 
organic solvents with trace water are frequently employed to perform silanization. However, it 
frequently leads to a heterogeneous surface chemistry, where grafting occurs with higher 
density in pore openings but at a lower eﬃciency on the interior framework106. 
1.3.3.3 Polymer coating 
Surface polymerization of silica nanoparticles can be achieved by physical absorption and 
chemical conjunction. The silica surface is negatively charged at pH above ca. 3,  that means it 
can easily adsorb positively-charged polymers for simple surface modification, such as PEI, for 
DNA delivery 107. Covalent grafting includes both “grafting to” and “grafting from” 
approaches108. “Grafting to” is performed via coupling of functionalized polymer with well-
matched silica surface groups. This method can lead to low grafting yield due to steric crowding 
of reactive sites. The “grafting from” method provides a higher control of functionality and 
density of the polymer coating. In this process, a higher grafting density can be attained by 
implementing small monomers with no steric limitation thus providing ease of access to the 
reactive sites on the particles surface. For instance, the hyperbranched ring-opening 
polymerization of aziridine induced by silanol groups constitutes hyperbranched 
polyethyleneimine-modiﬁed particle surfaces, which makes high positively-charged particles 
that have elevated electrostatic stability under physiological conditions109. The surface of 
organically-modified silica nanoparticles can also be grafted by various biomacromolecule 
agents such as carbohydrates, polypeptides, antibodies or nucleic acid aptamers110. Overall, 
many functional moieties can be conjugated to the surface of the silica nanoparticles due to the 
versatile silane chemistry. Thus, silica nanoparticles make it easy to obtain many of the desired 
surface properties for biomedical applications. 
 
1.3.4 Composite and hybrid silica nanoparticles 
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Besides surface modification, incorporation of additional molecules, polymers or particles to 
silica at the nanoscale has been widely described. For instance, silica-based composite 
nanostructures have been extensively studied. Three main approaches are possible: surface 
modification, internal encapsulation, and uniform compounding (Figure 1-19). 
The first approach where polymers are localized on the silica particles surface has been 
described above. But silica/polymer nanoparticles can also be achieved by “encapsulating” 
polymer nanoparticles or biomacromolecule with a silica shell. This core-shell nanohybrid 
usually start from polymer nanoparticles and then grow a silica layer on their surface. 
 
Figure 1-19 The three approaches for silica/polymer nanocomposites synthesis. (a) Surface 
modification. (b) Internal encapsulation. (c) Uniform compounding 
This structure can effectively overcome the flexibility of polymer materials and improve their 
stability in biological applications. Quesada et al. reported a novel type of hybrid material based 
on a PLGA nanoparticle core and a redox-responsive amorphous organosilica shell111. This 
silica/polymer nanoparticle exhibit excellent stability and show great potential as stimuli-
responsive vehicles for drug delivery. Moreover, the rigid inorganic silica layer can protect the 
biological macromolecules such as proteins or nucleic acids from being prematurely degraded 
when these molecules encapsulated inside. Fujiwara and co-workers succeeded in the direct 
encapsulation of bovine serum albumin (BSA) and duplex DNA in silica microcapsules by 
microemulsion112. They found these systems can achieve controlled release by carefully design 
the silica shell. These microcapsule materials encapsulating biomacromolecules also have been 
applied to biotechnologies such as immobilized enzyme etc. The other strategy for 
silica/polymer nanocomposite refers to construct homogenous silica/polymer nanocomposites. 
One possibility is to introduce the polymer in the initial silica precursor solution, and then 
spontaneous form a uniform silica/polymer materials by sol-gel or microemulsion methods, as 
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shown for PLLA or PEG113. Alternatively, the use of spray-drying techniques has been 
efficiently used for one-pot preparation of silica/poly-L-lysine/alginate nanocomposites that 
exhibit homogeneous structures114.  
Alternatively, hybrid functional silica nanoparticles or nanohybrids can be designed that own 
specific optical, magnetic or thermal properties from small molecular or inorganic nanoparticles 
associated with silica. The encapsulation approach can be realized during the process of silica 
polymerization either with Stöber or reverse micelle method. Tan and co-workers develop a 
series of dye-doped silica nanoparticles using a reverse microemulsion method which exhibit 
an excellent optical stability in biomedical imaging115. In parallel, many MRI contrast agents, 
photosensitizers, and inorganic nanoparticles, such as gold, iron oxide, quantum dots, Gd2O3 
etc also used to build the core-shell structured hybrid silica nanoparticles with different 
structures22, 116, 117 (Figure 1-20). 
 
 
Figure 1-20 Schematic (a-e) pictures of different structure of core-shell nanoparticles 
Zhao et al. encapsulated gold nanorods with a mesoporous silica shell by the modified Stöber 
method. After modifying with a targeting peptide RGD, the hybrid nanoparticles showed 
significantly enhanced sensitization of triple-negative breast cancer to megavoltage energy118.  
Many examples of inorganic colloids grafted onto the surface of silica nanoparticles are also 
found in the literature. Stoeva et al. used an amino-modified silica as a core, and then the 
assembly of iron oxide nanoparticles as a first shell, followed by the electrostatic-mediated 
deposition of Au seeds to form a gold shell around the SiO2-Fe3O4 particles. The multilayer 
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magnetic nanoparticles exhibited multifunctional properties including magnetic and optical, as 
well as cooperative DNA binding119.  
1.4 Silica-based nanomaterials in biology and medicine 
1.4.1 Toxicity of silica nanoparticles in vitro and in vivo 
In recent years, large-scale production and application of silica nanoparticles lead to the risk of 
increased exposure to workplace staff. Silica food additive also in a nanometer size range so 
the general population may be more exposed than initially expected. In addition, medical 
applications of silica nanoparticles will also introduce them into the human body for disease 
diagnosis and treatment. Therefore, this growing exposure potential has caused global concern 
about the safety of silica nanoparticles. More and more research was devoted to the toxicology 
research of silica nanomaterials. Although it remains to be clarified, studies have shown that 
physicochemical properties such as size, surface area, and surface characteristics play a key 
role in the toxicity of silica nanoparticles.  
Nanoparticle-induced oxidative stress (reactive oxygen species production, ROS) may damage 
cellular components and cause cell death through the interaction between surface silanol groups 
and cell membrane120. Yu et al. explored the impacts of geometry, porosity, and surface charge 
of SiO2 on cellular toxicity and hemolytic activity. Results demonstrated that toxicity of SiO2 
was highly cell typed and nanoparticle concentration dependent121. For non-porous silica 
nanoparticles, toxicity increases with decreasing particle size. However, mesoporous materials 
have the opposite effect with increasing porosity. Interestingly, a recent study showed that the 
mesoporosity of some silica particles tends to collapse with time, increase the plain surface of 
the colloid and there or its toxicity122. Along the same lines, grafting the particle surface with 
cationic groups (such as amino) or neutral hydrophilic groups (such as PEG )or preparing hybrid 
particles incorporating cationic polymer (such as chitosan) decreases the observed toxicity123. 
Indeed, all these effects were shown to dose-and cell-dependent. 
Several in vivo toxicity studies of silica-based nanoparticles have been carried out using rats 
and mice, and exposure through various routes of administration124, 125. In general, short-term 
exposure to SiNPs induced adverse effects in the lungs, kidneys, liver, and brain. SiNPs 
administered mainly via inhalation, ingestion, and intravenous routes were majorly distributed 
in the liver, lungs, spleen, and kidneys, and in the brain of the intranasally exposed rats. Most 
of the administered SiNPs were excreted via feces and to a lesser extent via urine, in a size and 
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shape dependent manner. However, in most cases, the administered doses were very high 
compared to relevant human inhalation and ingestion exposures to amorphous silica. Some 
studies showed an accumulation of SiNPs in organs such as the liver, but such accumulation 
was not associated with any major effects126. However, long-term effects of accumulated SiNPs 
were not studied. It is surprising that in contrast to acute studies, no toxicity (local or systemic) 
was observed in chronic oral and dermal exposure studies, regardless of the size of SiNPs and 
the high doses used. Moreover, surface-modifed SiNPs showed a signifcant increase in 
absorption by the GI tract compared to bare SiNPs. Dosing SiNPs via intravenous injection 
showed in all studies some sign of damage/toxicity127. No clear type or size-dependent effect 
can be identified from the set of reviewed studies. Furthermore, where genotoxicity was studied, 
it was not clear whether SiNPs were taken up by the target cells or were able to reach the tissue 
examined, which is obviously needed to exert a direct genotoxic effect. 
1.4.2 Degradation of silica nanoparticles 
Typically, the produced silica nanoparticles aqueous suspension stored at or below room 
temperature with relatively high silica concentration and low ionic strength (less than 0.01 M 
to avoid aggregation). However, when placed in simulated (in vitro) or effective (in vivo) human 
conditions, a fast dissolution in physicochemical conditions occur, especially at higher 
temperatures and ionic strength128. The dissolution process of amorphous silica in aqueous 
media includes three steps: i) hydration, in which water is absorbed onto the siloxane 
framework, ii) hydrolysis, in which siloxane are hydrolyzed into silanols, and ii) ion exchange 
processes, which consists of nucleophilic attack of OH- leading to the leaching of silicic acid 
(Figure 1-21). As a result, the synthetic process, post treatments and surface functionalization 
of silica NPs ought to affect their hydrolytic stability. Investigations have thus been carried out 
to assess the direct influence of the following parameters on the degradation of silica NPs, 
including size and porosity, morphology and degradation medium, ipore size, condensation 
degree, functional groups, and concentration of the particles. Kuroda and co-workers studied 
the dissolution behavior of colloidal silica with various diameters under static aqueous 
conditions. The results showed that nonporous silica nanoparticles were degraded much more 
slowly than mesoporous silica nanoparticles and the 10 nm particles were degraded more slowly 
than the 5 nm ones129. This highlights that the diameter of the silica NPs does affect their 
degradability rate as the relative outer surface of NPs increases as the NPs diameter decreases.  
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Figure 1-21 Mechanisms and regulating factors of the degradation of silica nanoparticles in 
aqueous media122. 
The key role of the surface area was further demonstrated by the comparison between 
aggregated MSN (non-dialyzed) and colloidal MSNs (dialyzed), which revealed that 
aggregated MSNs were not fully degraded (65 wt%) even after 2 weeks. However, Lu and co-
workers showed that the degradation of MSNs is independent of their diameter with 390, 310, 
200, and 150 nm NPs in simulated body fluid (SBF) at 37 °C. This suggests that for large 
particles whose accessible surface is mainly internal (i.e. porosity) a variation of the NP 
diameter would play an insignificant role in the degradation130. Varying condensation degrees 
of the silica matrices also allow for tuning their dissolution rate. Hence, calcined mesoporous 
silica hardly degrades in months, well-condensed MSNs slowly degrade in weeks, and partly 
condensed MSNs degrade in a few days (down to 24 h for large-pore MSNs). Nanospheres 
have been shown to dissolve faster than nanorods, and so do smaller nanorods when compared 
with longer ones131.  
The surface functionalization and aggregation of the NPs, as well as the degradation media 
(water, PBS, serum, pH, NPs concentration, closed or continuous flow systems), impacted 
significantly the degradation kinetics. The incorporation of organic moieties was reported to 
also control the degradation kinetics. Noncovalently doped silica NPs were prepared in order 
to create defects in the silica matrix and to accelerate its dissolution while releasing a molecule 
of biological interest132. Silica or PMOs were also covalently linked with specific redox-
cleavable (disulfides, tetrasulfide, platinum complexes) or enzymatically cleavable (oxamide, 
lysine, ester) organic moieties in order to trigger the degradation of the NPs inside cells133. 
These concepts were demonstrated both in solution and in cells via various techniques. On the 
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contrary, stable silica nanoparticles and PMOs have been designed to inhibit hydrolytic 
degradation, thanks to hydrophobic and chemically stable ethylene, ethylene-coumarin, 
ethenylene, and phenylene bridges. The degradation in aqueous solution could thus be inhibited 
for at least 15 to 28 d, or, triggered in a few days via external stimuli and the careful selection 
of silsesquioxane bridges134. 
Much less is known about the intracellular degradation of silica nanoparticles. Earlier reports 
on the evolution of silica-biopolymer nanoparticles within the intracellular space of mammalian 
cells have suggested that, after 24 h, only the bio-organic fraction was degraded while the 
inorganic part remained intact135, 136. Further experiments performed with mesoporous 
nanoparticles evidenced that after uptake and intracellular trafficking, they can be released by 
the cells.137 However no modification in particle size or morphology was reported. Later on, it 
was demonstrated that plain silica particles could undergo a surface erosion process within 
endosomal compartments, with the release of soluble forms of silica outside the cells138. Since 
then, further evidences of the ability of silica to dissolve intracellularly were accumulated139-
142. So far, the most plausible mechanism is related to the dissolution equilibrium of silica 
between intracellular compartments exhibiting a high silica content and the intracellular space 
where the concentration of silica species is low. Hence, no specific biodegradation pathway has 
been identified. 
1.4.3 Drug delivery applications 
1.4.3.1 Drug loading 
The use of silica materials for delivery and controlled release of drug payloads was reported as 
early as 1983. Initially, silica was used mainly in the form of xerogels loaded with bioactive 
agents. For example, silica xerogels have been used as an implantable carrier for controlled 
drug release143. Silica nanoparticles emerged as a popular drug delivery system about 10 years 
later. A wide range of different kinds of payloads, including small molecule drugs, 
photosensitizers for photodynamic therapy (PDT), proteins, peptides, DNAs, and RNAs, have 
been incorporated into silica nanoparticles to target diseases such as cancer, heart disease, and 
Parkinson’s disease144-146. Using silica nanoparticles to deliver bioactive molecules can protect 
them from degradation under physiological conditions, allow for controlled release, prolong 
their blood circulation, improve disease targeting, and minimize side effects on healthy tissues. 
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Depending on the properties of the cargoes delivered, different formulation strategies were used 
for preparing silica nanomedicines. 
There are several strategies for loading drugs into silica nanoparticles: encapsulation and 
surface grafting, mesoporous adsorption. 
Encapsulation. The simplest method is to capture a hydrophilic drug or imaging agent in a 
silica matrix by non-covalent interaction. Initially, this method was typically used for the 
preparation of fluorescent silica nanoparticles for optical imaging. Luminescent metal 
complexes such as Ru(bpy)3
2+ have also been incorporated into SiNPs for fluorescent imaging, 
for instance allowing to follow their biodistribution and urinary excretion147. Further this 
method was used to construct silica nanocarriers for drug delivery. Schmidt et al. prepared green 
fluorescent protein (GFP)-doped silica nanoparticles with a narrow size distribution. GFP was 
chosen as a model protein using for intracellular protein delivery148. However, neither the 
previously described Stöber method nor the inverse microemulsion method effectively binds 
hydrophobic molecules to the silica matrix. In order to solve this problem, organically modified 
silica nanoparticles can be used. The hydrophobic drug is first dissolved in the organic phase 
of the inverse microemulsion, which allows for more efficient distribution into the aqueous 
water droplets and is more efficiently captured within the silica nanoparticles by hydrolysis of 
the silane precursor149. Some recent experimental results indicate that some therapeutic 
photosensitizing agents can be encapsulated within the nanoparticles as nano-therapeutic 
agents. On the one hand, the photosensitizer retains the function of producing singlet oxygen 
after being embedded in the silica matrix, and on the other hand, the negative effects of the 
photosensitizer, such as toxicity or hydrophobicity, are reduced when embedded in the silica150. 
 
Figure 1-22 Structure of mesoporous silica nanoparticles applied for delivery of siRNA 
Surface grafting. Drugs can also be grafted on the surface of silica nanoparticles by chemical 
binding or physical adsorption. A typical example is fluorescent dyes or contrast agents 
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decorating silica nanoparticle via covalent cross-linking, such as EDC/NHS condensation 
chemistry. Rieter et al. synthesized silica nanoparticles containing Ru(bpy)3
2+ via the reverse 
microemulsion method and functionalized the surface of the silica with Gd3+-chelating ligands 
for intracellular dual-functional imaging151. Other methods of grafting include a click reaction 
or a disulfide bond152, 153. However, the electrostatic forces that govern the physical adsorption 
of biocompatible macromolecules are often the most simple and efficient method for 
immobilization. Many macromolecules (protein, DNA, RNA) can be physically adsorbed onto 
the nanoparticles surface for drug delivery154, 155. As shown in Figure 1-22, phosphonate-
modified mesoporous silica nanoparticles were further surface modified using electrostatic 
attachment of a polyethyleneimine (PEI) polymer, which was used for subsequent covalent 
attachment of poly(ethylene glycol) (PEG) or electrostatic based loading of siRNA107.  
Pore impregnation. The MSN-based drug loading method mainly involves physical adsorption 
as a result of particle impregnation by a highly concentrated solution of the active molecule. 
Wang et al. reported a method in which MSN was immersed in a drug-containing solution until 
equilibrium was reached, and most of the drug penetrated deeply into the pores or hollow shell 
of the carrier156.  
1.4.3.2 Targeted delivery and control release 
Targeted delivery. One of the main issues in biomedical sciences nowadays is to develop drug 
systems that can be specifically targeted to the desired site where there is solely diseased tissue, 
thereby avoiding interaction with healthy tissue. Cell-specific targeting with nanocarriers may 
be accomplished by using passive or active mechanisms157 (Figure 1-23). Passive route is 
directly related to circulation time and can be realized by the enhanced permeability and 
retention (EPR) effect158. Polymers are the most commonly used passive targeting agents, 
which exhibits relatively long blood circulation and low uptake of the reticuloendothelial 
system (RES) organs. As a result, when these passive groups are used to modify SiNPs these 
show better passive targeting of tumor sites159. Xia and coworkers reported 50 nm mesoporous 
silica nanoparticles coated with PEI/PEG copolymer reached a high passive accumulation of 
about 12% at the tumor site, compared with 1% of 100 nm phosphonate-coated mesoporous 
silica nanoparticles. The increased tumor accumulation further brought an enhanced tumor 
inhibition rate160. Active targeting involves surface modification with antibodies, peptides, folic 
acid, or aptamers. For example, SiNPs modified with folic acids through EDC-NHS 
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conjugation showed an excellent to label cells 161. Dye-doped SiNPs modified with two 
aptamers allowed to improve their efficiency for cancer imaging and therapy162. 
 
 
Figure 1-23 Passive or active mechanisms of silica nanoparticles applied for drug delivery 
Prolonged release. The simplest method to control the drug release behavior is through 
encapsulation inside the silica matrix that can change the release by adjusting the composition 
and structure of silica nanoparticles. Mebert et al. encapsulated two types of antibiotics via 
multilayer silica shell forming core-shell silica particles. In particular the silica shell deposition 
was favored by the positively charged layer of gentamicin coating on the core particle surface. 
Shell modification by thiol groups finally allowed for rifamycin sorption. The antibacterial 
activity of the core-shell particles against Staphylococcus aureus and Pseudomonas aeruginosa 
demonstrated the dual release and action of the two antibiotics163. The porous features of MSNs 
also offer an interesting parameter to control the drug release. Recently, Zhang et al. discovered 
that mesoporous silica improves the dissolution rate and bioavailability of hydrophobic 
telmisartan (TEL) after oral administration164. Increasing the pore size also improves the drug 
dissolution rate because of decreased diffusion hindrance.  Pore morphology is believed to 
greatly affect the properties of the material and the loading of the drug. Wang et al. found that 
cilostazol has a faster diffusion rate from MCM-48 with interconnected pore structure 
compared to MCM-41 with an unconnected pore network165,166. 
Endogenous stimuli-responsive drug delivery. Endogenous stimuli are intrinsic conditions of 
diseased tissues, such as strong redox conditions, acidic environments, and the presence of 
certain types of enzymes. The design of nanocarriers that are sensitive to endogenous stimuli 
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can provide good inspiration for controlled drug delivery. Silica nanoparticles with pH-
sensitive gates have been developed. Many materials including polyelectrolytes, 
supramolecular, pH-sensitive linkers, and acid decomposable inorganic materials are 
commonly used as drug barriers for pH-responsive drug delivery systems. Feng et al. 
constructed MSN-based pH-responsive drug delivery systems using polyelectrolyte 
multilayers. Doxorubicin was loaded into the polyelectrolyte layers and nanopores of the 
prepared MSN. The results show that MSN can achieve controlled release of the drug under 
acidic conditions167 (Figure 1-24).  
 
 
Figure 1-24 Schematic illustration for the fabrication of pH-responsive carrier systems based 
on polyelectrolyte multilayer-MSN 
Disulfide bonds have caused great interest in controlled drug delivery systems due to its high 
redox sensitivity, particularly in tumor tissue. Giri and coworkers synthesize an MCM-41-based 
controlled release delivery system that is capped with disulfide bonds and superparamagnetic 
Fe3O4 nanoparticles and was stimuli-responsive and chemically inert to guest molecules 
entrapped in the matrix168. The upregulated expression profile of specific enzymes (matrix 
metalloproteinases, Cathepsin B, β-d-galactosidase) in pathological conditions such as cancer 
or inflammation, makes it an interesting stimulus to achieve enzyme-mediated drug release169. 
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In addition, there are some biological substances including glucose, ATP, and H2O2, which are 
also used to design responsive drug delivery systems170. Sun et al. introduced a glucose response 
controlled the release of the new insulin system by applying a multi-layer of glucose oxidase 
and catalase to the surface of the MSN171. MSN is used as a drug reservoir, and a multi-layer 
of glutaraldehyde cross-linked enzyme is used as a valve to control the release of insulin in 
response to exogenous glucose levels.  
 
Exogenous stimuli-responsive drug delivery. Unlike endogenous stimuli, exogenous stimuli 
are performed by externally applied stimuli, including temperature changes, magnetic fields, 
ultrasound, and light and electric fields. Although this approach appears to be unattractive, 
exogenously stimulating reactive drug delivery systems may be more beneficial due to 
heterogeneous physiological conditions in the population.  
 
Figure 1-25 Schematic illustration of the behavior of dual-responsive release system in aqueous 
medium 
As an example, Poly(N-isopropylacrylamide) (PNIPAM) is well-known as a thermally 
responsive polymer. Chen et al. reported the thermal response of silica nanoparticles covalently 
modified with PNIPAM. The nanocarriers prevent drug release above 30 ° C, whereas at 
temperatures between 25 ° C and 30 ° C, the embedded drug can be released quickly due to the 
polymer chain stretching and swelling in aqueous solution172. Drug release can also be 
controlled by the application of a magnetic field. Chen et al. used a simple technique to 
conjugate amine-modified MSNs and 2,3-dimercaptosuccinic acid-functionalized Fe3O4 
nanoparticles173. While a negligible amount of drug is released in the absence of a magnetic 
field, its application removes some of the iron oxide nanoparticles by breaking the chemical 
bonds, which in turn leads to a rapid release of the drug. Furthermore, the results show that the 
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release profile depends on the intensity and duration of the magnetic field. An ultrasound-
responsive MSN drug delivery system was also developed by Paris and coworkers174. As 
illustrated in Figure 1-25, the temperature-ultrasound dual responsive random copolymer was 
grafted on the MSN surface to act as a gatekeeper. The temperature conversation is an on-off 
switch for model drug loading. At low temperature, 4°C, the model drug molecules could be 
diffused into the open nanopores, whereas at a temperature of 37°C, the hydrophobic polymer 
tightly collapsed onto the MSN to block the drug molecules in the nanopores. Upon ultrasound 
irradiation, the sensitive polymer changes its hydrophobicity and conformation toward coil-like 
gate-opening and cargo-releasing.  
1.4.3.3 Summary 
Here gathered selected examples illustrate the tremendous past developments and recent 
activity in the field of silica-based nanomaterials intended as carriers for controlled drug 
delivery. The versatility of silica chemistry combined with elaborated organic synthesis offers 
an unlimited playground to design more and more sophisticated devices. These developments 
are indeed not limited to silica and are fed by advances in biology and medicine to enhance 
targeting specificity and therapeutic efficiency. Although not thoroughly discussed here, similar 
trends exist in the area of biomedical imaging and the emerging field of theranostics clearly 
demonstrate how nanotechnology should, in a close future, allow to strongly improve 
healthcare.  
However, the use of nanoscale materials still raises many safety concerns that explain, at least 
for some part, why nanomedicine products are still scarce on the market. A major issue 
currently faced is related to the evaluation of these safety concerns while avoiding animal tests. 
In particular, while the in vivo behavior of molecules can be quite well-predicted on the basis 
of simple physicochemical parameters (pKa, solubility, hydrophilicity), colloidal stability, 
tissue adhesion/penetration, extra- and intracellular degradation are, among many others, 
parameters that have to be fully taken into account for nanomaterials. Going from a 2D 
perspective to a 3D approach may allow progress in the study, understanding, and applications 
of nanomedicine.  
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1.5 Silica-biopolymer composite hydrogels 
1.5.1 Nanocomposite hydrogels 
Hydrogels are polymeric three-dimensional networks that can maintain up to 99% of water and 
are increasingly attractive as scaffolds for tissue engineering and drug delivery because of their 
similarity to microenvironments of native tissues175 (Figure 1-26). They can exhibit several 
remarkable characteristics, such as versatility in fabrication, variety in composition, high 
tunability in the physical, and chemical properties, high moldability in shape and excellent 
biocompatibility. Moreover, some hydrogels could undergo reversible and significant changes 
in structure, shape, or property after being exposed to external stimuli, such as pH value, 
temperature, ionic strength, enzymatic activity etc. Therefore, hydrogels as promising materials 
are of greatest significance in the biomedical fields and have been extensively studied in drug 
delivery.  
  
Figure 1-26 Cross-linked nanocellulose hydrogel and their applications in wound dressing 
Since Wichterle and Lim first reported a hydrogel for contact lens application in 1960 based on 
crosslinked poly-2-hydroxy-ethylmethacrylate (PHEMA) hydrogel by use of ethylene glycol 
dimethacrylate (EGDMA), significant progress has been achieved and a diverse range of 
polymers have been used for the synthesis and fabrication of hydrogels for various 
applications176. Besides PHEMA, a great number of synthetic polymers were explored for the 
preparation of hydrogels by polymerization or cross-linking, such as PEG, PVA, PAA, PVP, 
PHPMA as well as polypeptides and polyesters. Polymeric hydrogels from synthetic sources 
are advantageous because they usually possess controllable chemical structure and architecture, 
degradation rates, and mechanical strengths. However, most of them lack biological cues for 
biological applications177, 178. Natural hydrogels derived from natural sources, such as chitosan, 
hyaluronic acid, gelatin, collagen, alginate are appealing for biological applications because of 
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their cell-interactive properties, cell adhesion and cell signaling, as well as biodegradability and 
excellent biocompatibility179-182. 
Hydrogels have a variety of properties, such as absorption capacity, swelling behavior, stability, 
permeability, mechanical properties. The highly porous structure of hydrogel allows for a depot 
maintaining a high local concentration of drug at the targeted tissues. Despite the many 
favorable characteristics of hydrogels, problems still exist in many aspects, for example, for the 
hydrogel-based drug delivery system, the homogeneity and quantity of drug loading into 
hydrogels is often very difficult, particularly in the case of hydrophobic drugs183. The large pore 
sizes and high water content of most hydrogels often lead to relatively rapid drug release. The 
premature drug release outside the targeted site not only decreases the therapeutic efficacy but 
also causes serious local or systemic toxicity. Besides, some hydrophobic drug crystal 
precipitation tends to occur in the hydrogels, generally causing poor formulation stability and 
a low drug-loading capacity184. Moreover, hydrogels are generally prepared from a single 
polymer network, which often does not hold all the required mechanical and biological 
properties for tissue engineering applications. As a result, it is imperative to develop new 
materials and novel strategies for the introduction of physicochemical, mechanical, and 
biological functionality into hydrogels to meet the rigorous and diverse demands.  
 
Figure 1-27 Schematic illustration of typical nanocomposite hydrogels from hydrogels and 
drug-loaded nanoparticles 
One of the efficient and simple approaches to improve the hydrogels properties and to include 
multiple functionalities is the incorporation of different entities into hydrogels to fabricate 
composite hydrogel matrices. A variety of nanoparticles have distinct physicochemical 
properties and favorable functions that are not commonly found in polymers. Recently, 
considerable efforts have been made to incorporate various kinds of nanoparticles into gel 
matrices to create novel nanocomposite hydrogels with superior properties and tailored 
functionalities. In particular, the previously mentioned challenges in the application of 
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hydrogels and NPs could potentially be overcome by the fabrication of bionanocomposites that 
associate biomacromolecules and inorganic nanoparticles185, 186. For instance, incorporation of 
drug-loaded nanocarriers within a biocompatible matrix would allow (i) to avoid direct contact 
between nanoparticles and living tissues, (ii) increase the mechanical stability of the hydrogel 
and (iii) control the drug release as the bioactive molecule must escape both the NPs and the 
hydrogels while the polymer/particle interface may decrease the NPs degradation. 
The nanocomposite hydrogels can be defined as composite material that physically or 
covalently incorporates nanosized particles or nanostructures into a matrix of cross-linked 
polymer networks (Figure 1-27). These nanocomposite hydrogels have found fascinating 
interest for various biomedical applications due to combining the characteristics of a 
nanoparticulate material with hydrogel system. As a result, the challenges in the application of 
hydrogels and NPs, as mentioned above, could potentially be overcome by the fabrication of 
nanocomposite hydrogels. In recent reports, nanocomposite hydrogels prepared by 
incorporation of silica nanoparticles with hydrogels showed remarkable improvements in 
mechanical stiffness, tissue stickiness and bioactivity compared with unmodified hydrogels.  
Various kinds of silica-based nanoparticles have been incorporated in different synthetic and 
natural polymers via physical or chemical approaches to obtain bioactive nanocomposite 
hydrogels. These resulting hydrogels with enhanced mechanical properties, good 
biocompatibility and biodegradability, tunable cell and tissue adhesion, or improved drug 
loading and drug release profiles, have exhibited plenty of important applications in biomedical 
and pharmaceutical fields, such as injectable or implantable sustained drug delivery system, 
controlled cell and tissue adhesion surfaces, antimicrobial films or wound dressings, tissue 
engineering and cell-based therapies. The study demonstrated that incorporating silica 
nanoparticles at a high density within a polymer hydrogel can not only result in mechanically 
strong and tissue-adhesive nanocomposite hydrogels but also fabricate soft materials with a 
unique and counterintuitive response to environment-stimuli. The protease responsive hydrogel 
nanocomposites reported in this study could offer avenues in degradation-stiffening and 
collapsing materials for a variety of biomaterial applications.  
1.5.2 Silica-collagen hydrogels  
Collagens are the most abundant proteins in the mammalian body, accounting for 20-30% of 
the total protein. Collagens form a large family of triple helical molecules with about 28 
different types described, with types I, II, III, and IV being the most commons.  
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All collagens share the same triple-helical structure where three parallel polypeptides, α-chains, 
coil around each other forming a right-handed triple helix chain 187  
In animals, these collagen triple helices are known as tropocollagen and its hierarchical 
organization into more complex structures generates the fibers and networks in tissues such as 
bone, skin, and tendons188(Figure 1-28). 
 
Figure 1-28 The hierarchical structure of collagen fibers 
The primary functions of type I collagen are to provide mechanical support and to control cell 
adhesion and migration. Thanks to the above-mentioned characteristics, collagen is frequently 
used to prepare wound dressings 189. (Figure 1-29). However, collagen-based materials suffer 
from uncontrolled degradation and low mechanical strength, which necessitate the chemical 
and physical modifications of the collagen. 
 
Figure 1-29 (A) Collagen hydrogel. (B) Collagen sponge. (C) Collagen hydrogel scaffold. (D) 
Hematoxylin and eosin staining of collagen hydrogel scaffold 
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Composite collagen-based hydrogels obtained by introducing other natural (e.g. elastin, 
hyaluronan) or synthetic (e.g. PEG) polymers and particulates (e.g. calcium phosphate particles, 
silica nanoparticles) have been widely used to add strength and functionality to the system190. 
As an example, Raftery et al. studied collagen-based scaffolds for localized gene delivery, 
where chitosan-DNA was loaded by surface adsorption191. The scaffolds used in the study 
include a collagen scaffold and collagen-hydroxyapatite (CHA) scaffold for bone repair, and a 
collagen-hyaluronic acid (CHyA) with properties optimized for cartilage regeneration. 
Sustained gene expression from mesenchymal stem cells (MSCs) seeded on the scaffolds was 
maintained for 28 days, and its efficiency depended on the composition of the scaffold. 
 
Figure 1-30 Various configurations for gene delivery in silica-collagen nanocomposites: (1) 
particles out/cells in; (2) particles and cells in; (3) particles in/cells out 
The ease to prepare collagen hydrogel facilitates the incorporation of other ingredients (e.g. cell 
culture medium, bioactive proteins, drugs), which makes collagen-based materials appealing 
candidates for bioactive wound dressing fabrication. However, fast release of biomolecules and 
limited mechanical strength remains drawbacks of this system. In this context, it has been 
suggested that the combination of collagen hydrogels with silica could improve their 
performance. Various silica species have been reported for silicification of soluble collagen, 
fibrils, fibers, films, gels or scaffolds for different medical applications192. In our group, 
preliminary biocompatibility studies by subcutaneous implantation of collagen-silica 
bionanocomposites in rats showed the absence of significant inflammation, efficient infiltration 
of fibroblast cells and initiation of vascularization193. The controlled release of antibiotics, 
initially encapsulated within Stöber silica nanoparticles, from collagen-silica nanocomposites 
was demonstrated in vitro and in vivo 194. However, no noticeable improvement of the hydrogel 
mechanical stability was measured. Finally, the co-encapsulation of silica nanoparticles coated 
with PEI as gene carriers and of fibroblast cells within collagen hydrogels allowed to evidence 
the possible gene delivery within the matrix195, 196. However, it was also shown that the 
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efficiency of this process depends on the chemical bonding between silica and PEI and also 
whether the particles and cells are co-encapsulated or if only one of the components is 
immobilized within the collagen hydrogel (Figure 1-30). 
1.5.3 Open questions and motivations of this work 
These results open many intriguing questions. First, the success of gene delivery requires very 
specific events occurring intracellularly, especially the escape of the plasmid from endosomal 
compartments. How this happens with silica particles remains unclear and is strongly related to 
the intracellular fate of these particles. As a matter fact, if one could predict the degradation 
pathway of such nanocarriers inside the cells, it should allow to optimize their composition 
and/or structure for intracellular drug delivery. The second question is related to the role of the 
3D environment (i.e. the collagen hydrogel) on the cell-particle interactions. Indeed, it is 
expected that diffusion issues can affect the particle mobility while cell motility may also be at 
stake. This is an interesting point to consider knowing that, in many in vivo applications, 
targeted cells are not free floating or on a surface but within an extracellular 3D matrix. 
Answering these two questions was the first goal of this PhD project and my research along this 
direction is presented in the following chapters 2 and 3. 
Considering the bionanocomposite approach per se, we have already pointed out that while its 
benefit to tune the drug release rate from silica nanoparticles was clearly demonstrated, its 
advantage for the stability of the collagen network was not yet clearly evidenced. As it is well-
known in the area of nanocomposite, improved mechanical properties of a polymer matrix can 
be achieved by enhancing particle/polymer chemical interactions and/or creating a percolating 
network of nanoparticles. As such a percolation is more easily achieved with high aspect ratio 
particles rather than with spherical ones, we explored the possibility to design and use silica-
based nanorods to tune the mechanical behavior of collagen hydrogels and, at the same time, 
using them to study the cells growth and reproduction performance which is very important for 
the further drug delivery and biological applications, Moreover, a novel magnetic composite 
hydrogel has also been prepared for the magnetic manipulation in 3D hydrogels. This part of 
my PhD work is presented in chapter 4 of this manuscript. 
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Chapter 2 Comparison of extracellular and intracellular 
degradation of nanostructured silica particles 
 
 
“路曼曼其修远兮，吾将上下而求索” 
 
《离骚》 
 
Abstract 
This study aimed to better understand the intracellular fate of silica nanoparticles. We have 
prepared three types of particles with different nanostructures and studied their degradation in 
a buffer, a culture medium and in contact with human dermal fibroblasts. All the particles 
dissolve in solution, leading to an increase in the porosity and / or the precipitation of new 
colloids and finally to their fragmentation, and more rapidly in culture medium than in buffer. 
All particles are also internalized without significant cytotoxic effect. Their intracellular 
degradation occurs faster than in suspension but following quite similar dissolution 
mechanisms. These results strongly suggest that, under these conditions, the silica nanoparticles 
must be mainly considered as degraded by hydrolysis and not biodegraded. 
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Comparaison de la dégradation extracellulaire et 
intracellulaire de particules de silice nanostructurées 
 
 
 
Résumé 
Cette étude vise à mieux comprendre le devenir intracellulaire des nanoparticules de silice. 
Nous avons préparé trois types de particules avec différentes nanostructures et étudié leur 
dégradation dans un tampon, un milieu de culture et au contact de fibroblastes dermiques 
humains. Toutes les particules se dissolvent en solution, conduisant à une augmentation de la 
porosité et/ou à la précipitation de nouveaux colloïdes et finalement à leur fragmentation, et ce 
plus rapidement en milieu de la culture qu’en tampon. Toutes les particules sont également 
internalisées sans effet cytotoxique significatif. Leur dégradation intracellulaire survient plus 
rapidement qu'en suspension mais suivant des mécanismes de dissolution assez similaires. Ces 
résultats suggèrent fortement que, dans ces conditions, les nanoparticules de silice doivent être 
principalement considérées comme dégradées par hydrolyse et non biodégradées. 
Publié dans 
Y. Shi, C. Hélary, B. Haye, T. Coradin, Extracellular versus Intracellular Degradation of 
Nanostructured Silica Particles, Langmuir, 2018, 34, 406-415. 
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2.1 Introduction 
As pointed in the previous chapter, very little is known about the intracellular fate of silica 
nanoparticles. Earlier reports using mesoporous nanoparticles evidenced that their cellular 
uptake was followed by their exocytosis1. In addition, the released particles were associated 
with proteins located in the cellular membrane or involved in the vesicular trafficking. 
However, no modification in particle size or morphology was reported. A first insight in the 
intracellular dissolution pathway of plain silica nanoparticles was obtained by Quignard et al. 
through a combination of TEM imaging and identification of the products of their degradation2. 
A decrease of particle size was observed and attributed to surface erosion as a result of the 
dissolution equilibrium of silica. Since then, further evidences of the ability of silica to dissolve 
intracellularly were accumulated3-6. Yet, considering the complexity of the accompanying 
trafficking events, that can include pH modifications and protein deposition, defining the exact 
conditions in which silica particles are degraded remains highly challenging. 
At present, there are mainly three strategies to load small molecular drugs and biological 
macromolecules within silica nanomaterials. The first is to mix the drugs with the silica 
precursor to form nanocomposites7, 8. The second is through the layer-by-layer method9, 10. The 
third involves the impregnation of mesoporous or hollow silica nanoparticles11, 12. As far as we 
know, there is no report comparing the degradation behavior of these three types of silica 
nanoparticles in biologically-relevant conditions. With this purpose, we have prepared 
PEGylated fluorescent silica particles with different internal structures (bio-composite, 
multilayered and hollow mesoporous) and studied their time evolution in abiotic (phosphate 
buffer, culture medium) conditions and then in the presence of normal human dermal 
fibroblasts. Structural degradation and dissolution kinetics of the nanoparticles were studied in 
parallel with their cytotoxicity.  The here-gathered data suggest that, for these systems, the 
intracellular fate of silica nanoparticles can be explained on the sole basis of physico-chemical 
processes. This provides new and strong evidences that, in the intracellular space, silica 
nanoparticles should be considered as hydrolytically-degradable rather than biodegradable 
materials, a result of great consequences for the design of silica-based biomaterials. 
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2.2 Experimental Section 
2.2.1 Materials  
Tetraethyl orthosilicate (TEOS), (3-Aminopropyl)triethoxysilane (APTES), Branched PEI 
trimethylammonium bromide (CTAB) were obtained from Sigma-Aldrich. Fluorescein 
Isothiocyante (Isomer I) (FITC), N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-
dimethylaminopropyl)-carbod2mide (EDC) were obtained from Alfa Aesar. 
Methoxypolyethylene glycol acetic acid N-succinimidyl ester (NHS-PEG5000-MAL), 
dimethylsulfoxide (DMSO), triethanolamine (TEA) and ethylenediamine tetraacetic acid 
(EDTA) were obtained from Sigma-Aldrich. Dubelcco’s Modified Eagle Medium (DMEM) 
and Fetal Calf Serum (FCS) was purchased from Gibco BRL. Unless specified, all the 
commercial products were used without further purification. 
2.2.2 Synthesis of PEGylated silica nanostructures 
The sol-gel synthesis used makes it possible to obtain spherical particles. A series of fluorescent 
silica nanoparticles of different sizes (10 to 200 nm) were prepared by the method described by 
modified Stöber method. Here we add the APTES-FITC solution during the hydrolysis of 
tetraethoxysilane in a solution of ammonia in ethanol, which is obtained by condensation of 3-
aminopropyl)triethoxysilane with fluorescein isothiocyanate13. The structure of the three 
PEGylated silica nanoparticles mentioned above is as shown in Figure 2-1 
 
Figure 2-1 The structure of PEGylated silica nanoparticles (BSNPs, PSNPs, HSNPs) 
PEGylated BSA@silica nanoparticles (BSNPs) 
BSA@silica nanoparticles were synthesized via a modified Stöber method14. First, 30 mg BSA 
were diluted in 3 mL deionized (DI) water and then added to 20 mL of ethanol containing 2 mL 
ammonia. After 5 minutes, 1 mL TEOS was added under stirring for 1 hour. Lastly, 50 µL 
APTES-FITC was added three times every two hours, followed by vigorous stirring for 24 
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hours. Another 50 µL APTES was added and after for 24 hours under stirring, amine-
functionalized BSA@silica-NH2 particles were obtained, recovered by centrifugation and 
washed with ethanol twice. Next, BSA@ silica-NH2were re-dispersed in 5 mL of PBS 
(phosphate buffer saline, 1X), and 8 mg of NHS-PEG5000-MAL was added
15. The mixture was 
then stirred at room temperature for 2 hours before harvesting PEGylated particles by 
centrifugation (Figure 2-2).  
 
 
Figure 2-2 Process for preparing PEGylated BSA@silica nanoparticles 
Synthesis of PEGylated double-layered PEI-Silica nanoparticles (PSNPs).  
For the synthesis of SiO2@PEI, 20 mL of a suspension of 100 nm FITC-doped silica 
nanoparticles (vide supra) was added dropwise to the same volume of an aqueous solution of 
PEI (10 mg/mL)16.  
 
 
Figure 2-3 Process for preparing PEGylated double-layered PEI-silica nanoparticles 
After 3 additional hours of mixing, particles were recovered by centrifugation, washed 2 times 
in DI water and finally re-suspended in DI water. For the synthesis of SiO2 @PEI@SiO2
10, 8.0 
mL of the SiO2@PEI solution was mixed with 5.0 mL absolute ethanol and 0.8 mL of ammonia 
and stirred for 10 minutes at room temperature. Then 0.2 mL of TEOS and 20 µL APTES-FITC 
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was added and the mixture was allowed to react at room temperature for 16 h. Afterward, 
SiO2@PEI@SiO2 nanoparticles were washed with water and ethanol and suspended in 20 mL 
of water. For the deposition of the second PEI and silica layers, the synthetic procedure was 
similar to the previous one, except for the final addition of 200 µL APTES to obtain 
SiO2@PEI@SiO2@PEI@SiO2-NH2 nanoparticles. Next, these particles were re-dispersed in 5 
mL of DMSO, and 8 mg of NHS-PEG5000-MAL was added. The mixture was then stirred at 
room temperature for 2 hours under anhydrous conditions before harvesting by centrifugation 
（Figure 2-3）. 
Synthesis of PEGylated hollow mesoporous silica nanoparticles (HSNPs). 
Fluorescent uniform ~100 nm sized SiO2 nanoparticles were obtained using a modified Stöber 
method17 (Figure 2-4).  
 
 
Figure 2-4 Process for preparing PEGylated hollow mesoporous silica nanoparticles 
In a typical synthesis, 35.7 mL of absolute ethanol was mixed with 5 mL water and 0.8 mL of 
ammonia and stirred for 5~10 minutes at room temperature. Then 1.0 mL of TEOS and 1.0 mL 
of APTES-FITC were added and the mixture was allowed to react at room temperature for 1 h. 
Afterward, SiO2 nanoparticles were washed with water and ethanol and suspended in 20 mL of 
water. To prepare hollow mesoporous silica nanoparticles18, CTAB (2.0 g) and TEA (20 mg) 
were dissolved in 20 mL of DI water and stirred at room temperature for 1 h. Then, 10 mL of 
the previous SiO2 suspension was added and stirred at room temperature for 1 h before addition 
of 0.15 mL of TEOS. The mixture was stirred for 1 h at 80 °C in a water bath and the mixture 
was then cooled down to 50°C followed by addition of 636 mg of sodium carbonate (Na2CO3), 
under constant stirring for 30 min. To remove the CTAB, the product was extracted for 24 h 
with a 1 wt% solution of NaCl in methanol at room temperature. This process was carried out 
for at least 3 times to ensure complete removal of CTAB. For PEG grafting, 8 mg of the 
  
79 
 
recovered particles were dispersed in 50 mL of DMSO and then 500 μL of APTES were added. 
After the mixture was stirred for 20 hours, amine-functionalized HSNPs (HSNP-NH2) were 
recovered by centrifugation and washed with ethanol twice. Next, HSNP-NH2 particles were 
re-dispersed in 5 mL of DMSO, and 8 mg of NHS-PEG5000-MAL was added. The mixture was 
then stirred at room temperature for 2 hours under anhydrous conditions before being harvested 
by centrifugation. 
2.2.3 Nanoparticle characterization and instruments.  
Size distribution and Zeta potential 
The particle size measured in a dynamic light scattering (DLS) instrument is the diameter of a 
sphere that diffuses at the same rate as the particle being measured. The zetasizer system 
determines the size of the measured nanoparticles by first measuring the Brownian motion of 
the particles in the sample using DLS and then using established theories. 
 
Figure 2-5 Process for measurement of nanoparticles by DLS 
Brownian motion is due to the random motion of the particles in the liquid due to the 
bombardment of the molecules around them. The speed at which the particles in the liquid move 
randomly can be used to determine the size of the particles. Experienced surface small particles 
move or spread faster in larger liquids, and this movement is ongoing. Therefore, if we separate 
the two "pictures" of the sample for a short period of time, we can see the moving distance of 
the particles and calculate their size according to the existing theory (Figure 2-5). If there is 
minimal particle movement between the two images, the particles in the sample can be inferred 
to be large, and similarly, if there is a large amount of movement between the two images, the 
particle diameter in the sample is smaller. Using these theories and the relationship between 
diffusion speed and size, the size of these particles can be determined. 
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Most liquids contain charged cations and anions. When charged particles are suspended in the 
liquid, oppositely charged ions will be attracted to the surface of the suspended particles. If the 
negatively charged particles attract positive ions in the liquid, conversely, the positively 
charged particles attract negative ions. Ions near the surface of the particle will be strongly 
bound, while ions that are further apart will loosely combine to form a so-called diffusion layer. 
There is a nominal boundary in the diffusing layer. When the particles move in the liquid, any 
ions in the boundary will move with the particles, but any ions outside the boundary will stay 
where they are - this boundary is called the sliding plane. There is a potential between the 
surface of the particle and the dispersion which varies according to the distance from the surface 
of the particle - this potential on the sliding plane is called the zeta potential (Figure 2-6). At 
present, the Zeta potential is mainly measured by laser Doppler electrophoresis. This method 
measures the speed at which particles move in a liquid when an electric field is applied to its 
velocity. Once we know the particle's velocity and the applied electric field, we can calculate 
the zeta potential from the known sample viscosity and dielectric constant. 
 
Figure 2-6 The principle of zeta point measurement 
TEM  
Transmission electron microscopy projects an accelerated and concentrated electron beam onto 
a very thin sample. The electrons collide with atoms in the sample to change direction, resulting 
in solid angle scattering. The size of the scattering angle is related to the density and thickness 
of the sample so that images with different brightness and darkness can be formed, and the 
image will be displayed on the imaging device, and photosensitive coupling component) after 
being enlarged and focused. Since the electron De Broglie wavelength is very short, the 
resolution of the transmission electron microscope is much higher than that of the optical 
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microscope and can reach 0.1 to 0.2 nm, and the magnification is tens of thousands to millions 
of times. Figure 2-7 shows the two basic operation modes of TEM-imaging and diffraction 
modes. In both cases, the specimen is illuminated with the parallel beam, formed by electron 
beam shaping with the system of Condenser lenses and Condenser aperture. After interaction 
with the sample, on the exit surface of the specimen two types of electrons exist-unscattered 
(which will correspond to the bright central beam on the diffraction pattern) and scattered 
electrons (which change their trajectories due to interaction with the material). 
 
Figure 2-7 Schematic view of imaging and diffraction modes in TEM 
Characterization 
Particle size distribution, polydispersity index and zeta potential (ζ) were measured in DI water 
or cell culture medium (DMEM) using a ZetaSizer Nano (Malvern Instruments Ltd., 
Worcestershire, UK). Particles were also imaged using Transmission Electron Microscopy 
(TEM) on a Tecnai G2 Spirit electron microscope (TEM) (FEI Company, Philips, Netherlands). 
Dynamic Light Scattering (DLS) was used to determine the hydrodynamic diameter of the 
nanoparticles in Milli-Q water or in culture medium. The reading was carried out at an angle of 
90° to the incident beam (632 nm). The Contin algorithm was used to analyze the 
autocorrelation functions. Fluorescence spectra of the particles suspended in water were 
recorded on a Horiba Jobin Yvon fluorescence spectrometer with an excitation wavelength of 
485 nm. Nitrogen (N2) sorption measurements were performed at 77K using an accelerated 
surface area and porosimetry analyzer with Brunauer-Emmett-Teller (BET) calculations for the 
surface area. 
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2.2.4 Dissolution and degradation assays in buffer and culture medium.  
To carry out the in vitro degradation experiments in abiotic conditions, a suspension of each 
type of PEGylated particles at a 0.4 mg/mL concentration was left under mild stirring at 37°C 
in phosphate buffer saline (PBS) 1X or DMEM. The fluorescence intensity of the medium was 
analyzed at selected time intervals after centrifugation in a Nanosep® 3kD centrifugal device 
to separate particles, that were further used for TEM observation, and solutions to monitor the 
proportion of released silane-FITC over time2. All experiments were performed in triplicate. 
2.2.5 Cells and treatments with nanoparticles.  
Normal human dermal fibroblasts (from Promocell) were grown in DMEM supplemented with 
FCS (10%), penicillin (100 units/mL), streptomycin (100 mg/mL, from Gibco BRL) and 
fungizone (0.25 mg/mL, from Gibco BRL). The culture flasks (75 cm2) were kept at 37 ℃ in 
95% humidity and 5% CO2 atmosphere. At confluence, fibroblasts were removed from cultured 
flasks by treatment with 0.1% trypsin and 0.02% EDTA. Cells were rinsed, centrifuged and 
dispersed in the supplemented DMEM medium. Fibroblasts were used at passage 8 for the 
experiments.  
2.2.6 Nanoparticle internalization, degradation and release.  
The cells were seeded at a density of 30,000 cells per well in 24-well plate with round glass 
coverslips at the bottom of the wells and kept 24 h with culture medium at 37 °C in 95% 
humidity and 5% CO2 atmosphere previous to incubation with 0.4 mg/mL of the three types of 
silica nanoparticles. For fluorescence microscopy, cells were collected at day 1, 2 and 7, washed 
three times with PBS 1X, and fixed with 4% paraformaldehyde in PBS (1 h, 4 ℃). Staining of 
the nuclei with DAPI (Invitrogen) was perform via incubation for 15 min at room temperature 
and rinsing with HBSS 1X before observation with a fluorescent microscope (Axio 100, Carl 
Zeiss). For TEM, cells were fixed at day 1, 2 and 7 using 3.63% glutaraldehyde in a 0.05 M 
sodium cacodylate buffer with 0.3 M saccharose for 1 h at 4 °C. Samples were washed three 
times before post-fixing with 2% osmium tetraoxide for 1 h at 4 ℃. Cells were then detached 
from the culture flasks by scratching and centrifuged. The pellets were embedded in a 4 mg/mL 
collagen hydrogel to ease sectioning and cellular observations. With this purpose, 50 µL of the 
type I collagen solution (in 17 mM acetic acid) was neutralized by 5 µL of PBS and mixed with 
the pellet. Mixtures were left for 30 minutes at 20°C to allow collagen gelation. Recovered 
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hydrogels were fixed with 4% paraformaldehyde in PBS (1 h, 4 ℃). Last, cell-containing 
collagen hydrogels were dehydrated with an ascending ethanol series ending with propylene 
oxide and embedded in araldite. Ultrathin sections were prepared with an Ultracut 
ultramicrotome (Leica, France). Slides were analyzed with a Tecnai G2 Spirit electron 
microscope operating at 120 kV.  
To follow the kinetics of particles degradation and release, continuous cultures were first 
performed over 1 week in the presence of 0.4 mg/mL silica nanoparticles. After this delay, the 
culture medium was removed and cells were rinsed before adding fresh medium and performing 
an additional incubation period of 7 days. Fluorescence and TEM imaging, as well as 
fluorescence measurements of the whole medium and of its soluble content were performed as 
described above. All experiments were performed in triplicate.  
2.2.7 Toxicological assays.  
Cellular metabolic activity of cells in 24-well plate after 2 days of contact with silica particles 
at concentrations 0.025-0.400 mg/mL and after 1, 2, 7 and 14 days of incubation with 0.4 
mg/mL silica nanoparticles was evaluated using Alamar Blue assay (n=6). After incubation, 
cells were rinsed with medium and incubated at 37 °C in a humidified 5% CO2 air atmosphere 
for 4 h with a 10% solution of Alamar blue in phenol red-free culture medium. Absorbance of 
the medium at 570 nm and 600 nm was recorded with a UV-visible spectrophotometer and the 
percentage of dye reduction was calculated. The results were expressed as a percentage of 
viability assessed in control samples (incubated with no nanoparticles). It is worth mentioning 
that incubation of the particles alone with Alamar Blue gave negligible absorbance values. 
2.2.8 Statistical analysis.  
Graphical results are presented as mean ± SD (standard deviation). Statistical significance was 
assessed using the student’s-test compared with control groups. The level of significance in all 
statistical analyses was set at a probability of P < 0.05. 
2.3 Results  
2.3.1 Synthesis and functionalization of nanostructured silica particles  
Silica nanoparticles with different internal structures were synthesized and characterized using 
transmission electron microscopy (TEM), dynamic light scattering (DLS) and zeta potential 
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measurements. PEGylated BSA-coated silica nanoparticles, PEI-coated silica nanoparticles and 
hollow mesoporous silica nanoparticles were named as BSNPs, PSNPs and HSNPs 
respectively. 
Fairly uniform BSNPs were prepared by using a modified Stöber method in the presence of 
BSA. As shown in the TEM images (Figure 2-8a, d), the BSNPs are spherical in shape with a 
mean diameter of ~45 nm. They exhibit a well-contrasted core-shell structure suggesting that 
they consist of a silica-rich layer coating a BSA-rich internal domain14. 
 
Figure 2-8 TEM images of the as-prepared PEGylated fluorescent silica nanoparticles: (a, d) 
BSNPs; (b, e) PSNPs and (e, f) HSNPs 
DLS measurements in deionized water indicated a two-fold increase in the mean diameter Dm, 
compared to TEM, suggesting that some aggregation occurred, although to a limited extent 
(Table 2-8). This aggregation was confirmed by performing a DLS analysis of a BSNPs 
suspension just after sonication, yielding to a Dm value of 44  10 nm. Successful 
functionalization with amine and PEG groups was confirmed by the changes of size and ζ value 
(Table 2-1): whereas the as-prepared BSA@SiO2 exhibited a strongly negative ζ value, APTES 
grafting led to a slightly positive ζ value due to ammonium groups. This was correlated with an 
increase in the Dm value as obtained by DLS, in agreement with the decrease of ζ absolute value 
leading to a lower colloidal stability. After PEG grafting, the Dm value obtained by DLS 
decreased, due to the ability of the polymer coating to limit BSNPs aggregation, and the ζ value 
became negative, due to the reaction of some of the surface amine groups with NHS-PEG5000-
MAL. 
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Table 2-1 Mean diameter Dm from DLS and TEM, Zeta potential ζ in deionized water and 
culture medium 
 Dm DLS (nm) Dm TEM (nm) Ζ water (mV) Ζ medium (mV) 
BSNPs 109  6 44  2 -15  1 -8  1 
PSNPs 190  6 176  4 -8  1 -5  1 
HSNPs 310  10 261  7 -11  1 -7  1 
 
PSNPs were obtained from plain silica nanoparticles by a layer-by-layer method using branched 
PEI (25 kDa). Starting from ~100 nm Stöber nanoparticles, two successive sequences of PEI 
deposition/silica coating were performed. Variations in ζvalue occurred as expected, i.e. ζ > 0 
for outer PEI layer and ζ < 0 after silica deposition (Table 2-2). Again, APTES grafting turned 
the particle surface positive while PEG conjugation ultimately led to negatively-charged PSNPs 
in deionized water (Table 2-1). 
 
Figure 2-9 Particle size distribution of a) BSNPs; b) PSNPs; c) HSNPs d) BSNPs just after 
sonication measured by DLS in deionized water 
The accompanying modifications of hydrodynamic diameter, as obtained by DLS, are difficult 
to analyze in detail in terms of size variations as they are the result of PEI conformation on the 
particle surface, silica layer thickness as well of the aggregation tendency of the different 
systems. Nevertheless, TEM imaging (Figure 2-8b) provides a Dm value of ~ 175 nm and 
therefore an overall coating thickness of ~ 35 nm, clearly evidenced at higher magnification 
(Figure 2-8e). Hollow HSNPs were prepared by etching 100 nm-Stöber nanoparticles 
following the method proposed by Chen et al.18. TEM imaging clearly showed that HSNPs have 
a spherical morphology and uniform particle size ~ 260 nm, with a porous shell thickness of ~ 
50 nm and a highly porous core, although a central denser region, corresponding to unreacted 
part of the starting Stöber particles, could sometimes be distinguished (Figure 2-8c, f). 
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Table 2-2 Average diameter (by DLS) and zeta-potentials of nanoparticles at various stages of 
their synthesis 
  Dm (nm) (n=3) ζ (mV) (n=3) 
BSNPs BSA@SiO2 77±3 -54±9 
BSA@SiO2-NH2 130±4 10.5±2 
BSA@SiO2-PEG(BSNPs) 109 ±6 -15 ±1 
PSNPs SiO2 104±5 -40 ±1 
SiO2@PEI 134±4 21 ±2 
SiO2@PEI@SiO2 171±6 -44 ±3 
SiO2@PEI@SiO2@PEI 166±7 20 ±1 
SiO2@PEI@SiO2@PEI@SiO2 195±5 -36 ±7 
SiO2@PEI@SiO2@PEI@SiO2-NH2 242±8 12 ± 2 
SiO2@PEI@SiO2@PEI@SiO2-PEG(PSNPs) 190±6 -8 ± 1 
HSNPs SiO2 104±5 -40 ±1 
HSNP-CTAB 376±9 -22 ±1 
HSNP-NH2 780±40 16 ± 1 
HSNP-PEG (HSNPs) 310±10 -11 ± 1 
 
The overall synthetic process was also followed by DLS and ζ-metry (Table 2-2), showing that 
despite the fact that APTES-modified intermediates are particularly prone to aggregation (Dm 
= 780  40 nm), the PEG coating efficiently enhances the colloidal stability of final HSNPs 
particles (Dm = 310  10 nm in deionized water compared to 260  7 nm from TEM) (Table 2-
1). Nitrogen adsorption-desorption isotherm measurements indicated that the HSNPs had a 
relatively high specific surface area of ca. 550 m2/g and a well-defined mean pore size of 3.9 
nm (Figure 2-3).  
Altogether, when the three types of particles are compared, their size, as obtained from both 
DLS in deionized water and TEM, vary in the order HSNPs > PSNPs > BSNPs. In terms of 
surface properties, their zeta potential in deionized water (pH 6.5) is always negative and 
follows the PSNPs > HSNPs > BSNPs evolution. 
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Figure 2-10 N2-sorption isotherms at 77 K and pore size distribution of HSNPs particles 
Interestingly, the same order of ζ values is found for NH2-grafted particles, suggesting that the 
PEG coupling occurred in a similar extent for the three systems. This order is preserved over 
the whole pH 2-11 range with apparent isoelectric points (IEP) of ca. 4.5, 5.5 and 6.2 for BSNPs, 
HSNPs and PSNPs, respectively (Figure 2-10).  
 
Figure 2-11 Evolution of the zeta potential of BSNP, PSNP and HSNP nanoparticles with pH 
It is also maintained in cell culture medium although with some minor variations between the 
different particles. A systematic increase in ζ values compared to deionized water is observed 
that very likely indicates the surface adsorption of positively-charged proteins present in FCS-
enriched DMEM (Table 2-1)19. 
The incorporation of FITC within the different nanoparticles was checked by fluorescence 
measurements. As shown in Figure 2-12, the FITC-doped silica nanoparticles gave rise to a 
 
88 
strong emission, with no significant shift in the maximum wavelength compared to the dye 
alone. However, at a constant particle concentration, the signal intensity varied from one 
particle type to the other. Such a difference may reflect various silica contents in the 
nanoparticle structures. For instance, the lowest intensity was obtained for BSNPs, i.e. hybrid 
nanoparticles containing large amounts of BSA. However, other processes such as FITC 
fluorescence variations due to different dye environment and mobility may also contribute to 
these differences20.  
 
Figure 2-12 FTIC fluorescence spectra in solution and within silica nanoparticles:  a) FITC, 
1.0 μg/mL and b) BSNPs; c) PSNPs; d) HSNPs 50 μg/mL, respectively 
2.3.2 Behaviour of nanoparticles in buffer and cell culture medium.  
To investigate the influence of the internal structure of silica nanoparticles on their degradation 
in abiotic (i.e cell-free) media, TEM imaging and monitoring of the kinetics of silica dissolution 
was first performed in a PBS buffer (pH 7.4) at 37 ℃ over 2 weeks. After one week, all 
nanoparticles showed a clear tendency to form aggregates under TEM imaging conditions. 
As shown in Figure 2-13, the core-shell structure of BSNPs is overall preserved but some 
particles appear to have grown in size and the contrast between the inside and outside parts has 
increased compared to the initial particles. For PSNPs, the outer silica shell is less well-defined. 
No further evolution could be evidenced for these two sets of particles after one additional 
week, except for a higher tendency to aggregate. In parallel, the internal structure of HSNPs 
does not appear much modified after one week but some deformed particles are observed. After 
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two weeks, they have turned into highly porous particles with a weaker contrast between the 
shell and the core parts, some of them being obviously fractured. 
 
Figure 2-13 TEM imaging of the structural evolution of silica nanoparticles in PBS after (a-c) 
one and (d-f) two weeks 
 
Figure 2-14 TEM imaging of the structural evolution of silica nanoparticles in DMEM culture 
medium after (a-c) on week and (d-f) two weeks. (scale bar = 100 nm) 
The dissolution of these different particles was also studied in the DMEM cell culture medium 
at 37 ℃ (Appendix 1 and Figure 2-14 for higher magnification images). For BSNPs, after one 
week, some particles have grown in size while others are broken. Only small fragments could 
be recovered after 2 weeks. For PSNP samples after 1 week, the outer coating has a shallow 
appearance and is decorated with porous particles 10-30 nm in diameter. Strikingly, after two 
weeks, two populations of particles are observed: larger ones, ca. 100-150 nm in diameter, 
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exhibiting a dense core and a porous shell, and smaller ones, 20-50 nm in size, with a porous 
internal structure resembling that of previously-observed decorating particles.  
For HSNPs, TEM images after 1 week are highly reminiscent of those previously obtained in 
PBS after 2 weeks (Figure 2-13 and 2-14). Within two weeks, after centrifugation and washing, 
only a few of these nanoparticles could be recovered with an intact morphology and imaged. 
These particles seem to have grown in size and the shell and core particle appear denser and 
separated by a highly porous, if not empty, region. Hence, overall, the culture medium appears 
to speed up the degradation process of all particles compared to PBS at a similar pH. 
In parallel, the dissolution rate of the particles in culture medium was investigated through the 
monitoring of the fluorescence of the solution after centrifugation and filtration. Because these 
steps eliminate silica particles and since FITC forms a stable covalent bond with the silica 
network, the fluorescence signal can only correspond to FITC-silane or soluble FITC-
polysiloxane molecules released upon silica dissolution2. 
 
Figure 2-15 Evolution of the content of the culture medium over 2 weeks in the presence of 
silica nanoparticles as monitored by the fluorescence intensity of FITC-labelled soluble forms 
of silica 
After 1 day, more than 50 % of the BSNPs particles are dissolved and the maximum dissolution 
of 65 % is reached after 1 week (Figure 2-15). For HSNPs, a similar rapid dissolution is 
observed but the maximum dissolution of 40 % is reached after 1 week. PNSPs dissolve much 
more slowly (ca. 10 % after 1 day) and, after 2 weeks, only 30 % of the initial fluorescent 
silanes are present in a soluble form. These data confirm the low stability of BSNPs in DMEM. 
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For PNSPs, the low degradation rate and extent are in favor of the proposed mechanism of 
progressive reprecipitation of the soluble forms originating from the shell and then core particle 
dissolution. HSNPs represent an intermediate case, with fast initial dissolution rate followed by 
a plateau and low dissolution extent, suggesting that some reprecipitation reactions also occur, 
but in a less efficient manner than in PNSPs 
2.3.3 Nanoparticles behaviour in the presence of fibroblasts.   
To study the possible impact of nanoparticle structure and degradation on cell viability, NHDF 
cells were used as model organisms and the Alamar Blue method, which measures the 
mitochondrial activity of the cells, was selected to monitor the cellular response to nanoparticles 
(Figure 2-16).  
 
Figure 2-16 (a) NHDF cells after incubation with silica nanoparticles at various concentrations 
(25-400 μg/mL) for 2 days. (b) NHDF cells after incubation with 400 μg/mL of silica 
nanoparticles at various time intervals 
After a 48 h incubation period, in all the range of concentrations tested, BSNPs and HSNPs did 
not show a significant toxicity while PSNPs induced an initial slight reduction of cell viability 
in all conditions, down to 75% of cell viability at a 400 μg/mL dose. However, at this 
concentration, NHDFs recovered from PSNPs cytotoxicity after 1 week. Referring to the 
dissolution kinetics shown in Figure 2-15, neither BNSPs nor their degradation products have 
significant cytotoxic effects. PNSPs are cytotoxic on the short term, a period where the outer 
layers are slowly dissolving. This result can be correlated to previous reports showing that the 
presence of an external silica layer decreases the toxicity of poly-lysine-coated gold 
nanoparticles21. On this basis, it can be suggested that the initial dissolution of the silica layers 
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leads to the release of cytotoxic PEI. However, the redeposition of smaller silica particles on 
PNSPs surface, as observed in Figure 2-14, may circumvent this effect on the longer term.  
 
Figure 2-17 Fluorescence optical imaging of human dermal fibroblast cells after (a-c) 7 days 
and (d-f) 14 days of contact with 400 μg/mL silica nanoparticles 
The particle uptake by NHDFs in culture medium was followed by fluorescent microscopy 
using the same silica concentration (400 μg/mL) (Figure 2-17). Silica nanoparticles associated 
with cells were evidenced but many of them appeared to be attached to the cell membrane as 
aggregates. With time, these aggregates became less visible and the fluorescent signal appeared 
confined within the cell interior, with a higher intensity for PSNPs and HSNPs compared to 
BSNPs after 2 weeks.  
 
Figure 2-18 TEM images of NHDF cells after (a-c) 1 week and (d-f) 2 weeks of contact with 
400 μg/mL silica nanoparticles 
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However, to fully ascertain particle internalization, TEM imaging was performed (Figure 2-
18). After 1 week, BSNPs are sparingly found as intracellular aggregates of particles that have 
decreased in size as an apparent consequence of shrinking after core material removal. PSNPSs 
and HSNPs are more easily distinguished both outside and inside the cells. The former appear 
as plain particles decorated with smaller particles. For HSNPs the shell has grown in thickness 
while the internal structure has started to degrade, as previously observed in DMEM after 2 
weeks.  
2.3.4 Degradation and release kinetics.  
The kinetics of degradation and release of the nanoparticles was further studied by keeping 
NHDFs in contact with silica nanoparticles for 1 week after which the cells were rinsed off the 
remaining external particles and incubated in fresh culture medium for an additional week. Over 
the first 24 h, for all particles, the total fluorescence of the solution is initially very low and then 
increase progressively up to ca. 80 % of the intensity of the initial particle suspension (Figure 
2-19a). This can be correlated with fluorescence optical imaging indicating that particles first 
adhere on the cell surface (decreasing the amount of free particles in solution) and are then 
progressively detached. Yet a decrease in total fluorescence intensity is observed after 48 h, 
that may reflect enhanced particle internalization2. Considering the release of soluble forms in 
the culture medium, the kinetics profiles are very similar to those obtained in the absence of 
NHDF. However, the maximum apparent dissolution ratio is significantly smaller for BSNPs 
(50 % compared to 60 % without NHDF) and PSNPs (20 % compared to 30 %). This would 
suggest that a fraction of the soluble forms is retained by the cells. 
 
Figure 2-19 Evolution of the content of the NHDF cells culture medium as monitored by the 
fluorescence intensity of FITC-labelled condensed and soluble forms of silica (filled symbols) 
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and soluble forms only (open symbols) (a) over 1 week in the presence of silica nanoparticles 
and (b) over 1 additional week in a fresh medium 
After cell rinsing and incubation in a fresh, particle-free medium for an additional week, 
intracellular nanoparticles were more difficult to observe in TEM imaging fields (Figure 2-18 
and Figure 2-19). When this was possible, we did not evidence any clear change for BSNPs 
compared to day 7. PSNPs have significantly decreased in size and exhibit a porous structure. 
No well-defined HSNPs could be observed after this period and only fragments could be imaged 
that may originate from their full dissociation. In parallel, the total FITC fluorescence intensity 
in the culture medium, initially equal to zero because of the incubation in a fresh medium, 
increased with time (Figure 2-19b). At the end of this additional period, almost all the initial 
fluorescence intensity (as calculated by adding 1 week values obtained from Figure 2-19a and 
2 weeks values from Figure 2-19b) was recovered for the three kinds of particles, indicating 
that a negligible fraction of silica remains inside the cells, in agreement with TEM experiments. 
However, whereas BSNPs and HSNPs were almost fully released in a soluble form, more than 
30 % of PSNPs were externalized in a colloidal form. 
2.4 Discussion 
Here gathered data clearly evidence that the pathways by which the three types of nanoparticles 
are degraded are rather similar in the three considered environments, i.e. buffer, culture medium 
and intracellular space of fibroblasts. However the resulting structural evolution is highly 
dependent on their initial composition and nanostructure. In this discussion, we have tried to 
analyze and compare the degradation of each type of particle. 
BSNPs initially show TEM-contrasting internal features that suggest that they consist of a 
protein-rich interior surrounded by a silica-rich coating. In PBS, these particles grow in size, 
with an apparent leakage of the core material, the process being accelerated in culture medium. 
Finally, particle degradation occurs, leaving much smaller empty particles. A similar process 
seems to occur within the NHDF cells, although at a higher rate. Additional experiments 
performed using BSNPs incorporating FITC-labelled BSA showed that, after one week of 
contact with NHDF, the protein was hardly detectable within or at the vicinity of the cells 
whereas silica was still present in large amounts (compare Figure 2-20 with Figure 2-17a). 
The most likely explanation of these evolutions is that water penetration within the particle 
leads to the swelling of the BSA core, disruption of the silica shell and leakage of the protein  
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(Figure 2-21). As suggested earlier, the enzymatic degradation of BSA in the intracellular 
compartment may contribute to accelerate these processes. 
 
 
Figure 2-20 Fluorescence optical imaging of human dermal fibroblast cells after 7 days of 
contact with 400 μg/mL BSNPs nanoparticles using FITC-labelled BSA. (Scale bar = 40 μm) 
For HSNPs, silica dissolution in PBS apparently occurs first from the shell, resulting in particles 
that are almost uniformly porous except for the central part and are prone to deformation and 
breaking (Figure 2-21). The same process occurs in culture medium but after two weeks, the 
only remaining particles exhibit a highly contrasted shell and a denser central part, separated 
by a nearly empty corona. Such structures were also observed after one week within cells and 
evolved towards a complete disintegration after 2 weeks. While the initial shell dissolution 
should be favored by its mesoporous structure, the following process can be explained 
considering the dissolution of the more porous (i.e. more soluble) silica corona located between 
the shell and the core particle and its reprecipitation on these two denser (i.e. less soluble) 
regions, based on the Ostwald ripening principle.  
Overall BSNPs and HSNPs evolve more rapidly but along similar pathways in PBS, in DMEM 
and in the intracellular space. When experiments in buffer and culture medium are compared, 
pH and total silica concentration are similar. Ionic strength of DMEM is 0.13 M, being therefore 
comparable with the 0.16 M value for PBS 1X. However, DMEM supplemented with FCS 
contains several bio-organic components (amino acids, proteins) that can interact with silica. 
For instance, it was shown that histidine and phenylalanine could promote silica dissolution 22. 
Extending this discussion to intracellular compartments is indeed difficult as their composition 
is complex and variable. Nevertheless it is worth pointing out that lysozomes were reported to 
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contain a high fraction of free amino acids23. It is also interesting to note that intracellular 
compartments that are involved in nanoparticle trafficking are reported to be slightly 
(endosomes) to significantly (lysozomes) acidic so that a decrease of silica dissolution rate 
could be expected compared to neutral conditions of PBS/DMEM medium. While this point 
would require a detailed investigation of the particle structural modification in the first hours 
of the internalization process, our experiments suggest that the difference in pH conditions is 
not of primary importance for their long-term fate.  
 
Figure 2-21 Schematic representation of the degradation pathways of BSNPs, HSNPs and 
PSNPs in DMEM culture medium 
However, another important point must be taken into consideration. The full release of silicon 
species from the cells to the medium clearly demonstrates that the products of the intracellular 
dissolution reaction can be externalized in a continuous manner. Hence, whereas the extent of 
particle dissolution in solution is limited by the silica limit of solubility, the conditions of 
degradation within intracellular compartments can be compared to that of an open reactor, 
although previous reports evidenced that the exocytosis extent was dependent on the amount of 
silica in the medium24. This can explain the difference evidenced for PNSPs in DMEM and 
within NHDFs. In the culture medium, a decrease in initial particle size is observed after 1 week 
Si(OH)4
BSNPs
HSNPs
PSNPs
Si(OH)4
Si(OH)4
Dense silica Porous silica BSA PEI
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and smaller particles are clearly visible at their vicinity (Figure 2-21). This suggests that the 
outer PEI/silica layers first dissolve but, because PEI is known to promote silica precipitation25, 
the released soluble silica species and the polyelectrolyte chains can react together to form these 
new particles, as previously suggested26. In a second stage, the largest particles turn porous, 
indicating that further dissolution occurs and feeds the growth of the external smaller particles. 
Noticeably, within the cells, these additional particles are hardly distinguished although the 
transformation from plain to porous large particles is also observed. This result nicely correlates 
with our observation that, whereas BSNPs and HSNPS are almost exclusively released in 
soluble forms during the second week, almost 30 % of PNSPs are externalized in a colloidal 
form that may correspond to the newly-formed silica nanoparticles that are small enough to be 
expelled.  
2.5 Conclusion 
By following the evolution of silica nanoparticles with different internal nanostructures in 
solution and within normal human dermal fibroblasts, we show that their degradation pathways 
are very similar in all conditions although their structure, composition and their precise 
environment can impact on the kinetics of the degradation. This supports previous assumptions 
that within such cells silica nanoparticles undergo a hydrolytic degradation process, related to 
silica chemistry, and not a biodegradation route, that would involve a specific biological 
activity27. It must be pointed out that these results cannot fully exclude that some biodegradation 
is at stake, but it does not seem to prevail in the here-investigated system. Indeed these studies 
would deserve to be performed in other types of cells, including macrophages that have specific 
modes of degradation or cancer cells, that are responsible for acidic conditions that should 
strongly impact on silica stability. Bone cells that are known to respond to the presence of silica 
would also be interesting to study28. Another point of importance is the pathway by which 
particle are internalized, that impact on their following intracellular trafficking. In this matter, 
a detailed study of the influence of inhibitors of specific endocytosis pathways (such as clathrin- 
and caveolae-mediated routes) or of the grafting cell-penetrating peptides would be of particular 
interest.  
From a more practical point of view, our study implies that the intracellular fate of silica-based 
nanomaterials can be controlled and predicted on the basis of physico-chemical considerations. 
However a different situation is met when these nanomaterials integrate some bio-responsive 
moieties. In this case the intrinsic complexity of biological systems makes a prediction of 
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nanoparticle behavior more difficult. Nevertheless, as shown in the next chapter, the set-up of 
biomimetic environmental conditions may be useful to perform more reliable in vitro evaluation 
of functional nanomaterials. 
References 
1. Slowing, II; Vivero-Escoto, J. L.; Zhao, Y.; Kandel, K.; Peeraphatdit, C.; Trewyn, B. 
G.; Lin, V. S. Y., Exocytosis of Mesoporous Silica Nanoparticles from Mammalian Cells: 
From Asymmetric Cell-to-Cell Transfer to Protein Harvesting. Small 2011, 7, (11), 
1526-1532. 
2. Quignard, S.; Mosser, G.; Boissiere, M.; Coradin, T., Long-term fate of silica 
nanoparticles interacting with human dermal fibroblasts. Biomaterials 2012, 33, (17), 
4431-4442. 
3. Zhai, W. Y.; He, C. L.; Wu, L.; Zhou, Y.; Chen, H. R.; Chang, J.; Zhang, H. F., 
Degradation of hollow mesoporous silica nanoparticles in human umbilical vein 
endothelial cells. Journal Of Biomedical Materials Research Part B-Applied 
Biomaterials 2012, 100B, (5), 1397-1403. 
4. Chen, G. T.; Teng, Z. G.; Su, X. D.; Liu, Y.; Lu, G. M., Unique Biological 
Degradation Behavior of Stober Mesoporous Silica Nanoparticles from Their Interiors 
to Their Exteriors. Journal Of Biomedical Nanotechnology 2015, 11, (4), 722-729. 
5. Kempen, P. J.; Greasley, S.; Parker, K. A.; Campbell, J. L.; Chang, H. Y.; Jones, J. 
R., et al.Jokerst, J. V., Theranostic Mesoporous Silica Nanoparticles Biodegrade after 
Pro-Survival Drug Delivery and Ultrasound/Magnetic Resonance Imaging of Stem Cells. 
Theranostics 2015, 5, (6), 631-642. 
6. Bergman, L.; Kankaanpaa, P.; Tiitta, S.; Duchanoy, A.; Li, L.; Heino, J.; Linden, M., 
Intracellular Degradation of Multilabeled Poly(Ethylene imine)-Mesoporous Silica-
Silica Nanoparticles: Implications for Drug Release. Molecular Pharmaceutics 2013, 10, 
(5), 1795-1803. 
7. Couleaud, P.; Morosini, V.; Frochot, C.; Richeter, S.; Raehm, L.; Durand, J. O., Silica-
based nanoparticles for photodynamic therapy applications. Nanoscale 2010, 2, (7), 
1083-1095. 
8. Montalti, M.; Prodi, L.; Rampazzo, E.; Zaccheroni, N., Dye-doped silica nanoparticles 
as luminescent organized systems for nanomedicine. Chemical Society Reviews 2014, 
43, (12), 4243-4268. 
9. Li, Z. B.; Yuan, D.; Jin, G. R.; Tan, B. H.; He, C. B., Facile Layer-by-Layer Self-
Assembly toward Enantiomeric Poly(lactide) Stereocomplex Coated Magnetite 
  
99 
 
Nanocarrier for Highly Tunable Drug Deliveries. Acs Applied Materials & Interfaces 
2016, 8, (3), 1842-1853. 
10. Mebert, A. M.; Aime, C.; Alvarez, G. S.; Shi, Y. P.; Flor, S. A.; Lucangioli, S. E., et 
al.Coradin, T., Silica core-shell particles for the dual delivery of gentamicin and 
rifamycin antibiotics. Journal Of Materials Chemistry B 2016, 4, (18), 3135-3144. 
11. Andersson, J.; Rosenholm, J.; Areva, S.; Linden, M., Influences of material 
characteristics on ibuprofen drug loading and release profiles from ordered micro- and 
mesoporous silica matrices. Chemistry Of Materials 2004, 16, (21), 4160-4167. 
12. Bouledjouidja, A.; Masmoudi, Y.; Van Speybroeck, M.; Schueller, L.; Badens, E., 
Impregnation of Fenofibrate on mesoporous silica using supercritical carbon dioxide. 
International Journal Of Pharmaceutics 2016, 499, (1-2), 1-9. 
13. Nyffenegger, R.; Quellet, C.; Ricka, J., Synthesis of Fluorescent, Monodisperse, 
Colloidal Silica Particles. J. Colloid Interface Sci. 1993, 159, (1), 150-157. 
14. Zhou, Z. J.; Zhang, C. L.; Qian, Q. R.; Ma, J. B.; Huang, P.; Zhang, X., et al.Cui, D. 
X., Folic acid-conjugated silica capped gold nanoclusters for targeted fluorescence/X-
ray computed tomography imaging. Journal Of Nanobiotechnology 2013, 11. 
15. Nakamura, T.; Sugihara, F.; Matsushita, H.; Yoshioka, Y.; Mizukami, S.; Kikuchi, 
K., Mesoporous silica nanoparticles for F-19 magnetic resonance imaging, fluorescence 
imaging, and drug delivery. Chemical Science 2015, 6, (3), 1986-1990. 
16. Wang, X. L.; Masse, S.; Laurent, G.; Helary, C.; Coradin, T., Impact of 
Polyethylenimine Conjugation Mode on the Cell Transfection Efficiency of Silica 
Nanovectors. Langmuir 2015, 31, (40), 11078-11085. 
17. Vanblaaderen, A.; Vrij, A., SYNTHESIS AND CHARACTERIZATION OF 
COLLOIDAL DISPERSIONS OF FLUORESCENT, MONODISPERSE SILICA 
SPHERES. Langmuir 1992, 8, (12), 2921-2931. 
18. Chen, F.; Hong, H.; Shi, S. X.; Goel, S.; Valdovinos, H. F.; Hernandez, R., et al.Cai, 
W. B., Engineering of Hollow Mesoporous Silica Nanoparticles for Remarkably 
Enhanced Tumor Active Targeting Efficacy. Scientific Reports 2014, 4. 
19. Drescher, D.; Orts-Gil, G.; Laube, G.; Natte, K.; Veh, R. W.; Osterle, W.; Kneipp, 
J., Toxicity of amorphous silica nanoparticles on eukaryotic cell model is determined by 
particle agglomeration and serum protein adsorption effects. Analytical And 
Bioanalytical Chemistry 2011, 400, (5), 1367-1373. 
 
100 
20. Noble, J. E.; Wang, L.; Cole, K. D.; Gaigalas, A. K., The effect of overhanging 
nucleotides on fluorescence properties of hybridising oligonucleotides labelled with 
Alexa-488 and FAM fluorophores. Biophysical Chemistry 2005, 113, (3), 255-263. 
21. Soule, S.; Bulteau, A. L.; Faucher, S.; Haye, B.; Aime, C.; Allouche, J., et 
al.Martinez, H., Design and Cellular Fate of Bioinspired Au-Ag Nanoshells@Hybrid 
Silica Nanoparticles. Langmuir 2016, 32, (39), 10073-10082. 
22. Ehrlich, H.; Demadis, K. D.; Pokrovsky, O. S.; Koutsoukos, P. G., Modern Views 
on Desilicification: Biosilica and Abiotic Silica Dissolution in Natural and Artificial 
Environments. Chemical Reviews 2010, 110, (8), 4656-4689. 
23. Tappel, A. L.; Shibko, S.; Stein, M.; Susz, J. P., Studies on the Composition of 
Lysosomes. Journal of food science 1965, 30, 498-503. 
24. Chu, Z. Q.; Huang, Y. J.; Tao, Q.; Li, Q., Cellular uptake, evolution, and excretion 
of silica nanoparticles in human cells. Nanoscale 2011, 3, (8), 3291-3299. 
25. Demadis, K. D.; Pachis, K.; Ketsetzi, A.; Stathoulopoulou, A., Bioinspired control 
of colloidal silica in vitro by dual polymeric assemblies of zwitterionic 
phosphomethylated chitosan and polycations or polyanions. Advances In Colloid And 
Interface Science 2009, 151, (1-2), 33-48. 
26. Chen, K. H.; Zhang, J. X.; Gu, H. C., Dissolution from inside: a unique degradation 
behaviour of core-shell magnetic mesoporous silica nanoparticles and the effect of 
polyethyleneimine coating. Journal Of Materials Chemistry 2012, 22, (41), 22005-
22012. 
27. Croissant, J. G.; Fatieiev, Y.; Khashab, N. M., Degradability and Clearance of 
Silicon, Organosilica, Silsesquioxane, Silica Mixed Oxide, and Mesoporous Silica 
Nanoparticles. Advanced Materials 2017, 29, (9). 
28. Shie, M. Y.; Ding, S. J.; Chang, H. C., The role of silicon in osteoblast-like cell 
proliferation and apoptosis. Acta Biomaterialia 2011, 7, (6), 2604-2614. 
  
101 
 
Chapter 3 Synthesis and properties of theranostic 
nanoplateform from 2D to 3D 
“天行健，君子以自强不息”  
 
《易经》 
 
Abstract 
This study aimed to synthesize nanoparticles for theranostic applications and to evaluate the 
influence of a three-dimensional environment on their functionality. These particles combining 
controlled drug delivery properties, MRI contrast agent and cancer cell targeting were prepared 
by combining hollow mesoporous silica particles containing doxorubicin, MnO2 nanosheets 
and an aptamer. Monolayer cultures showed that these particles penetrated model cancer cells, 
leading to increased MRI signals and releasing doxorubicin, both effects being significantly 
more significant than in healthy cells. In addition, the functionality and specificity of the 
particles were preserved when the cells were immobilized in collagen hydrogels. This approach 
could therefore be used for a rapid assessment of the biofunctionality of nanoparticles before 
setting up in vivo experiments. 
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Synthèse et propriétés de nanoplateformes pour la 
théranostique: du 2D au 3D 
 
 
 
 
Résumé 
Cette étude vise à synthétiser des nanoparticules pour des applications théranostiques et évaluer 
l’influence d’un environnement tri-dimensionnel sur leur fonctionnalité. Ces particules alliant 
des propriétés de délivrance contrôlée de médicaments, d’agent de contraste pour l’IRM et de 
ciblage de cellules cancéreuses ont été préparées en combinant des particules de silice 
mésoporeuses creuses contenant de la doxorubicine, des nanofeuillets de MnO2 et un aptamère. 
Les cultures monocouches ont montré que ces particules pénétraient les cellules cancéreuses 
modèles, conduisant à l’augmentation des signaux IRM et libérant la doxorubicine, les deux 
effets étant nettement plus significatifs que dans des cellules saines. De plus, la fonctionnalité 
et la spécificité des particules ont été préservées lorsque les cellules ont été immobilisées dans 
des hydrogels de collagène. Cette approche pourrait donc servir pour une évaluation rapide de 
la biofonctionnalité des nanoparticules avant de mettre en place des expériences in vivo. 
 
Y. Shi, F. Guenneau, W. Wang, C. Hélary, T. Coradin, MnO2-gated Nanoplatforms with 
Targeted Controlled Drug Release and Contrast-Enhanced MRI Properties: from 2D Cell 
Culture to 3D Biomimetic Hydrogels, Nanotheranostics, 2018; 2(4): 403-416. 
  
103 
 
3.1 Introduction  
Despite the rapid improvement of modern medicine, the early diagnosis and therapy of cancer 
is still a challenge. The continuous development of nanotechnology and the emergence of 
targeted treatments provide an inequivalent opportunity in this area. The past decade has 
witnessed the engineering of many theranostic nanosystems, where the integration of different 
imaging agents and therapeutic drugs into a single nanoparticle (NP) has made it possible to 
exhibit multiple functionalities1-4. Extensive efforts have also allowed for the identification of 
active targeting reagents, such as folic acid, hyaluronic acid, aptamers, or transferrin, that bind 
with high specificity to the cancerous cell membrane5-8. At the same time, strategies were 
developed to achieve a controlled drug release triggered by intrinsic physiological 
microenvironment changes (pH, redox, enzyme, heat, etc.) and/or external stimuli (including 
light, magnetic/electronic ﬁeld, ultrasound, etc.)9-11. All those developments taken together, it 
becomes possible to simultaneously reduce the side-effects of anticancer agents to normal 
tissues and enhance their therapeutic efﬁciency12. Indeed, there still is some room for large 
improvement, in terms of drug loading and targeting efficiency. 
 From an imaging perspective, signals of most previously-reported nanosystems are “always 
on” regardless of the absence or presence of the target cells, resulting in a low contrast 
detection13. Among available nanoparticles, Mesoporous Silica Nanoparticles (MSNs) have 
been widely considered for the delivery of anticancer drugs11, 14, 15. To tackle MSNs intrinsic 
limited loading capacity, Hollow MSNs (HMSNs) with rattle or hollow structure have been 
prepared as they can efficiently accommodate drugs not only into mesoporous channels of their 
shell but also within their internal cavity16-18. Moreover, recent progress in the design of gated 
HMSNs has shown some promise in the development of controlled-release theranostic 
nanosystems. Different “gatekeepers”, such as organic molecules, biomacromolecules and 
nanoparticles, have been used, allowing pore-opening under the stimulation of pH change, 
temperature, nucleotides, antibodies, enzymes, glucose, or photoirradiation19-21. However, 
these gated nanosystems usually require a highly-sophisticated design that has a strong impact 
on synthesis time and development cost, ultimately hindering their transfer to the market, 
despite their demonstrated functionality.  
Recently, MnO2 nanosheets, a 2D ultrathin semiconductor material with wide applications in 
the energy field22, has attracted large attention as a gatekeeper for drug nanocarriers23-25. They 
exhibit a broad and intense absorption band at around 374 nm, making MnO2 nanosheets an 
efficient broad-spectrum quencher26. Moreover, MnO2 can be converted to Mn
2+ via reduction 
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by endogenous glutathione (GSH), leading to decomposition of the MnO2 nanosheets
27. While 
manganese (IV) ions in the nanosheets are shielded from water due to their 6-fold coordination 
with oxygen atoms, free solvated Mn2+ ions are efficient T1 contrast agents for Magnetic 
Resonance Imaging (MRI)28. GSH is an essential endogenous antioxidant that has many cellular 
functions and high GSH levels are implicated in many diseases typically associated with cancer, 
liver damage, or heart problems29. Therefore, much attention has been paid to the use of GSH 
to design intracellular controlled release systems30. In addition, whereas the extracellular pH of 
normal tissues and blood is constant at 7.4, the measured extracellular values of most solid 
tumors range from pH 6.5 to 7.2, such lower pH values being more favorable for the reaction 
between MnO2 and GSH
31. Based on this principle, several MnO2@SiO2-based controlled-
release nanosystems with GSH-induced contrast-enhanced magnetic resonance signal have 
already been described23, 32, 33.  
Another key challenge in this area lies in the precise control of the drug release using stimuli-
responsive systems. Thus, tumor microenvironment, that has a crucial role in cancer 
progression, exhibit several specific biological and physico-chemical features that can be 
exploited to trigger the drug release at the tumor site34. However, the efﬁciency and stimulation 
of nanosystems are often tested in two-dimensional (2D) systems, in which seeded cancer cells 
do not experience the real microenvironment they ﬁnd in vivo, where physiological fluids, 
tissues as well as interactions between cancer and stromal cells may impair the drug delivery 
or its functionality. The transfer from 2D data to in vivo during preclinical studies may therefore 
be extremely time-consuming and costly. Therefore, the design of three-dimensional (3D) 
environments exhibiting some features of in vivo tumors, such as three-dimensional 
architecture, cell-cell interaction and hypoxia should provide highly useful tumor tissue in vitro 
models for testing anticancer therapeutics35, 36. In this context, the use of type I collagen, the 
major protein in most animal tissues, to prepare biomimetic constructs is of particularly 
relevant37-39. Most importantly, it has been shown in our group that they could act as models to 
study the interactions between nanoparticles and cells in a 3D environment40, 41. 
In this work, we aimed at designing multifunctional nanoprobes for contrast-enhanced bimodal 
cellular imaging and targeted therapy and to study how their interactions with normal human 
cells and model cancer cells could be impact by in traditional 2D cell culture and in cellularized 
3D hydrogels. Our strategy for the design of the nanoplatforms was to use the above-described 
MnO2 nanosheets as a coating of doxorubicin-loaded HMSNs that could act as both gatekeeper 
for DOX release from and contrast agent for MRI. Another key element of our nanoplatforms 
was the use of a cancer cell-targeting aptamer (AS1411), that bind to nucleolin, a nucleolar 
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phosphoprotein which is overexpressed on the surface of certain cancer cells28, 42, 43. Noticeably, 
at the time where we started this project, there was only one paper available in the literature 
that used a quite similar strategy23 but other related works were published while we were 
developing our own project, especially for Yang et al. and Li group 32 33. However none used 
HMSNs as starting silica nanostructures and our attempt to evaluate their behavior in 3D models 
was not reported so far.  
3.2 Materials and methods 
3.2.1 Materials and reagents 
All chemical reagents were analytical grade and used without further purification. 
Cetyltrimethylammonium bromide (CTAB), tetraethyl orthosilicate (TEOS), sodium carbonate 
(Na2CO3), absolute ethanol, concentrated hydrochloric acid, ammonium aqueous solution (25-
28%), triethanolamine (TEA), 3-triethoxysilylpropylamine (APTES), potassium permanganate 
(KMnO4), 2-(N-Morpholino)ethanesulfonic acid hydrate (MES), doxorubicin hydrochloride 
(DOX) and fluorescein isothiocyanate (FITC) were purchased from Sigma-Aldrich. MilliQ 
water (18MΩ, Millipore, France) was used for the preparation of the solutions and for all rinses. 
4,6-diamidino-2-phenylindole (DAPI). Fetal bovine serum, Dulbecco’s Modified Eagle’s 
Medium (DMEM), trypsin, glutamine, penicillin-streptomycin solution and AS1411 aptamer 
(5′-NH2-GGTGGTGGTGGTTGTGGTGGTGGTGG-3′) were purchased from ThermoFisher.  
3.2.2 Preparation of HMSNs@MnO2/apt  
Synthesis  
Bare HMSNs were prepared using previously reported methods44, 45. To functionalize the 
particle surface with amine groups, as-synthesized HMSNs were first dispersed in 20 mL of 
toluene, followed by addition of 1mL of APTES. The system was sealed and refluxed at 120 
°C in oil bath for 12 h. Afterward, the mixture was centrifuged and washed with ethanol for 
several times to remove the residual APTES. Then, 20 mg of HMSNs-NH2 was dispersed in 
4.2 mL MES buffer (0.1M, pH 6.0) and then 0.8 mL of 5 mM KMnO4 in water was added to 
the mixture under ultrasonic condition. The resulting mixture was sonicated for another one 
hour during which brown-black colloids were observed. Subsequently, the raw product was 
collected by centrifugation, washed several times with deionized water and alcohol to remove 
any possible residual reactants, and redispersed in 2 mL PBS solution (pH 7.4). The physical 
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adsorption of aptamer on HMSNs@MnO2 was carried out by mixing 0.8 mL of 
HMSNs@MnO2 (20 mg/mL) in PBS and 200 µL of AS1411 (1 µM). After 3 h of incubation, 
the solution was centrifuged at 6000 rpm, washed several times, and then dispersed in PBS (pH 
7.4) for further application. The preparation of fluorescently-labeled hollow mesoporous silica 
nanoparticles was performed by adding FITC to the starting solution used for bare HSMNs 
preparation. 
 
Characterization  
Transmission Electron Microscopy (TEM) studies were performed on a FEI Tecnai G2 Spirit 
microscope operating at 120 kV. Scanning electron microscopy (SEM) images were obtained 
on a Hitachi S-3400N scanning electron microscope with a ﬁeld emission electron gun. 
Nitrogen sorption-desorption isotherms were measured at 77 K with a Micromeritics 
ASAP2010 analyzer. Fluorescence images were recorded on a LEICA microscope. Dynamic 
Light Scattering (DLS) was used to determine the hydrodynamic diameter of the nanoparticles 
in Milli-Q water or in culture medium with Mastersizer 3000 Particle Size Analyzer. The 
reading was carried out at an angle of 90° to the incident beam (632 nm). The Contin algorithm 
was used to analyze the autocorrelation functions. X-ray Photoelectron Spectroscopy (XPS) 
analyses were performed with a PHOIBOS 100 spectrometer from SPECS GmbH. Inductively 
Coupled Plasma Mass Spectrometry (ICP-MS) was used to determine the Mn content of the 
nanoparticles. 
3.2.3 Drug loading and release in vitro 
10 mg of HMSNs@MnO2 nanoparticles were mixed with 1.5 mg of DOX in 1.5 mL of 
PBS/DMSO (1:1) mixture solution and then stirred under dark conditions for 24 h. 
Subsequently, the product was collected by centrifugation and washed several times with PBS 
to remove the free DOX. Then 100 µL of AS1411 (1 µM) in PBS was added, and after 3 h of 
stirring, the resulting HMSNs@MnO2(DOX)/apt nanoparticles were collected by 
centrifugation and re-dispersed in PBS solution for subsequent use. To evaluate the DOX 
loading, the remaining DOX molecules in the supernatant solutions were determined by 
ﬂuorescence spectroscopy (λex= 500 nm, λem = 590 nm). The loading of the nanoparticles was 
expressed as the mass percentage of DOX with respect to the total mass of 
HMSNs@MnO2(DOX)/apt nanoparticles.  
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In vitro DOX release from the HMSNs@MnO2(DOX)/apt nanoparticles was studied in PBS 
buffer in absence or presence of GSH at pH values of 7.4 and 5.5. For each release study, 1.0 
mL of DOX-loaded nanoparticles (1.0 mg/mL) were dispersed inside a dialysis bag that was 
soaked in 9.0 mL PBS and shaken at room temperature. At selected time intervals, the sample 
was collected and 2 mL of solution outside the dialysis bag was removed. Then, 2 mL of fresh 
PBS buffer was added.  The removed solution was properly diluted and the amount of DOX 
molecules present was measured by ﬂuorescence spectroscopy. The same amount of the DOX 
solution was introduced in the dialysis bag and was used as control.  
3.2.5 In vitro cytotoxicity assays and cell uptake studies 
Cell culture 
Normal Human Dermal Fibroblasts (NHDF) and HeLa cells were cultured in complete cell 
culture medium (DMEM with GlutaMAX™, without phenol red supplement, with 10% fetal 
serum, 100 U.mL-1 penicillin, 100 μg/mL streptomycin). Tissue culture flasks (75 cm2) were 
kept at 37 °C in a 95% air: 5% CO2 atmosphere. Before confluence, the cells were removed 
from culture flasks by treatment with 0.1% trypsin and 0.02% EDTA. Cells were rinsed and 
resuspended in the above culture medium before use. 
 
In vitro cytotoxicity assays 
First, HeLa were seeded in a 24-well plate at a density of ~5×104 cells/well overnight to allow 
cell attachment onto the surface of the wells. Then, 0.5 mL of fresh medium containing various 
concentrations of HMSNs@MnO2(DOX)/apt was added into the wells. After incubation for 24 
h, cell activity was evaluated by the Alamar Blue assay. Control experiments were performed 
by incubating HeLa cells with free DOX and HMSNs@MnO2(DOX) at various drug contents 
or HMSNs@MnO2(DOX)/apt at equivalent particle concentration for 24 h. To confirm the 
cytotoxicity of DOX released from the nanoplatform under GSH, control similar experiments 
were performed with NHDF cells incubated in presence of 5 mM GSH. 
 
Cell uptake studies by fluorescence imaging  
NHDFs and HeLa cells were seeded in a round glass disk that was inserted in 24-well plate 
(~5×104 cells per well) and cultured for 24 h. The cell medium was removed, and then cells 
were incubated with 0.5 mL of fresh cell medium containing FITC labeled 
HMSNs@MnO2(DOX)/apt nanoparticles for another 12 h.  After medium removal, the cells 
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were washed with PBS for several times, and then 0.5 mL of fresh cell medium with or without 
5 mM GSH was added and incubated for another 3 hours. Fixation of the cells was carried out 
using 4% (v/v) paraformaldehyde (PFA) for 2 h and rinsed three times using PBS. After 
washing, cellular nuclei were stained with 1% (v/v) solution of DAPI in PBS buffer for 20 min 
and washed with PBS three times. Last, cell imaging was carried out by ﬂuorescence 
microscopy. For the HeLa cells imaging, the procedure was similar, except that 
HMSNs@MnO2(DOX) or HMSNs@MnO2(DOX)/apt particles were added and no GSH 
treatment was performed.  
3.2.6 Measurement of MRI relaxation properties 
Imaging of MRI phantoms measurement was performed with a Bruker Avance 3 HD 300 
spectrometer, equipped with a 10 mm micro imaging probe, having a maximum gradient 
capacity of 3 T m-1 in the x, y and z directions. The Multi Slice Multi Echo (MSME) pulse 
sequence was used, acquiring 1 echo but 8 slices with a slice thickness of 1 mm. The size of the 
images was: 128×128 with a Field of View of 9.5×9.5 mm, resulting in a voxel size of 74×74 
µm. Images were acquired with 1 scan and T1 weighting was obtained by using a short repetition 
time (TR) of 200 ms and using the shortest possible echo time (TE), namely 4.92 ms, in order 
to minimize the effect of T2 relaxation. 
3.2.7. Cytotoxicity and functionality within 3D models 
Preparation of hydrogel 3 D models 
Type I collagen was purified from rat tails and the final concentration was estimated by 
hydroxyproline titration, as previously described37. Tubes separately filled with collagen 
solution (2 mg/mL in 17 mM acetic acid), whole cell culture medium, and 0.1 M NaOH were 
kept in ice bathes for 1 h before preparation to slow down the gelling kinetics of collagen. 
Firstly, 500 μL of collagen solution and 400 μL of culture medium were added to a 1.5 mL tube 
and vortexed vigorously. After addition of 30 μL of 0.1 M NaOH and strong vortexing, 125 μL 
of the NHDF or HeLa cell suspension at a density of 106 cells/mL was added and mixed 
homogeneously. Then 0.9 mL was sampled from the mixture and deposited into a 24-well plate. 
The plate was then incubated at room temperature for 10 min for complete gelling of collagen.  
 
Cytotoxicity and functionality 
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Two sets of experiments were designed41. In a first approach, selected particles were introduced 
in the cell suspension prior to their addition to the collagen solution, at a final concentration of 
100 μg mL-1. Then collagen gels were formed by pH increase to 7. After 48 h of incubation, the 
cell viability was assessed in the same way as for 2D tests except that 800 μL water were first 
added to the collagen gel, left for 0.5 h at room temperature in order to extract the Alamar Blue 
solution trapped in the gel, and then collected for the absorbance measurements. Particle 
internalization was also studied in the same configuration. For this, after the 48 h incubation 
period, the gels were rinsed 3 times with PBS, and fixed with 4% paraformaldehyde overnight. 
Next, the fixed samples were dehydrated in ethanol and butanol, and incorporated in paraffin 
to be able to obtain 10 μm histological sections with a manual microtome. Before observation, 
the as-obtained samples were immersed in toluene, ethanol, and then water for rehydration. The 
cell nuclei were stained with DAPI for 10 min and rinsed with PBS before observation. The 
second approach consisted in adding 1.0 mL of a 0.2 mg/mL suspension of the 
HMSNs@MnO2(DOX)/apt particles onto the surface of particle-free cellularized collagen gels. 
After 3 hours of contact, the MR imaging experiments were performed as described above. 
3.2.8. Statistical Analysis 
Graphical results are presented as mean ± SD (standard deviation). Statistical significance was 
assessed using the student’s-test compared with control groups. The level of significance in all 
statistical analyses was set at a probability of P < 0.05. 
3.3. Results and discussion 
3.3.1 Preparation and characterization of the nanoplatforms 
The HMSN@MnO2/apt nanoparticles were prepared according to the process depicted in 
Figure 3-1. In brief, monodisperse solid SiO2 nanoparticles (sSiO2) were prepared using a 
modified Stöber method. They were then coated with a CTAB/SiO2 shell via base-catalyzed 
hydrolysis of TEOS and condensation of silica onto the surface of CTAB pre-coated sSiO2. The 
resulting particles were simultaneously treated with Na2CO3 to remove sSiO2, and NH4NO3 to 
remove CTAB, resulting in HMSNs with hollow cores and penetrating pore channels.44 APTES 
was grafted on the surface of nanoparticles to get HMSN-NH2. Finally, ultrathin MnO2 
nanosheets were formed onto the surface of HMSN-NH2 thanks to the reaction with MES and 
KMnO4 to obtain HMSN@MnO2. DOX was then loaded inside or on the surface of the 
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nanoparticles by the impregnation. To end, AS1411 aptamers were attached on the surface of 
MnO2 nanosheets thanks to π-π interaction.  
 
Figure 3-1 Schematic illustration of the preparation of HMSN@MnO2(DOX)/apt and the drug 
release mechanism 
As shown in the TEM image of Figure 3-2, the prepared hollow mesoporous HMSN 
nanoparticles exhibit a uniform diameter of ~140 nm and form a colorless well-dispersed 
suspension in deionized water (DI). The diameter measured by DLS, Dm, is about 200 nm in 
DI, which is slightly larger than the TEM data and may reflect some aggregation.  
 
Figure 3-2 TEM images of (a) HMSNs, (b) HMSN@MnO2/apt, (c) HMSN@MnO2/apt after 
GSH treatment and the corresponding digital images from left to right (d, e, f) 
The contrast between shell and core of the silica nanospheres confirms their hollow structure. 
The shell of the HMSN with a thickness of ~25 nm displays an obvious mesoporous silica 
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structure generated by the removal of pore templates. In DI water, the obtained HMSNs 
exhibited a negative zeta potential ζ of -18.4 mV, as expected for silica surfaces (Table 3-1). 
Table 3-1 Mean diameter Dm from DLS with corresponding polydispersity index (PDI) and 
Zeta potential ζ in deionized water 
Sample Dm DLS (nm) PDI ζ (mV) 
HMSNs 200 ± 18 0.254 -18.4 ± 0.5 
HMSNs-NH2 256 ± 27 0.317 +10.4 ± 0.3 
HMSNs@MnO2 319 ± 41 0.579 -15.4 ± 0.2 
HMSNs@MnO2(DOX) 316 ± 26 0.500 -7.3 ± 0.8 
HMSNs@MnO2(DOX)/apt 248 ± 15 0.279 -16.1 ± 0.3 
 
The N2 adsorption-desorption isotherm of the HMSN showed a type IV curve quite typical of 
surfactant-assisted mesoporous silica with a double, strong, and sharp adsorption step at 
intermediate relative partial pressure values around 0.4 (Figure 3-3a). This feature is associated 
with the nitrogen condensation inside the mesopores by capillarity. The application of the 
Brunauer-Emmett-Teller (BET) model resulted in a high value for the speciﬁc surface of 840 
m2 g-1. In parallel, the Barrett-Joyner-Halenda (BJH) model applied on the adsorption branch 
of the isotherms led to an average pore diameter of 3.89 nm (Figure 3-3b).  
 
Figure 3-3 (a, c) N2 adsorption-desorption isotherm at 77 K and (b,d) the corresponding pore 
diameter distribution obtained by the BJH method on the adsorption branch for (a,b) HMSNs 
and (c,d) HMSNs@MnO2 
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The successful surface functionalization of silica nanoparticles using APTES could be checked 
by the increase of the zeta potential that reached a positive value (+10.4 mV) (Table 3-1). Upon 
contact with MES and KMnO4, a visual color change from white to brown was observed 
(Figure 3-2e). After extensive washing, UV-vis spectra clearly evidenced a strong absorption 
at 400 nm, that can be attributed to the MnO2 nanosheets, whose intensity increase with the 
initial KMnO4 concentration (Figure 3-4a). The formation of composite nanoparticles 
(HMSN@MnO2) with a rough capping layer was conﬁrmed by TEM images (Figure 3-2b). 
Moreover, the average diameter of HMSN@MnO2 was changed from 200 nm to ca. 320 nm, 
accompanied by a PDI change from 0.254 to 0.579, which suggests that the MnO2 coating 
induces a slight tendency for the particles to aggregate. The zeta potential of nanoparticles was 
also modified, from +10.4 mV down to -15.4 mV after functionalization, in agreement with 
values in the literature46. Sorption isotherms also confirmed the coating of the nanoparticles. 
HMSN@MnO2 presented ﬂat sorption curves when compared to those of HMSN (at P / P0 = 
0.4) (Figure 3-3a), thus indicating a signiﬁcant pore blocking. Nonetheless, HMSN@MnO2 
showed an additional inﬂection at P / P0 > 0.8, that can correspond to secondary macropores 
resulting from the MnO2 capping layer with rough surface. A weak peak at pore diameter of 
2.35 nm was also obtained, conﬁrming the partial pore blocking effect of the MnO2 layer. 
Finally, when HMSN@MnO2 were put in contact with GSH (10 mM), the color of the 
suspension changed back from brown to white, indicative of the disappearance of the MnO2 
layer (Figure 3-2f). TEM images clearly conﬁrmed the regeneration of the smooth surface and 
clear mesoporous structure of HMSN (Figure 3-2c).  
 
Figure 3-4 Absorbance spectra of the HMSNs after addition of KMnO4 with different 
concentrations and the corresponding insert images with color change. (b) Absorbance spectra 
of the DOX, MnO2, and a series of nanoparticles 
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Doxorubicin (DOX) was then selected as a guest molecule to confer anticancer properties to 
the nanoparticles. The loading was performed by a simple impregnation route in a mixed 
aqueous/organic medium. The resulting DOX-loaded HMSN@MnO2 particles had a size 
distribution similar to unloaded particles but the zeta potential changed from -15.4 mV to -7.3 
mV, suggesting that at least part of the drug is adsorbed on the MnO2 coating. The UV-vis 
spectra of the loaded particles showed an additional absorption band at ca. 480 nm similar to 
the one of DOX (Figure 3-4b). The DOX loading of HMSN@MnO2, as estimated by 
fluorescent emission measurements of the supernatant after impregnation, reached ca. 80 
µg.mg-1. As a final step, the anti-nucleolin AS1411 was adsorbed on the 
HMSNs@MnO2(DOX) particles which resulted in a significant decrease in the average particle 
diameter and of the PDI (Table 3-1). This can be correlated with the more negative value of 
the zeta potential (from -7.6 mV without aptamer to -16.1 mV after AS1411 adsorption), that 
results in an enhanced particle colloidal stability thanks to additional electrostatic repulsion. 
 
Figure 3-5 XPS analysis of the HMSNs@MnO2(DOX)/apt nanoparticles: (a) full XPS 
spectrum with atomic analysis and deconvoluted signals with proposed attributions at the (b) 
Mn2p, (c) Si2p and (d) O1s levels 
To characterize the chemical compositions of the final HMSNs@MnO2(DOX)/apt 
nanoparticles, their element composition was determined by XPS (Figure 3-5a). Mn, Si, C, O 
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and N peaks were observed. Indeed, considering that the analysis depth of XPS analysis is 10 
nm at maximum, it only probes the outer surface of the particles. It is therefore not surprising 
that the content of Si is rather low (19.8 %), corresponding to ca. 40 wt% of SiO2. In contrast, 
the contribution of Mn (0.9 wt %) and of organic molecules (DOX and AS1411) (> 35 % C) is 
enhanced compared to the whole particle volume.  
 
Figure 3-6 Deconvoluted XPS spectra of (a) C1s, (b) N1s for HMSNs@MnO2(DOX)/apt 
At the Mn2p level (Figure 3-5b), the two peaks at 642 eV and 653.8 eV unambiguously sign 
for the presence of MnO2, as also confirmed by the peak at 530.1 eV on the O1s spectrum
47 
(Figure 3-5d). The peaks at 103.2 eV on the Si2p spectrum (Figure 3-5c) and 532.4 eV on the 
O1s spectrum are characteristic of hydrated silica48. Additionally, deconvoluted spectra at the 
C1s and N1s levels evidenced the presence of C-C, C-O, C=O, C-N and N-C=O groups (Figure 
3-6). The latter indicates the presence of the aptamer on the particle surface49, while the others 
can belong to both AS1411 and DOX. 
3.3.2 Drug release and MRI imaging properties of the nanoplatforms. 
 
Figure 3-7 Images of HMSNs@MnO2/apt suspensions in different conditions, (a) pH 7.4; (b) 
pH 5.5; (c) pH 7.4, 5mM GSH; (d) pH 7.4, 10mM GSH; (e) pH 5.5, 5mM GSH 
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The feasibility of MnO2 degradation when treated with GSH and pH was ﬁrst investigated. As 
shown in the Figure 3-7, the HMSNs@MnO2/apt nanoplatforms were stable at neutral pH, but 
after interaction with GSH, the color of the system quickly changed from brown to colorless, 
with a more pronounced effect when GSH concentration was increased from 5 mM to 10 mM. 
Acidic pH slightly destabilized the nanoplatform, due to the intrinsic instability of MnO2 in 
these conditions, as well as enhanced the effect of GSH. These observations were quantitatively 
assessed by monitoring DOX release in different conditions (Figure 3-8). In the absence of 
GSH, the DOX release was less than 10 % over 50 h at pH 7.4. When the MnO2 coating was 
destabilized, either in acidic conditions or by addition of GSH at neutral pH, ca. 20 % of the 
DOX content was released within 10 h and then a slower release, up to ca. 35-40 %, occurred 
in the next 40 h. When GSH was added in acidic conditions, the shape of the release curve was 
quite similar (i.e. fast release during 10 h followed by slower release) but the amount of released 
DOX at the end of the first phase was much higher (ca. 50 %) than in the two previous 
conditions and the total release after 50 h was larger than 60 %. 
 
Figure 3-8 Cumulative release of the HMSNs@MnO2(DOX)/apt in different conditions: (blue) 
pH 7.4, (black) pH 5.5, (green) pH 7.4+ 5 mM GSH, (red) pH 5.5 + 5 mM GSH. Control 
samples: (pink) free DOX and (pale green) uncoated HSMNs(DOX) in PBS solution (pH =7.4) 
As pointed out earlier, DOX molecules may be located on the MnO2 surface, inside the porous 
silica shell and within the particle empty core. Assuming that the GSH-free neutral pH 
conditions induce no significant dissolution of the MnO2 nanosheets, then the measured low 
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release (less than 10 % of the initial dose) should correspond to surface-adsorbed DOX 
molecules. Upon GSH addition or acidification, much more DOX molecules are released 
following a two-step process.  
It is worth emphasizing that silica nanoparticles are less soluble in acidic than in neutral pH 
conditions and not sensitive to GSH unless specifically modified50. Thus it can be suggested 
that the first step corresponds to the release of DOX molecules both adsorbed on the surface 
and trapped in the porous shell due to the MnO2 coating dissolution, while the second one would 
sign for the slow diffusion of the drug located within the particles.  However, when both acidic 
conditions and GSH addition are combined, the overall release profile, and especially the 
duration of the fast-release period, is not significantly modified but more DOX is initially 
released. This may be interpreted considering that, in these conditions, the MnO2 degradation 
is efficient enough to uncap all pores before diffusion of DOX molecules from the inside of the 
particle starts. In contrast, in GSH-only or acidic pH-only conditions, the MnO2 degradation 
process is less efficient and only part of the pores is uncapped before diffusion from the inside 
compartment becomes effective. 
Because the reduction of MnO2 by intracellular GSH could produce a large amount of Mn
2+, 
which are efficient T1 contrast agents, the nanoplatform could also afford GSH/pH-activated 
detection by MRI. To verify this hypothesis, T1-weighted MR images of HMSN@MnO2/apt 
aqueous suspensions under different conditions were first performed. As shown in Figure 3-9a, 
the MRI signal of the HMSN@MnO2/apt sample in PBS at pH 7.4 didn’t exhibit an obvious 
T1-MRI signal difference compared to that of deionized water. A significant T1-MRI signal 
enhancement could be observed at pH 5.5. Adding 5 mM GSH in neutral and then acidic 
conditions further improved the T1-MRI signal intensity. The r1 relaxivity of the nanoplatform 
suspensions was also measured (Figure 3-9b) for HMSN@MnO2/apt at pH 5.5 in the presence 
of GSH, reaching a value of 9.25 mM-1 s-1 which is remarkably higher than that of the GSH-
free solution at pH 7.4 (r1 = 1.68 mM
-1 s-1). Importantly such r1 values are higher than those 
reported for other Mn-based nanocontrast agents (Mn3O4 nanoparticles, 8.26 mM
−1 s−1; Mn-
MSNs, 2.28 mM−1 s−1 and MnO nanoplates, 5.5 mM−1 s−1)51-53. The above results suggest that 
the MnO2 nanosheets can efficiently be converted into Mn
2+ in a mildly acidic/GSH 
environment, explaining the rapid enhancement of the longitudinal relaxation rate with 
concentration. In conclusion, HMSNs@MnO2/apt present a clear pH/GSH-responsive T1-MRI 
performance. 
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Figure 3-9 T1-weighted MR images of HMSN@MnO2/apt under different conditions. (i: H2O; 
2: pH 7.4; 3: pH 5.5; iv: pH 7.4 + GSH 5 mM and v: pH5.5 + GSH 5 mM). (b) 1/T1 versus Mn 
concentrations for HMSN@MnO2/apt at (black) pH 7.4 and (red) pH 5.5 + 5 mM GSH 
In a second step, it was necessary to check that the designed nanoplatforms could efficiently 
kill cancer cells while being safe for normal cells. Firstly, the impact of HMSNs@MnO2(DOX) 
and HMSNs@MnO2(DOX)/apt particles on HeLa cells viability after 24 h of contact was 
studied using the Alamar blue test and compared to free DOX.  
 
Figure 3-10 (a) HeLa cell viability after incubation with DOX, HMSNs@MnO2, 
HMSNs@MnO2(DOX) and HMSNs@MnO2(DOX)/apt for 24 h as a function of DOX dose. 
(b) Cell cytotoxicity of HMSNs@MnO2(DOX)/apt after 24 h of incubation with NHDF, HeLa 
and NHDF cells treated with GSH as a function of particle concentration 
The concentrations indicated on Figure 3-10a correspond to DOX, either free or within the 
particles. No difference in performance between free and encapsulated drug could be observed, 
with a continuous decrease of HeLa cells activity with increasing DOX dose down to ca. 50 % 
for the highest investigated dose (16 µg/mL). The presence of the aptamer had no influence 
either. Control experiments performed with DOX-free HMSNs@MnO2 in the same particle 
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amount as for HMSNs@MnO2(DOX) showed negligible cytotoxicity. In a second step, the 
effect of HMSNs@MnO2(DOX)/apt particles on HeLa and NHDF cells was monitored. In this 
case, the dose is presented in particle concentration (Figure 3-10b). In the 5-160 µg mL-1 range, 
HMSNs@MnO2(DOX)/apt particles have no obvious impact on NHDF while they are toxic for 
HeLa cells (i.e. viability below 80 %) for particle concentrations of 10 µg mL-1 or more. 
Importantly, if GSH (5 mM) was present in the NHDF culture medium, then high cytotoxicity 
was also measured, confirming its ability to trigger DOX release.  
 
Figure 3-11 Fluorescent images of (a) NHDF cells incubated with HMSNs@MnO2(DOX)/apt 
nanoparticles, (b) NHDF cells incubated with HMSNs@MnO2(DOX)/apt nanoparticles and 5 
mM GSH, (c) HeLa cells incubated with HMSNs@MnO2(DOX)/apt nanoparticles, (d) HeLa 
cells incubate 
To confirm this hypothesis, the internalization of the HMSNs@MnO2(DOX)/apt was studied. 
As shown in Figure 3-11a-d, accumulation of the nanoplatforms, visualized by the green 
fluorescence of encapsulated FITC, in contact or within the cells could be observed for NHDF, 
without or with GSH, and HeLa cells. In the latter case, bright green aggregates are located near 
the nuclei, which appear blue after DAPI staining, strongly supporting their intracellular 
localization. For this sample, colocalization of the nanoplatform (green signal) and the DOX 
molecules (red signal) is evidenced. Noticeably, when no aptamer was present on the surface, 
low particle accumulation was observed and no clear red signal could be imaged (Figure 3-
11d). For NHDF cells without GSH, the red areas are hardly seen whereas they are more clearly 
visible/detectable when GSH was present. It is important to point out that MnO2 nanosheets 
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have previously been shown to efficiently quench the fluorescence of dyes in the UV-visible 
range54. Thus the observation of red signals on the fluorescence images indicates that DOX is 
no longer interacting with the manganese oxide coating, probably because the MnO2 nanosheets 
were reduced to Mn2+ by GSH. Noticeably, in the case of HMSNs@MnO2(DOX)/apt 
interacting with HeLa, the strong co-localization of FITC and DOX inside the cells would 
suggest that the MnO2 layer has been degraded but that part of the drug remains inside the 
particles (Fig 3-11c). In sharp contrast, for HMSNs@MnO2(DOX)/apt interacting with NHDF 
in the presence of GSH, many particles visualized by monitoring the green fluorescence do not 
exhibit a red fluorescence (Fig 3-11b).  This can be attributed to the fact that the MnO2 layer is 
degraded by GSH leading to DOX release before the internalization process. 
Altogether, HMSNs@MnO2(DOX)/apt nanoplatforms have the ability to be internalized by 
HeLa cells with a clear benefit of the presence of the targeting aptamer on the efficiency of this 
process. After degradation of the MnO2 coating, that may be due to both acidic pH of the 
lysosome and enhanced GSH expression, the particles can thereby release DOX molecules at 
the vicinity of the nucleus, resulting in an efficient cancer cell killing. At the same time, the 
formation of Mn2+ ions should allow for the detection of the cancer tissue via T1-weighted MRI. 
Very importantly, our experiments also indicate that these nanoplatforms are safe for normal 
NHDF cells in the absence of GSH.  
3.3.3 Functionality of nanoplatforms in 3D biomimetic collagen matrices 
At this stage of similar studies, in vivo evaluations are usually undertaken using tumor-bearing 
animals. However, in this work, we chose instead to go deeper into the understanding of the 
impact of a 3D environment on the functionality of the nanoplatform, a point that was not 
previously assessed in the literature. For this we prepared type I collagen matrices in conditions 
compatible with cell immobilization and particle encapsulation or diffusion40, 41. 
To check whether the nanoparticles preserved their efficiency and selectivity as cancer cell 
killing agents, the viability of NHDF and HeLa cells co-encapsulated with HMSNs@MnO2, 
HMSNs@MnO2(DOX), and HMSNs@MnO2(DOX)/apt at a dose of 100 μg/mL within the 
collagen matrices was studied (Figure 3-12a).  
After 24 h, compared to the control group, the unloaded HMSNs@MnO2/apt showed very little 
toxicity for both types of cells. After DOX-loading, the HMSNs@MnO2(DOX)/apt 
nanoparticles neither showed much effect the viability of NHDF cells but exhibited a clear 
cytotoxic effect on HeLa cells, that was independent of the presence of the aptamer on the 
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surface. Importantly, the decrease of HeLa cell viability was more significant than in the 2D 
experiments (see Figure 3-10b above), suggesting that the confinement of the cells and particles 
within the matrices strongly favors their interaction. As a matter of fact, SEM imaging allowed 
for the observation of nanoparticle aggregates at the close vicinity of the HeLa cells (Figure 3-
12b). In such conditions, our results suggest that it may be no longer necessary to specifically 
target the cells by using the AS1411 aptamer.  
 
Figure 3-12 (a) Viability of NHDF and HeLa cells within different types of 3D collagen/silica 
nanocomposites after 24 h of incubation. (b) SEM image of nanoparticles (red arrow) 
interacting with HeLa cells (white arrow) within collagen hydrogels 
Fluorescence imaging of the encapsulated HeLa cells also evidenced the co-localization of 
DOX with the nuclei-staining DAPI, signing for their successful internalization (Figure 3-13). 
However red fluorescence signals could also be visualized outside the cells, suggesting that 
some MnO2 degradation also occurred outside the cells.  
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Figure 3-13 Fluorescent images of HeLa cells incubated with HMSNs@MnO2(DOX)/apt 
within a collagen hydrogel for 24 h, (a) bright field; (b) blue channel (DAPI); (c) red channel 
(DOX) and (d) merge 
Finally, to evaluate whether such an ultrasensitive GSH-responsive is suitable for in vivo tumor 
imaging by magnetic resonance, another configuration was used where selected nanoparticles 
were placed onto cellularized collagen hydrogels and left to diffuse for 3 h.  
 
 
Figure 3-14 T1-weighted MR images of collagen gels (a) without cells, (b,c) with NHDF cells 
and (d-f) with HeLa cells after 3h diffusion of (b,d) 0.2 mg/mL HMSNs@MnO2(DOX) (c,e) 
0.2 mg/mL  HMSNs@MnO2(DOX)/apt and (f) 0.4 mg/mL  HMSNs@MnO2(DOX)/apt. 
As shown in Figure 3-14, a weak MRI signal was obtained for all samples prepared in the 
absence of HeLa cells or in the presence of NHDF cells, in agreement with the fluorescence 
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image in Figure 3-13 that suggested partial destabilization of the nanoplatforms in contact with 
the collagen network. While comparable results were obtained when the aptamer-free particles 
were added to HeLa cells, HMSNs@MnO2(DOX)/apt particles led to a significant enhancement 
of the intensity of T1-weighted images, that was increased when the initial particle concentration 
was increased. These results clearly demonstrate that the functionality and specificity of the 
HMSNs@MnO2(DOX)/apt nanoplatforms is preserved within the 3D models. 
Interestingly, in this configuration, particles are not initially confined at the proximity of the 
cells but must find their way through the collagen network and bind to HeLa cells. This explains 
why, in contrast to the previous system, the presence of the aptamer does have a significant 
beneficial effect on the MRI signal. In these 3D models, determination of the r1 value is difficult 
as it would require to determine the precise amount of particles that have diffused inside the 
matrices and interacted with the cells. However, when comparing Figure 3-9 and 3-13, it is 
quite clear that the T1 relaxation time is lower in the matrix than in suspension and that the 
decreased stability of the nanoplatforms in the collagen gels ultimately impacts on its 
contrasting efficacy, i.e. its ability to differentiate safe and tumor tissues.  
3.4 Conclusion 
In this work, we were able to synthesize and fully characterize well-defined multi-functional 
nanoparticles combining several complementary properties that fit with the requirements of 
theranostic systems for cancer treatment12. Indeed many other similar or closely-related systems 
have been described in the literature, to which our particles must be compared1-3. The main 
advantages of our strategy is the use of MnO2 as both a gating system and source of MRI-active 
species that makes our system simpler to prepare, especially compared to many other examples 
where complex modifications of the silica particles with stimuli-responsive organic molecules 
are described55. This coating also allows for the direct conjugation of the targeting aptamer 
without any additional surface modification. This is indeed of deep interest because an increase 
in the number of synthetic steps not only impact cost but it is also usually correlated with a 
decrease in the batch-to-batch reproducibility of the resulting particles in terms of size and 
composition, complexifying scale-up processes. However, compared to other hollow silica-
based nanosystems, our doxorubicin loading is quite moderate (8 w/w % compared to up to ca. 
30 % in  Liu group’s work56. This is due to the fact that the MnO2 coating is deposited before 
the loading step to avoid DOX degradation by KMnO4. We must also point out that certain 
MnO2 nanoparticles have been shown to exhibit toxicity in rat models, although this study 
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involved a repeated oral exposure over ca. 1 month57. Therefore, only in vivo evaluation of our 
particles would allow to fully assess their full clinical potential.  
However, there is currently an increasing growing consensus to limit animal tests and, 
consequently, a rapid development of new in vitro methods with a better ability to predict the 
in vivo behavior of pharmaceuticals58, 59. This is in fact one of the main motivations for the 
development of artificial tissues and organs. Indeed the collagen hydrogels we used in this study 
do reflect the chemical and structural complexity of in vivo environments. However they 
allowed us to get some insights on the influence of cells confinement in a 3D environment on 
the ability of our nanoparticles to interact with them. Based on the encouraging observations of 
the preserved functionality and specificity of our nanoplatforms, it is now necessary to improve 
our model hydrogel, including increasing collagen concentration as well as adding other 
components of the extracellular matrices such as other proteins of glycosaminoglycans. 
Coming back to the objective of this PhD project, we have shown here the possibility to transfer 
the functionality of suspensions of silica-based nanoparticles from 2D cell culture liquid 
medium to cellularized 3D environments. In the rest of this manuscript, we will describe our 
studies of the mirror configuration, when silica particles are placed within a hydrogel, i.e. in a 
3D environment, and cells cultured on their surface, i.e. in 2D.  
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Chapter 4 Silica nanorods-collagen composite hydrogels: 
preparation, properties and magnetic engineering 
 
“爱人者，人恒爱之”  
 
《孟子》 
 
Abstract 
Nanocomposite hydrogels associating biological polymers with nanomaterials have been 
widely used as tissue engineering scaffolds and wound dressings. Especially collagen-silica 
bionanocomposites have shown great promises due to their versatility and good 
biocompatibility. In this chapter, we aimed at constructing new 3D collagen-based 
nanocomposites using silica nanorods instead of spherical nanoparticles previously reported. 
We have studied the relationships between the composite composition, structure and 
mechanical properties, emphasizing the key role of collagen-silica interactions. The influence 
of these parameters on the adhesion and proliferation of fibroblast cells was also investigated. 
In addition, we prepared and used magnetic silica nanorods to control particle orientation within 
the collagen network thanks to an external magnetic field. Our results bring new insights on the 
preparation and properties of bionanocomposites and open the route to multifunctional 
hydrogels. 
 
4.1 Introduction .................................................................................................................... 133 
4.2 Experimental section ...................................................................................................... 134 
4.2.1 Chemicals .............................................................................................................. 134 
4.2.2 Synthesis of SiNRs/collagen hydrogel composite ................................................ 135 
4.2.3 Characterizations ................................................................................................... 136 
4.2.4 Cell experiments .................................................................................................... 138 
4.2.5 Statistical Analysis ................................................................................................ 139 
4.3 Results and discussion .................................................................................................... 139 
4.3.1 Synthesis and characterization of Fe3O4-coated silica nanorods .......................... 139 
4.3.2 SiNRs-collagen hydrogel composites ................................................................... 144 
4.3.3 Magnetic SiNR-collagen hydrogels ...................................................................... 154 
4.4 Conclusion ....................................................................................................................... 158 
 
 
132 
Hydrogels composites à base de collagène et de nano-
bâtonnets de silice : synthèse, propriétés et contrôle 
magnétique  
 
 
 
 
 
 
Résumé 
Plusieurs études ont déjà démontré l’intérêt d’associer le collagène et des nanoparticules de 
silice pour la mise au point de biomatériaux tri-dimensionnels. Dans ce contexte, cette étude 
vise à étudier la possibilité d’utiliser des nanoparticules anisotropes, en forme de bâtonnets, 
plutôt que sphériques, pour atteindre un meilleur contrôle des propriétés mécaniques des 
nanocomposites et moduler leur influence sur des cellules animales. Pour cela, des hydrogels 
présentant des concentrations en collagène et en silice variables ont été préparés, caractérisés 
structuralement et nous avons étudié leurs propriétés rhéologiques. Le rôle clé joué par les 
interactions silice-collagène a alors pu être mis en évidence. La culture de fibroblastes humains 
sur ces nanocomposites a aussi été réalisée, montrant qu’un excès de nano-bâtonnets est 
défavorable à leur survie puisque celle-ci est liée à leur capacité à coloniser le réseau de 
collagène. Dans un deuxième temps, des nanobâtonnets magnétiques ont été synthétisés par 
croissance in situ de nanoparticules de magnétite à la surface de la silice. Nos premiers résultats 
indiquent qu’il est possible d’utiliser un champ magnétique externe pour contrôler l’orientation 
de ces particules au sein des nanocomposites. Ceci ouvre la voie à des hydrogels 
nanocomposites multifonctionnels. 
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4.1 Introduction 
Hydrogels are three-dimensional networks that crosslink through a hydrophilic polymer chain 
within an aqueous microenvironment1. The water-rich nature of hydrogels makes them widely 
used in many fields, including tissue engineering, drug delivery, soft electronics, and actuators2-
4. However, hydrogels generally have limited mechanical properties and are prone to permanent 
cracking5. Often, the lack of required dynamic cues and structural complexity within the 
hydrogel further limits their function, especially in a biological context. Therefore, extended 
applications of hydrogels require advanced parametric design, such as mechanical and 
spatiotemporal properties of the active or biologically active portion. The incorporation of 
nanostructured fillers into hydrogels has recently been developed as an innovative approach to 
create new materials with multiple functions and meet new challenges. The innovative 
combination of these two completely different types of materials is believed to produce not only 
structural diversity, but also a variety of performance enhancements. These enhancements are 
a major focus of hydrogel-nanoparticle composite research, which leads to improvements in 
mechanical strength and stimuli response (eg, optical, thermal, magnetic, and electrical). By 
using alternating layers of polyacrylamide hydrogel with and without polystyrene(PS) 
nanoparticle fillers,  Thevenot et al. have developed composite materials having different elastic 
moduli6. The physical deformation of the double layer gel creates an electrical potential that 
can be used to develop soft tactile sensing devices. Polypyrrole is a semiconductor conjugated 
polymer for organic based optoelectronic devices. Luo et al. developed an agarose/alginate 
double-network hydrogel containing polypyrrole nanoparticles for use as an infrared response 
release system, much like those using reduced graphene oxide NP7. In another example, gold 
nanoparticles were immobilized poly N-isopropylamide hydrogel, inducing significant changes 
in mechanical properties and thermal response8. Thus, the combination of nanoparticles and 
hydrogels results in advanced materials with unique properties that currently catalyzes intense 
research activities of nanoparticle hydrogel composite interfaces and is expected to be used in 
many applications. 
As already pointed out in the Chapter I, type I collagen is a protein of choice to prepare 
biomaterials 9. Collagen-based hydrogels are used as carriers for cell and drug delivery in bone 
and cartilage tissue engineering, wound dressings and substrates in cell culture10-12. The 
incorporation of nanoparticles into collagen matrices to develop functional hydrogel 
composites has become an important and active area. For instance, the incorporation of 
magnetic nanoparticles within collagen hydrogels has been reported. Thanikaivelan et al. have 
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described collagen-based  magnetic nanocomposites for selective oil absorption and magnetic 
tracking, making them useful for degreasing applications13. Magnetic hybrid hydrogels have 
also been used in biomedical applications in magnetic guided nerve repair. Shefi and colleagues 
developed magnetic particle/collagen hydrogel composites under external magnetic fields14. 
These hydrogels can control gel orientation and neuronal cell growth, which shows a significant 
promise for therapeutic engineering scaffolds. In parallel, as presented before, silica 
nanoparticles were also widely used to design collagen-based nanocomposites. As early as 
2010, Desimone et al. prepared a silica nanoparticle-doped composite nanohydrogel scaffold 
for cell fixation15. Yu et al. prepared a silica hybrid collagen hydrogel as a three-dimensional 
cell matrix. The results showed that the viscoelasticity and mechanical properties of the hybrid 
gel were significantly improved, and the observed cell behavior in the 3D gel matrix was 
completely different from that previously reported on the 2D substrate16. Recently, many 
spherical silica hybrid composite gels have been used for the delivery of antibacterial drugs and 
genes17, 18.  
However, silica nanorods have not been used to prepare such hybrid hydrogels. One-
dimensional nanorods have a large aspect ratio compared to spherical nanomaterials and have 
a large potential to enhance the mechanical strength of hydrogels. Thus we have here prepared 
such silica nanorods and used them to prepare collagen-based composite hydrogels. Their 
mechanical properties and biological behavior were studied. In a step further, we have prepared 
magnetic nanorods by inducing the in situ growth of iron oxide nanoparticles on the surface of 
the silica particles and used them to design a magnetic nanocomposite gel. Preliminary results 
are very encouraging in the capacity of this strategy to allow a better control of nanorods 
orientation and also open perspectives to use these magnetic properties in biomedical 
applications. 
4.2 Experimental section 
4.2.1 Chemicals  
All chemical reagents were analytical grade and used without further purification. 
Tetraethylorthosilicate (TEOS), absolute ethanol, n-pentanol, concentrated hydrochloric acid, 
3-Triethoxysilylpropylamine (APTES), polyvinylpyrrolidone (PVP, 40 kDa), sodium citrate 
dihydrate, ammonium aqueous solution (28%), Acetic acid (AR), tetraethylene glycol (TEG), 
Iron (Ⅲ) acetylacetonate were obtained from Sigma.  MilliQ water (18 MΩ, Millipore, France) 
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was used for the preparation of the solutions and for all rinses. 4,6-diamidino-2-phenylindole 
(DAPI), Fetal bovine serum, Dulbecco’s Modified Eagle’s Medium (DMEM), trypsin, 
glutamine, and penicillin-streptomycin solution were purchased from ThermoFisher. 
4.2.2 Synthesis of SiNRs/collagen hydrogel composite 
Synthesis of silica nanorods (SiNRs) 
The rod-like silica particles having lengths of about 3 μm and diameters of about 300 nm were 
synthesized according to the recipe recently reported by Kuijk et al.19 Typically, 30 g of PVP 
was added to 300 mL of n-pentanol and sonication for 3 hours. When all PVP had been 
dissolved, then 30 mL absolute ethanol, 8.4 mL ultrapure water and 2 mL of 0.18 M sodium 
citrate dihydrate aqueous solution were added to the solution following a sequence. The flask 
was shaken by hand to mix the content. Then, 6.75 mL of ammonia was added, the flask was 
shaken again and then 3 mL of TEOS was added to the mixture. After shaking again, the bottle 
was put into a water bath in 30 ℃ and the reaction was allowed to proceed 24 h. Next, the 
reaction mixture was centrifuged at 8000 rmp for 20 min. The supernatant was removed and 
the particles in the sediment were redispersed in ethanol. This centrifugation procedure was 
repeated at 4000 rmp for 15 minutes, 2 times with ethanol, 2 times with water and finally again 
with ethanol. To remove small rods and improve size dispersity, the rods were centrifuged two 
times at 500 g for 15 minutes and redispersed in fresh ethanol. 
 
Synthesis of Fe3O4-silica nanorods.  
Fe3O4-silica nanorods were prepared by high temperature thermal decomposition of iron 
precursor on the surface of silica nanorods. First, 100 mg of silica nanorods was dispersed in 1 
mL of water and sonication for 30 min. Then 10 g of TEG and 0.177 g (0.5 mmol) of Fe(acac)3 
were added. The mixture was first heated to 110 °C under vacuum for 1 h to remove water and 
then to 200 °C for 2 h under a flow of nitrogen. The system was finally refluxed at 300 °C for 
1 h and then cooled to room temperature. The final products also include a small fraction of 
unbound Fe3O4 nanocrystals. For the purification, acetone was added to the synthesis solution, 
and an external magnetic field was applied to precipitate the Fe3O4@SiO2. The supernatant that 
contained free Fe3O4 nanocrystals was then decanted. This process was repeated five times, and 
the product was dried under vacuum20.  
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Preparation of collagen-based hydrogel composites 
Type I collagen was purified from rat tails and the final concentration was estimated by 
hydroxyproline titration, as described in previous chapter. Nanocomposites were prepared by 
mixing a 5, 10, 20, 30 mg.mL-1 collagen suspension in 17 mM acetic acid solution with a 10 X 
phosphate buffer saline (PBS) solution containing the suitable amount of silica nanorods to 
reach a final pH of 7.0 and a final concentration of silica nanorods ranging from 30 to 120 
mg.mL-1. Resulting sols were quickly dispatched into different shaped mold and incubated at 
37ºC to trigger gel formation. Finally, gels were rinsed three times with PBS. For Fe3O4@SiO2 
hybrid collagen hydrogels, similar process was preformed except by mixing 10 mg.mL-1 
collagen suspensions (17 mM acetic acid) with 30 mg Fe3O4@SiNRs in absence or in presence 
of external field. 
4.2.3 Characterizations  
Characterization of nanorods-based silica materials  
Zeta potential (ζ) were measured in DI water using a Zetasizer Nano (Malvern Instruments Ltd., 
Worcestershire, UK). Particles were also imaged using Transmission Electron Microscopy 
(TEM) on a FEI Tecnai G2 Spirit microscope operating at 120 kV (TEM) (FEI Company, 
Philips, Netherlands). Nitrogen (N2) sorption measurements were performed at 77K using an 
accelerated surface area and porosimetry analyzer with Brunauer-Emmett-Teller (BET) 
calculations for the surface area. FTIR was performed by Perkin Elmer Spectrum 65 FTIR 
Spectrometer. X-ray Photoelectron Spectroscopy (XPS) analyses were performed with a 
PHOIBOS 100 spectrometer from SPECS GmbH. X-ray diffractometer was obtained using a 
Philips X-ray diffractometer with Cu-K α radiation (Philips PW 1830, Holland). Magnetic 
properties of Fe3O4@SiNRs was measured by a Quantum Design SQUID magnetometer 
MPMS XL-7. 
 
Quantification of iron concentration  
Inductively coupled plasma quadrupole mass spectrometry (ICP-QMS) was performed on an 
Agilent 7900 apparatus. For sample processing, a mass of nanoparticles was first weighed, then 
digested with nitric acid-perchloric acid (4:1) overnight, followed by evaporation of the solvent 
at high temperature, and the residues were dissolved in 0.5 N nitric acid with a series of 
concentrations of Fe ions and analyzed. 
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Behavior of Fe3O4@SiNRs in collagen solution in presence of magnetic field 
The Fe3O4@SiNRs powder was added into the collagen solution. The mixture was vortexed 
for 2 minutes to ensure uniform dispersion of the nanoparticles.  Then, the mixed solution 
was suctioned with a dropper and uniformly coated on a glass slide with a cover glass, and 
then the behavior of the sample under external magnetic field was observed under a LEICA 
fluorescence microscope with bright filed. 
 
Scanning electron microscopy (SEM) analysis  
The collagen nanocomposites were fixed in dimethyl citrate/sucrose buffer (0.05 M/ 0.3 M, pH 
7.4) at 4 ° C for 1 hour using 3.63% glutaraldehyde. After fixation, the samples were washed 
three times in the same buffer and dehydrated from 70% to 100% ethanol by a continuously 
increasing concentration of ethanol bath. Thereafter, the samples were freeze-dried and 
sputtered with gold (20 nm) for analysis. Samples were observed with a Hitachi S-3400N SEM 
operating at 8 kV or 10kV.  
 
Transmission electron microscopy (TEM) analysis  
The collagen nanocomposite was fixed with 4% PFA. After fixation and washing, the samples 
were fixed using 2% osmium tetroxide in cacodylate/sucrose buffer (0.05 M / 0.3 M, pH 7.4) 
at 4 ° C for 1 hour. The sample was then washed three times in cacodylate/sucrose buffer, 
dehydrated with ethanol and embedded in araldite. Thin araldite transverse sections (100-200 
nm) were made by Ultracut ultramicrotome (Reichert, France) and compared to 
phosphotungstic acid. It was then analyzed by a Cryomicroscope Tecnai spirit G2 electron 
microscope operating at 120 kV. 
 
Rheological measurements  
Shear oscillation measurements were performed on collagen nanocomposite discs using a 
Bohlin Gemini rheometer (Malvern) equipped with a flat acrylic 40 mm diameter geometry. 
Both the base and the geometric surface are rough to avoid slippage of the sample during the 
measurement. All tests were performed at 37 °C. The mechanical spectra were recorded at the 
applied 1% strain, ie the G' and loss G″ modulus versus frequency measurements were recorded, 
which correspond to linear and non-destructive conditions. In order to test all collagen matrices 
under similar conditions, the gap between the base and the geometry was chosen before each 
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run so that a slight positive normal force was exerted on the gel during the measurement. Four 
samples of each nanocomposite hydrogel were tested. 
Magnetic measurements 
Magnetic measurement. Variable temperature (2.0-200K) magnetic measurements were 
applied to the external field of 1T using a Quantum Design SQUID magnetometer MPMS XL-
7. To prevent loss of uncoordinated solvent, fresh samples were introduced at 200 K is frozen 
under a helium flow and purged under vacuum. Measurements were first made at 200K to 2.0K 
and then from 2.0 K to higher. These experiments were performed by Dr Yanling Li (IPCM, 
SU). 
4.2.4 Cell experiments  
Cell culture  
Normal Human Dermal Fibroblasts (NHDF) were cultured in complete cell culture medium 
(DMEM with GlutaMAX™, without phenol red supplement, with 10% fetal serum, 100 U.mL-
1 penicillin, 100 μg/mL streptomycin). Tissue culture flasks (75 cm2) were kept at 37 °C in a 
95% air: 5% CO2 atmosphere. Before confluence, the cells were removed from culture flasks 
by treatment with 0.1% trypsin and 0.02% EDTA. Cells were rinsed and resuspended in the 
above culture medium before use.  
 
Viability tests  
For viability test, NHDFs were seeded onto the hydrogel discs at a density of 5,000 cells/cm2. 
Following 24 h of culture, cell activity was evaluated by the Alamar Blue assay. Control 
experiments were performed using the pure collagen hydrogel by incubating NHDFs. There are 
four parallel samples for each sample. 
 
Cell adhesion and proliferation on hydrogels 
For adhesion and proliferation assessments, NHDFs were seeded onto the hydrogel discs at a 
density of 5,000 cells/cm2. Following 24 h, 48h and 72 h of culture, cells on hydrogel surfaces 
were washed with PBS twice and treated with a 4% PFA solution for 1h. Cells were then stained 
with DIPA. Fluorescence images of stained cells were used to quantify cell adhesion and 
fraction area coverage. Fluorescence images were transformed into 8-bit digital grayscale 
images using ImageJ software, followed by the selection of a threshold on gray levels in order 
to separate lighter appearing cells from the darker background. 
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4.2.5 Statistical Analysis  
Graphical results are presented as mean ± SD (standard deviation). Statistical significance was 
assessed using one-way analysis of variance (ANOVA) followed by Tukey (compare all pairs 
of groups) or Dunnett (compare a control group with other groups) post-hoc test. The level of 
significance in all statistical analyses was set at a probability of P < 0.05. 
4.3 Results and discussion 
4.3.1 Synthesis and characterization of Fe3O4-coated silica nanorods 
The Fe3O4 attached silica nanorods was prepared according to the method depicted in Figure 
4-1. In the first step, silica nanorods (SiNRs) were prepared using a wet-chemical synthesis 
method in one pot. Then, the magnetic Fe3O4 nanoparticle shell was deposited on the surface 
of the silica nanorods by in situ thermal decomposition of iron acetylacetonate.  
 
 
Figure 4-1 Schematic illustration of the preparation of Fe3O4 attached silica nanorods 
Fairly uniform silica rods were obtained using the Kuijk's method, at a reaction temperature at 
of 30 ℃. As shown from the TEM images in Figure 4-2, the synthesized silica nanorods exhibit 
good homogeneity, no spherical structure appears, and the nanorods have a diameter of about 
300 nm and a length of 3 m (i.e the aspect ratio is 1 to 15). The shape of these nanomaterials 
is somewhat special, with one end being rather flat and the other end being like a tip, more like 
the shape of a nail. 
Measurements by DLS were difficult because of the micron-size length of the rods. It was 
nevertheless possible to obtain a stable measurement of the zeta potential of prepared silica 
nanorods, -53.8 eV, similar to the surface charge of similar silica nanomaterials. 
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Figure 4-2 TEM images of silica nanorods with different magnifications 
Fourier transform infrared spectroscopy (FTIR) was used to further characterize the SiNRs. As 
shown in Figure 4-3, the typical peaks for hydrated silica can be observed at 1044 cm-1, that is 
caused by Si-O-Si stretching vibration, and at 953 cm-1 and 792 cm-1 which corresponds to Si-
OH mode and inter-tetrahedral Si-O-Si bending vibration, respectively. The presence of 
adsorbed water was observed near 3350 cm-1. The band at 1645 cm-1 may also correspond to 
adsorbed water but can also sign for the presence of remaining PVP on or within the SiNRs 
particles.  
 
 
Figure 4-3 The FTIR spectra of silica nanorods 
Attachment of the iron oxide nanoparticles to the SiNRs was operated by direct high 
temperature thermal decomposition of iron precursors on the surface of silica nanorods. The 
iron content of the rods, as obtained by ICP-QMS, was 9.6 %. Successfully coating the Fe3O4 
nanoparticles on the surface of the silica can be clearly on the TEM images. It can be seen a 
  
141 
 
high density of nanoparticles having an average diameter of ca. 10 nm that form a thin layer 
which is almost uniformly distributed on the surface of the silica nanorods (Figure 4-4). This 
size range was in good agreement with that obtained for iron oxide nanoparticles prepared by 
the same method but in the absence of silica nanorods (Figure 4-4). No separate magnetite 
nanoparticles were observed near the silica or in any other sample area. To examine the stability 
of the magnetite on the silica surface, a small vial containing a dispersion of as-prepared 
SiNR@ Fe3O4 was immersed in a 40 kHz ultrasonic bath for several different intervals. No 
observable change was found on the samples after continuous ultrasonic treatment, suggesting 
strong interaction of deposited nanoparticles with the silica surface. 
 
 
Figure 4-4 TEM images of (a-b) Fe3O4 nanoparticles, (c-d) SiNR@Fe3O4 materials 
XRD analysis confirmed that the nanocrystals on the silica surface were consisting of magnetite 
(Figure 4-5). 
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Figure 4-5 The XRD patterns of SiNR@Fe3O4 with standard reference magnetite (JCPDS 
No.19-0629) 
To further confirm the nature of deposited nanoparticles, the as-prepared materials were studied 
by XPS (Figure 4-6). The two photoelectron peaks at 710.6 and 724.1 eV are very close to the 
previously reported binding energy value of core-level Fe 2p lines in magnetite, confirming the 
phase of the iron oxide nanoparticles on silica surface. 
 
 
Figure 4-6 XPS spectrum at the Fe2p level of SiNR@Fe3O4 nanomaterials 
The composition of SiNR@Fe3O4 was examined in FTIR (Figure 4-7). The band at 588 cm
-1 
supported the formation of the magnetite phase. The emerging peaks in the 2800-3000 cm−1 
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domain, that were absent in pure silica nanorods, should arise from the C-H bond stretching 
from methylene groups, suggesting the presence of TEG molecules. 
 
 
Figure 4-7 The FTIR spectra of SiNR@Fe3O4 nanomaterials 
As a first insight into the magnetic properties of the modified nanorods, we observed that 
applying a magnet at the proximity of a SiNR@Fe3O4 aqueous suspension allow for its fast and 
efficient attraction on the glassware wall (Figure 4-8). 
 
 
Figure 4-8 SiNR@Fe3O4 dispersed in distilled water are efficiently attracted by an external 
magnetic field 
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Figure 4-9 (a) Hysteresis cycle recorded at temperature 2 K and 200 K for SiNR@ Fe3O4. Inset 
are the hysteresis cycles at low fields (b) ZFC and FC magnetization curves of SiNR@ Fe3O4 
at 100 Oe 
The magnetic properties of as-synthesized SiNR@Fe3O4 were then studied using SQUID 
magnetometer. Figure 4-9a shows the magnetization of SiNR@Fe3O4 as a function of applied 
field, M(H), recorded at 2 and 200 K. An open hysteresis loop is observed at 2 K with a coercive 
field Hc = 729 Oe. The hysteresis curve is substantially saturated at the highest applied field 
(>0.6T). However, when the temperature rises to 200K, the hysteresis loop becomes a straight 
line and the coercive force is almost zero. This is because the nanomaterial exhibits strong 
paramagnetism at room temperature of 200K. Figure 4-9b shows the zero-field-cooled (ZFC) 
and field-cooled (FC) magnetization of a powder sample of SiNR@Fe3O4. The ZFC 
magnetization curve increases with temperature, reaching a maximum at temperatures T=74.3 
K, which can be assumed, as a first approximation, to coincide with the blocking temperature 
TB. The FC curve increases as the temperature decreases and never reaches saturation at low 
temperature, suggesting that interparticle interactions do not significantly affect the relaxation 
dynamics. The ZFC and FC curves start to diverge at a temperature far above the TB estimated 
with the ZFC curve. This is due to relatively broad size and shape distributions of the samples. 
Indeed for this sample, according to the Néel model, the transition from the blocked to the 
superparamagnetic regime occurs at different temperatures for different particle sizes.  
4.3.2 SiNRs-collagen hydrogel composites 
The prepared silica nanorods were mixed with the collagen solution in acidic conditions by 
physical action, followed by adjusting the pH value of the mixed system to yield the SiNRs-
collagen hydrogel nanocomposites (Figure 4-10). 
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Figure 4-10 Schematic illustration of the preparation of SiNRs-collagen hydrogels 
 
Figure 4-11 SEM of SiNR-collagen composite hydrogels. (a) 10 mg/mL, (b) 20 mg/mL and 
(c) 30 mg/mL collagen withconcentrations of SiNRs: 1-30 mg.mL-1, 2-60 mg.mL-1, 3-90 
mg.mL-1, 4-120 mg.mL-1 
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Nanocomposite materials were prepared with collagen concentrations of 10 mg/mL, 20 mg/mL, 
30 mg/mL, and silica rod concentrations from 30 mg.mL-1 to 120 mg.mL-1 (final concentration) 
and imaged by SEM (Figure 4-11). [Note: for sake of clarity, we have selected the mg/mL 
notation for collagen and mg.mL-1 for silica] 
At 10 mg/mL collagen (Figure 4-11a), nanorods are initially difficult to identify within the 
highly porous fibrillar network. They become more and more easily evidenced with higher 
SiNRs amounts. However, at 120 mg.mL-1, different particles resembling SiNRs coated with 
some organic material are sometimes observed. At 20 mg/mL, the material appears denser and 
nanorods are sparingly observed on the surface or can be guessed below it, without a clear 
tendency as a function of silica concentration. Almost the same trend is observed at 30 mg/mL, 
except for the lowest silica concentration. However it is important to point out that, because of 
their high water content, hydrogel morphology as observed by SEM can strongly vary with 
drying conditions and surface (“crust”) effects are often detrimental to their accurate study by 
this technique. 
The mechanical properties of the nanocomposites were investigated by rheological 
measurements and compared to pure collagen hydrogels (Figure 4-12, Appendix 4). For all 
materials, the storage modulus G' was much higher than the loss modulus G", as expected for 
hydrogels with significant elastic properties. The measured moduli for the nanocomposites vary 
from ca. 750 to 3500 Pa. As a general trend, at a given silica concentration, G' increased with 
collagen concentration. At a fixed collagen concentration, the evolution of G' with SiNR content 
could significantly depend on the collagen content. 
 
Figure 4-12 Storage (G′) of SiNR-collagen composite hydrogels with various composition 
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In more details, when the concentration of collagen is low (5mg/mL), G' value increases for 
low silica content (30 and 60 mg.mL-1) and then slightly decreases. At 10 mg/mL collagen, 
there is a first maximum for 30 mg.mL-1 then G' decreases with 60 and 90 mL-1 SiNR and rises 
again for larger silica amount. A very similar trend is also observed at 20 mg/mL collagen. At 
30 mg/mL collagen, a decrease of G' is observed after addition of 30 mg.mL-1 silica but 
increasing further the SiNR content allows to obtain the highest modulus.   
It is important to consider that the G’ value reflects the response of the collagen or composite 
network to a shearing force. In pure collagen, the network cohesion is insured by inter-fibrillar 
interactions and its strength therefore increases with fibril density. When nanorods are added, 
several effects can occur: (i) the nanorods can perturb the fibrillar organization of collagen and 
therefore weaken its cohesion, (ii) the nanorods can bridge the fibrils and therefore increase the 
cohesion and (iii) interactions between nanorods can contribute to the response of the composite 
network to the shearing stress. In the conditions of formation of these materials, i.e. near neutral 
pH, no favorable chemical interactions are expected between the silica nanoparticles. In fact, 
being negatively-charged, it can even be expected a repulsive electrostatic interaction between 
them. However, it is possible to assume that collagen fibrils can bridge SiNRs together. 
Overall, introduction of silica nanorods in low amounts in the collagen network may destabilize 
the inter-fibril interactions but this can be at least partially compensated by favorable silica-
collagen interactions. If silica amount increases, SiNR-SiNR unfavorable interactions become 
prevalent and weaken the composite network. However, at higher silica concentration, the 
network mainly consists of close-packed silica nanorods that can be favorably bridged by 
collagen. Thus, at low collagen concentration (5 mg/mL), it can be suggested that SiNRs at low 
concentration can compensate the perturbation of the collagen network by introducing new 
collagen-silica interactions but the protein density is not enough to stabilize the close packed 
SiNRs network formed at high silica concentration. On the contrary, such a stabilization is 
observed at silica concentration from 120 mg.mL-1 at 10 mg/mL collagen, 90 mg.mL-1 at 20 
mg/mL collagen and 60 mg.mL-1 at 30 mg/mL collagen. 
To clarify this point, we selected hydrogels with similar rheological behaviour but different 
collagen/SiNR concentrations (Table 4-1).  
Table 4-1 Selected composite hydrogels with similar mechanical properties 
Sample a b c d 
Collagen 20 mg/mL 10 mg/mL 20 mg/mL 30 mg/mL 
Silica rods 0 120 mg.mL-1 60 mg.mL-1 30 mg.mL-1 
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Figure 4-13 SEM and TEM of (a) 20 mg/mL collagen. (b) 10 mg/mL collagen, 120 mg.mL-1 
SiNRs. (c) 20 mg/mL collagen, 60 mg.mL-1 SiNRs. (d) 30 mg/mL collagen, 30 mg.mL-1 SiNRs 
The pure collagen hydrogel with a concentration of 20 mg/mL showed an obvious fibrous 
collagen network on SEM and TEM evidenced densely-packed fibrils exhibiting a periodic 
band pattern of 67 nm, which is a typical feature of the physiological structure of type I collagen 
(Figure 4-13a). At 10 mg/mL collagen and 120 mg.mL-1 silica (Figure 4-13b), elongated 
objects with a rather undefined morphology are observed by SEM, that was, in a first instance, 
attributed to nanorods coated with collagen. By TEM, it was possible to visualize both striated 
collagen fibrils and other objects that we attributed to sections of nanorods cut at different 
orientations. This attribution was supported at higher magnification where various sections of 
the rods were clearly observed. Interestingly, when transversal sections are visualized, the core-
shell structure of the rods is revealed. In the case of longitudinal sections, it is possible to 
observed that, during the sample preparation, the ultramicrotome knife has fragmented the rods 
in slices, that could reflect the layer-by-layer growth mechanism of these particles. The 
nanorods appear highly densely packed, in agreement with the high silica concentration, and at 
least one large striated collagen fiber can be found in between the elongated mineral particles. 
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When increasing collagen concentration and decreasing SiNR concentration (Figure 4-13c), 
the nanorods are more easily distinguished on the SEM image. On TEM, many collagen fibrils 
are seen and less nanorod sections, in agreement with the higher collagen:silica ratio used here 
compared to the previous sample. At higher magnification, a very interesting phenomenon is 
evidenced: several striated fibers are observed that are aligned along the direction of the rods. 
Such an alignment not only concerns those fibers that are in close proximity with the silica 
surface but at least two other layers of collagen fibers also follow this direction. 
Finally, increasing further the collagen:silica ratio to 1:1 (Figure 4-13d), it becomes difficult 
to accurately decipher protein fibers from nanorods on the SEM images. Accordingly, on TEM, 
a very dense network of collagen is observed in which some nanorods appear to be buried. At 
high magnification, the silica nanorod appear surrounded by a continuous sheath of dense and 
well-aligned. 
The first important and surprising information resulting from these images is the high ability to 
the nanorods to orient the collagen fibers. To our knowledge, such an orientation was never 
reported before for collagen self-assembly in the presence of anisotropic particles. This 
observation clearly confirms the possible existence of strong interactions between the protein 
and the nanorods. 
The second point to raise is that, despite well-distinct structures, the four materials studied here 
have very similar G' values. Taking the pure 20 mg/mL collagen hydrogel (a) as a reference, 
the introduction of 60 mg.mL-1 SiNR (c) does not significantly modify its rheological behavior. 
Introducing more particles with lower collagen concentration (b) or less particles with more 
collagen (d) has a similar effect on G'. This confirms that densely packed silica nanorods can 
be efficiently “glued” by collagen fibers. At lower content, SiNRs have both positive and 
negative effect on collagen. On the one hand, surface interaction should enhance the strength 
of the mineral-protein bond. On the other hand, it will deplete the solution in collagen molecules 
available to form a network. The relative contribution of these two diverging effects is expected 
to depend on both collagen and SiNRs concentration. From a composite perspective, it means 
that the weakening of the matrix is compensated by the strengthening of the charge/matrix 
interactions.  
It is now well-admitted that the behavior of cells on a considered substrate is highly dependent 
on its mechanical properties. However, it is often difficult to modify these properties without 
changing other parameters of the substrate such as its composition or structure. Here we had 
the possibility to prepare materials with similar rheological properties but different 
compositions and structures, offering a fruitful opportunity to establish possible correlations 
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between cell activity and substrate properties.  For this we used NHDF cells that were seeded 
and grown for 72 hours. Their metabolic activity was evaluated by the Almar blue test. 
 
Figure 4-14 Metabolic activity of surface-cultured fibroblasts (Alamar blue assay) (a) at 
constant G' (ca. 2 kPa) value and (b) at constant SiNRs content. Control collagen hydrogels (20 
mg/mL) at day 1 were normalized to 100%.  
The pure collagen at 20 mg/mL after 24 h was taken as the 100 % reference. First, when 
comparing the four materials exhibiting similar G' values (ca. 2 kPa), no significant difference 
was observed after 24 h, indicating that cell adhesion was similar in all cases (Figure 4-14a). 
After 48 h, cell proliferation has occurred for all samples to a similar extent, except for sample 
(b) (10 mg/mL, 120 mg.mL-1). This difference was even more marked after 72 h and sample 
(d) (30 mg/mL, 30 mg.mL-1) also showed lower cell activity. The low activity measured for (b) 
is not completely unexpected as it contains the highest SiNRs concentration that are very likely 
to dissolve during the incubation and may therefore have some cytotoxic effect. The decrease 
in activity for sample (d) is more surprising. Since sample (c) with higher SiNR content does 
not show detrimental effect, direct cytotoxic effect from silica cannot account for the effect of 
(d). 
Aiming at understanding better these results, we compared a series of composite prepared at 
constant SiNR concentration (30 mg.mL-1) but various collagen content. As shown on Figure 
4-14b, the initial cell adhesion is similar for all hydrogels. After 48 h cell proliferation has 
occurred but to an extent that decreases with increasing collagen concentration. After 72 h, the 
cellular activity is the same for all samples except for the 30 mg/mL collagen, 30 mg.mL-1 SiNR 
composite (i.e. sample (d)). Again, if this detrimental effect was directly related to silica, then 
we could have expected that it would be more effective for the highest silica:collagen ratio. In 
fact, we observe the opposite trend.  
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We then used fluorescence microscopy and SEM to image the different samples. Figure 4-15 
gathers selected images for the first series of samples (similar G' but different compositions).  
 
Figure 4-15 Fluorescence (1-24 h, 2-72h) and SEM (3-72 h) images of NHDF incubated with 
(a) 20 mg/mL collagen. (b) 10 mg/mL collagen, 120 mg.mL-1 SiNRs. (c) 20 mg/mL collagen, 
60 mg.mL-1 SiNRs. (d) 30 mg/mL collagen, 30 mg.mL-1 SiNRs 
For the pure collagen, the extent of proliferation between 24 h (a1) and 72 h (a2) is validated 
by fluorescence microscopy. It was also quite clear that all cells are not in the same focus plan, 
especially after 72 h, indicating that colonization of the matrix has started. In the case of the 
composites, the presence of the silica nanorods made the imaging more difficult. However, it 
is possible to confirm that very few cells are present on the (b) sample and less are observed on 
(d) compared to (c) after 72 h. SEM imaging after 72 h (right hand column of Figure 4-15) 
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provided complementary information. The first striking observation is that silica nanorods are 
found in very large amount at the surface of the composite, in contrast to the initial cell-free 
SEM images shown in Figure 4-11. A second interesting point is seen for sample c (c3), where 
cells appear coated by a mixture of collagen fibrils and nanorods. However, it must be pointed 
out that observed NHDFs in b3 and c3 have a round shape which indicate poor adhesion. In the 
case of d3, it is even difficult to clearly identify the cells. 
Taken together, it appears that cells have strongly interacted and remodeled the composite 
hydrogel surface. It is fact well-known that upon adhesion on collagen, fibroblasts can rearrange 
their environment by pulling on the protein fibers and contract the collagen network. This 
remodeling is all the more efficient as the collagen network is weak. Noticeably, here, all 
composites have similar G’ value but the collagen matrix itself, to which NHDFs are more 
likely to adhere rather than on the silica nanorods, varies from one sample to the other.  
The key role played by the collagen matrix itself is clearly evidenced in the second series of 
composite hydrogels (constant SiNR concentration of 30 mg.mL-1) (Figure 4-16). Fluorescent 
imaging allows to point out the decrease in cell density with increasing collagen concentration, 
especially after 72 h (column 2). Thanks to the low SiNR content, it is also possible to better 
observe cells that have penetrated inside the matrix. In SEM, highly-adhering well-spread 
NHDF are observed after 72 h for all composites except for 30 mg/mL collagen, 30 mg.mL-1 
SiNRs, in agreement with cellular activity measurements. 
The most straightforward explanation for these observations is related to the influence of 
collagen concentration on hydrogel colonization. It has been previously demonstrated in our 
group that the rate of penetration of NHDFs within collagen hydrogels, that involves the 
degradation of the protein network by metalloprotease enzymes, decreases with increasing 
concentration. We should remind that the previous set of experiments has suggested that cell 
adhesion and proliferation is not favored on silica nanorods that were found in large amounts 
on the composite surface. Therefore, in low collagen composites, NHDFs cells may be able to 
penetrate the protein network and find a favorable environment for proliferation. On the 
contrary, for high collagen content, fibroblasts are stuck on the surface and their proliferation 
is hindered by the high density of silica nanorods. 
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Figure 4-16 Fluorescence (1, 2-72h) and SEM (3-72 h) images of NHDF incubated with (a) 5 
mg/mL collagen. (b) 10 mg/mL collagen (c) 20 mg/mL collagen (d) 30 mg/mL collagen, all 
supplemented with 30 mg.mL-1 SiNRs 
In summary, we were able to new nanocomposites materials with a wide range of collagen and 
silica nanorods content. It allowed us to obtain variable structures, from dense collagen 
networks entrapping dispersed nanoparticles to closely-packed assemblies of nanorods within 
which collagen fibrils can be formed. Interestingly, the rheological behavior of these 
composites did not vary in proportion to the content in one or the other component neither on 
their respective ratio. As evidenced by TEM, one reason for this is that strong interactions exist 
between silica and collagen, resulting in the striking observation of protein fiber alignment 
along the nanorod main axis. These results clearly enlighten that these materials can be truly 
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considered as composite structures at the macroscopic scale. However, our study of the 
behavior of NHDF seeded on their surface suggest that the cells do discriminate between the 
protein and the mineral phases, all the more as collagen represents a favorable environment for 
their proliferation whereas silica nanoparticles have a detrimental effect on their adhesion, and 
may even be cytotoxic in large amounts. Since such an inhibition of cell proliferation was not 
reported previously for collagen-silica nanocomposites prepared with smaller (up to ca. 400 
nm) spherical silica nanoparticles, it can be assumed that it is related to the fact that the length 
of the rods (ca. 3 m) is in the same order of magnitude as fibroblasts dimensions (10-15 m). 
It can also be noticed that, whatever the conditions, the improvement of the G’ value was quite 
moderate (max. 50 %). This can be due, at least for some part, to the lack of control of nanorods 
organization within the collagen hydrogels. As an answer to this problem, we attempted to take 
advantage of the magnetic properties SiNR@Fe3O4 to tune their orientation within the 
composite structure. 
4.3.3 Magnetic SiNR-collagen hydrogels 
The magnetic composite hydrogels were first prepared following the same procedure as for 
SiNR nanorods, i.e. in the absence of external magnetic field. From SEM, the morphology of 
the magnetic composite hydrogel (10 mg/mL collagen, 30 mg.mL-1 SiNR@Fe3O4) is very 
similar to the one obtained with non-magnetic nanorods (Figure 4-17).  
 
Figure 4-17 SEM (a, b) and TEM (c, d) images of SiNR@Fe3O4-collagen composite hydrogels 
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TEM also allows to evidence sections of the nanorods with various orientations. The thin layer 
of magnetic nanoparticles coating the rods is also easily visualized. The background collagen 
network is difficult to observe, probably due to the high contrast of the iron oxide nanoparticles. 
Indeed, once the collagen matrix is formed, the nanorods can no longer orient if an external 
magnetic field is applied. Such an orientation must therefore be achieved in the acidic collagen-
nanoparticle mixture before inducing gelation. We hypothesized that this process will highly 
depend on collagen concentration. More convincing results were obtained using a 10 mg/mL 
collagen concentration (Figure 4-18). 
 
 
Figure 4-18 Magnetically controlled nanomaterial behavior in 10 mg/mL collagen solution. (a) 
No magnetic field. (b) Magnetic fields in the opposite direction (N-N, or S-S). (c) Magnetic 
fields in the same direction (N-S, S-N). (d-f) Magnetic response time is 0, 2, 5 min, respectively 
In these experiments, a drop of the collagen solution was deposited on a glass slide and left as 
such (a) or placed between two plate magnets. The two plates were oriented with either same 
poles (i.e. fields in opposite directions) (b) or opposite poles (i.e. fields in same direction) (c) 
facing each other.  As seen by bright-field optical microscopy, the initially randomly aggregated 
nanorods tend to form more local assemblies in (b) and are very well-aligned in configuration 
(c). We also conducted a study of the kinetics of the process under the microscope with magnets 
placed around the glass slide. As shown on Figure 4-18(d-f), it took only 5 minutes for the 
nanorods to be aligned.  
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These conditions were then repeated for bulk hydrogels and the resulting composites were 
imaged by SEM and TEM. As seen on Figure 4-19, it is quite difficult to ascertain orientation 
of the nanorods on the sole basis of SEM characterization. TEM images are more informative. 
On the one hand, it seems that two nanorod orientations are favored, one parallel to the plane 
of the image, one perpendicular to it. On the other hand, and maybe more significantly, two 
rods well aligned along their main axis are observed. Indeed we would have needed to analyze 
much more images to ascertain these facts but they were quite encouraging. 
 
Figure 4-19 SEM and TEM images of SiNR@Fe3O4-collagen composite hydrogels under 
exteranl magnetic field 
Subsequently, we prepared three samples of magnetic hydrogel composites. Figure 4-20 shows 
the three configurations that we have explored. 
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Figure 4-20 Three different magnetic composite hydrogel models. (ii) horizontal magnetic 
field, (i) without magnetic field, (iii) vertical magnetic field 
These hydrogels were formed directly in the polymer capsule used for SQUID measurements, 
allowing to preserve their initial orientation when placed in the machine 
 
Figure 4-21 Hysteresis cycle recorded at (a) 2 K and (b) 200 K, (c) FC/ZFC curves and (d) 
rheological properties for magnetic composite hydrogels (i) without magnetic field. (ii) with 
horizontal magnetic field and (iii) with vertical magnetic field 
While composite hydrogels obtained without applied magnetic field or field applied parallel to 
the upper gel surface have almost identical magnetic behaviors, sample (iii) is clearly different: 
it presents a wider hysteresis at 2K and higher magnetizations in FC/ZFC curves (Figure 4-21).  
Although we don’t have a clear explanation for this difference, it should be related to the relative 
direction of the magnetic field within the SQUID equipment compared to the favored 
orientation of the nanorods within the samples.  
Accordingly, when the rheological properties under a shear stress parallel to the upper gel 
surface were measured, a lower G’ value was found for sample (iii). It is in agreement with the 
a b
c d
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fact that nanorods oriented perpendicular to the shear direction should have less impact on the 
deformation of the network compared to nanorods oriented in the same direction. 
Thus both methods are able to distinguish between vertically-oriented samples and horizontally 
or random composites. Although the effects are small, they at least indicate that the applied 
magnetic field had a measurable impact on the organization of the nanorods. This is a first 
validation of our strategy but we unfortunately lacked of sufficient time to progress further in 
the study of these original magnetic nanocomposites 
4.4 Conclusion 
Nanocomposite hydrogels combining biomacromolecules and nanomaterials offer versatile 
platforms whose mechanical properties can be adjusted and that can also exhibit multiple 
functions. Whereas the benefits of associating collagen hydrogels and silica nanomaterials have 
already been described, we have explored here a new approach using silica nanorods. The first 
expected benefit of the rod shape of the particles was to achieve a higher improvement of the 
mechanical properties of the collagen network at a lower silica concentration compared to 
spherical nanoparticles. What we found out is that this change of morphology also has an 
important impact on silica-collagen interactions as well as on the response of fibroblast cells to 
the composite materials.   
With the aim of minimizing the required amount of silica nanoparticles to be introduced in the 
collagen network, we have designed and use magnetically-responsive nanorods.  Our first 
results show that this strategy allows, at least to some extent, to control the orientation of the 
mineral particles within the collagen network. There is indeed plenty of room for improvement, 
including the preparation of smaller nanorods, while preserving their high aspect ratio, that may 
orient more easily along the external magnetic field in the initial collagen solution. Besides, 
another interesting option to explore in the future is to study the effect of such an external field 
once the nanocomposite is formed, which may open broad application prospects in biomedical 
applications whether in imaging, drug release, or medical treatment. 
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Conclusions and perspectives 
Summary 
A variety of structures based on silica nanomaterials are highly attractive in the field of 
biology, not only because of their variable and tunable physical and chemical properties 
and surface characteristics, but also because of their generally good biocompatibility. 
Although silica has been successfully explored for many applications in the biomedical 
field, such as bioimaging, drugs and gene delivery, there is still a long way to go for the 
design of materials with clinical application prospects. Therefore, studying the physical 
and chemical properties of silica nanomaterials and their behavior in a biological 
environment remains of high importance. In particular, in many in vivo situations, 
nanoparticles are very likely to interact cells incorporated in a 3D extracellular matrix.  
Such considerations have been so far poorly addressed in the literature and were the 
focused on this PhD project.  
With this aim, we conducted a large diversity of investigations involving silica 
nanomaterials, including physicochemical properties and biodegradation studies of 
nanostructured silica nanoparticles, control drug release and imaging performance of 
multifunctional silica nanoplatforms from 2D to 3D models, as well as preparation, 
structural properties and biological effects of multifunctional composite collagen 
hydrogels using rod-shaped silica nanomaterials. 
 
First of all, we prepared and characterized PEGylated fluorescent silica nanoparticles 
with various internal structures (core-shell bio-composite, multilayered and hollow 
mesoporous) whose morphology and surface properties were extensively characterized. 
Their degradation behavior in a buffer, a culture medium and in contact with human 
dermal fibroblasts were studied. Results showed that the degradation pathways are very 
similar in all conditions although their structure, composition and their precise 
environment can impact on the kinetics of the degradation. A major outcome of this 
work is that, under these conditions, the silica nanoparticles must be mainly considered 
as degraded by hydrolysis and not biodegraded. This suggests that the intracellular fate 
of silica-based nanomaterials can be controlled and predicted on the basis on physico-
chemical considerations. However, when these nanomaterials are used in actual 
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biological applications, different situations will be encountered. In this case, complex 
biological systems make prediction of nanoparticle behavior more difficult. Therefore, 
from a practical point of view, the setting of biomimetic environmental conditions may 
contribute to a more reliable in vitro assessment of functional nanomaterials. 
With this in mind, for the second step, we synthesized nanoparticles for theranostic 
applications and evaluated the influence of a three-dimensional environment on their 
functionality. Specifically, we use the hollow silica nanoparticles prepared above as a 
carrier to form an ultra-thin manganese dioxide sheet in situ on the surface by reduction 
reaction and further physically attached a targeting AS1411 aptamer. The main 
advantage of our strategy is the use of MnO2 as both a gating system and source of 
MRI-active species, making our system rather simple to prepare. A number of 
characterizations were conducted that indicate the existence of the MnO2 nanosheets 
on the surface of the hollow silica nanoparticles. The hollow nanomaterials have a high 
specific surface area and a small microporous structure which results in a high loading 
of doxorubicin hydrochloride. Both drug release profiles and MR imaging under 
physiological conditions indicate that the modified nanomaterials have pH and redox 
responsiveness characteristics. Cell experiments in 2D cultures showed that the 
nanoplatform has low cytotoxicity and confirmed that the degradation of manganese 
dioxide sheets allows for controlled release and enhanced imaging performances. 
Subsequently, we used a collagen hydrogel as a 3D model to evaluate the functional 
properties of the nanoplatforms. We found that the particles could find their way 
through the collagen network to the cells, with the help of the targeting aptamer. 
However the T1 relaxation time is lower in these 3D compared to the suspension, which 
can be attributed to the reduced stability of the nanoplatform within the collagen gel. 
This again enlightens the interest of designing and using 3D biomimetic models to 
evaluate nanomaterials prior to in vivo studies. 
Another possible application of silica nanoparticles in the biomedical field is their 
incorporation in 3D scaffolds for tissue repair or engineering. Previous silica-
biopolymer 3D nanocomposite hydrogels have shown good biocompatibility and high 
application prospects in wound dressings. However many questions remain about the 
benefit/risk balance of such composites compared to polymer-only hydrogels. Here, for 
the first time to our knowledge, highly anisotropic silica nanoparticles (ca. 300 nm in 
diameter and 3 m in length) were used to form a composite hydrogel with type I 
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collagen. A thorough investigation of the structure of these composites was performed, 
evidencing strong interactions between silica particles and collagen that result in a 
striking alignment of collagen fibrils along the main axis of the silica nanorods. Our 
results show that silica nanorods can improve the mechanical stability of the materials 
but that too high silica contents can be cytotoxic to human fibroblasts. Moreover, too 
high collagen concentrations were also unsuitable as they slow down the colonization 
of the protein network by the cells, exposing them to unfavorable interactions with the 
nanorods. One step further, it was possible to prepare magnetic silica nanorods by the 
in situ thermal decomposition of Fe(acac)3 yielding to a homogenous coating of 
magnetite nanoparticles. By using an external magnetic field, it was possible to align 
these magnetic silica rods in a collagen solution prior to gelation. Magnetic hydrogels 
were thus prepared whose directional alignment not only causes a change in the 
magnetic properties of the composite hydrogel, but also affects its mechanical 
properties. Such magnetically operable hydrogel composites have great application 
prospects as multifunctional biomaterials where the magnetic properties may be used 
for controlled drug release and imaging. 
 
Outlook 
Altogether, in this work, we could fully take advantage of the versatility of silica 
nanochemistry to design a wide range of nanomaterials with various shapes and internal 
nanostructures and associate them with other inorganic nanoparticles (MnO2, Fe3O4), 
molecules (doxorubicin, aptamer) and biomacromolecules (type I collagen). Some 
proofs of concept of their potentiality as drug release and/or imaging systems have been 
provided and there is plenty of room for future improvement in terms of composition, 
morphology and structure. 
However, understanding and controlling their behavior in a biological context- from in 
vitro degradation to in vivo metabolism-, although being a necessary stage before 
clinical application, remains highly challenging. Indeed not only silica “bio-chemistry” 
is still poorly known but, as multi-functional nanoparticles and composites are 
receiving more and more attention for the development of diagnostic and therapeutic 
integrated materials, the complexity of the underlying mechanisms is also increasing. 
Here our approach has been mainly focused on chemical and physico-chemical aspects. 
It is very clear that a more biological approach is now necessary, especially to identify 
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in a more detailed manner (i.e. besides viability tests) the cellular response to the 
different materials we prepared. Identification of the biological pathways driving the 
intracellular trafficking of silica nanoparticles would be of particular interest. 
We had hypothesized that going from a 2D to a more biomimetic 3D context would 
have a significant impact on silica-based nanomaterials reactivity and fate in a 
biological context, and therefore on their biofunctionality. Our results emphasize that 
two cases must be distinguished, whether the particles are present at the time of the 
formation of the 3D matrix and are therefore embedded within it or if they are added 
afterwards. Accordingly, the fact that the cells are encapsulated within the hydrogels or 
seeded on their surface also has strong consequences on their interactions with particles 
and/or their dissolution products. Facing this complexity, it seems more reasonable in 
to select the configuration that more closely mimic the targeted in vivo situation. 
Meanwhile future efforts must be devoted to elaborate more complex biomimetic 
matrices, for instance by introducing additional important components of the 
extracellular matrix, such as hyaluronic acid or glycosaminoglycans, in the collagen 
hydrogels 
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Appendix 
 
Appendix 1 TEM imaging of the structural evolution of silica nanoparticles in DMEM culture 
medium after (a-c) on week and (d-f) two weeks. (scale bar = 200 nm) 
 
 
Appendix 2 Additional TEM imaging of the structural evolution of PSNPs nanoparticles in 
DMEM culture medium after (a-e) 0, 1, 3, 7, 14 days, and f) the magnification image of the 
PSNPs in the medium in 7 days. 
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Appendix 3 TEM images of NHDF cells after (a-c) 1 week and (d-f) 2 weeks of contact with 
400 μg/mL silica nanoparticles 
 
Appendix 4 Loss modulus (G") of SiNR-collagen composite hydrogels with various 
composition 
 
